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I. Abbreviations 
11β-HSD:   11β-hydroxysteroid-dehydrogenase 
ACTH:   Adrenocorticotropic hormone 
ADHD:   Attention-deficit/hyperactivity disorder 
BARD1:   BRCA1 associated RING domain protein 1 
BC:    Breast cancer 
BCL-2:   B-cell CLL/lymphoma 2 
BRCA1/2:   Breast cancer 1/2, Early Onset 
BRIP1:   BRCA1 interacting protein C-terminal helicase 1 
CAN:   Central nervous system 
CDH1:   E-cadherin 
CHEK1/2:   Cell cycle checkpoint kinase 1/2 
COX-2:   Cyclooxygenase-2 
DHEA:   Dehydroepiandrosterone 
DHEAS:   Dehydroepiandrosterone sulfate 
DHRS7:   Dehydrogenase/Reductase SDR family member 7 
DNA:   Deoxyribonucleic acid 
DOC:   11-Deoxycorticosterone 
EGFR:   Epithelial growth factor receptor 
ER:    Estrogen receptor 
ERBB2:   V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 
FANCD2:   Fanconi anemia complementation group D2 protein, isoform 1 
FGFR:   Fibroblast growth factor receptor 
GR:   Glucocorticoid receptor 
HCC:   Hepatocellular carcinoma 
Her2:   Human epidermal growth factor receptor 2 
HPA axis:    Hypothalamic–pituitary–adrenal axis 
HPG axis:     Hypothalamic-pituitary-gonadal axis 
IC50:   Half maximal inhibitory concentration 
IGF-1:   Insulin-like growth factor-1 receptor 
LLOQ:   Lower limit of quantification 
MAPK:   Mitogen activated protein kinase 
MDMA:   3,4-Methylendioxymethamphetamine 
MPH:   Methylphenidate 
MR:   Mineralocorticoid receptor 
mRNA:   Messenger ribonucleic acid 
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mTOR:   Mammalian target of rapamycin 
MYC:   Avian myelocytomatosis viral oncogene homolog 
NAD (H):   Nicotinamide adenine dinucleotide (H) 
NADP (H):   Nicotinamide adenine dinucleotide phosphate (H) 
PCa   Prostate cancer 
PPAR:   Peroxisome proliferator-activated receptor 
PR:    Progesterone receptor 
PSA:   Prostate specific antigen 
PSDR1:   Prostate short-chain dehydrogenase/reductase 1 
PTEN:   Phosphatase and tensin homolog 
PTSD:   Post-traumatic stress disorder 
QC:   Quality control  
RAD51:   DNA repair protein, S.cerevisiae homolog  
SCD-1:   Stearoyl-CoA desaturase-1  
SDR:   Short-chain dehydrogenase/reductase 
SNR:   Signal to noise ration 
SPE:   Solid-phase extraction 
TMA:   Tissue microarray  
TNBC:   Triple negative breast cancer 
UPLC-MS/MS:  Ultra-pressure liquid chromatography tandem mass spectrometry 
VEGFR:   Vascular endothelial growth factor receptor 
Wnt:   Wingless-type MMTV integration site family   
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1. Summary 
Short-chain dehydrogenase/reductase (SDR) enzymes metabolize a broad spectrum of substrates and 
play a pivotal role in the regulation of different metabolic and signaling pathways. In one part of this thesis 
the activity and specificity of potential inhibitors of the SDRs were tested. These enzymes, 11β-
hydroxysteroid dehydrogenase type 1 and 2 (11βHSD1 and 2), are currently evaluated as potential novel 
therapeutic targets for several diseases, such as metabolic syndrome, atherosclerosis, osteoporosis and 
chronic kidney disease. 11βHSD1 is a well characterized SDR and its inhibition was suggested to be 
beneficial for several metabolic disturbances. In contrast to synthetic compounds, little is known about 
natural compounds activity on this enzyme. In this thesis, the inhibiting potential of constituents of the 
extract mastix gum, derived from the plant Pistacia lentiscus, on 11βHSD1 activity was examined. All 
tested mastic gum constituents exhibited an inhibitory potential with low micromolar IC50 values and 
selectivity for 11β-HSD1 over 11β-HSD2 in vitro. Compared with compounds currently being developed by 
several pharmaceutical companies, the mastix gum constituents inhibit 11β-HSD1 with much weaker 
efficacy. The investigation into the role of mastic gum as a therapeutic agent warrants further research, 
also to assess possible adverse effects of the plant extract. The constituents of mastic gum may as well 
target other pathways and it is important to delineate the positive from the negative effects of these 
molecules.  
In another study, the effects of 11β-aminoprogesterone derivatives were evaluated for their potential to 
inhibit 11βHSD2 in vitro. Inhibition of 11βHSD2 is usually avoided in the development of pharmaceuticals, 
since its systemic inhibition causes sodium and water retention, elevated blood pressure and 
hypokalemia. Nevertheless, selective 11βHSD2 inhibition has been suggested as a potential therapy for 
hemodialysis patients suffering from hyperkalemia or for patients with colon cancer. Thus, we tested a 
series of progesterone derivatives in bioassays and six of them showed selective inhibition of 11β-HSD2 
over 11β-HSD1. These compounds offer a good basis for the development of 11β-HSD2 inhibitors with 
optimized properties for topical applications. However, risk-benefit analysis as well as comparison with 
other potential selective inhibitors needs to be done. Thus, the assessment of the therapeutic potential of 
11β-aminoprogesterone derivatives warrants further research. 
The assessment of 11βHSD inhibitors in vivo requires analytical methods to detect changes in steroid 
levels. Therefore, another aim of this thesis was to establish an LC-MS/MS method to quantify 
corticosteroid hormones. The method was applied in a clinical study on the effects of the recreational drug 
3,4-methylenedioxymethamphetamine (MDMA) and the cognitive enhancer Methylphenidate (MPH) on 
circulating steroid hormones in healthy subjects. The serotonin releaser MDMA showed acute effects on 
circulating steroids. MDMA significantly increased the plasma concentrations of cortisol by more than 60% 
compared to control. These effects were not observed with MPH, which stimulates the dopamine and 
norepinephrine systems. Thus, the findings of this study support the view that serotonin mediates the 
acute pharmacologically induced stimulation of the Hypothalamic–pituitary–adrenal (HPA) axis in the 
6 
 
absence of other stressors. Since cortisol was elevated but cortisone levels were not altered, an effect on 
the activities of the glucocorticoid metabolizing 11β-HSD1 and 11β-HSD2 triggered by MDMA and/or MPH 
could not be fully excluded. 
The last and main part of this thesis focused on the “orphan” SDR DHRS7. Given that more than 70 SDRs 
have been discovered in humans and almost half of them have not been characterized, some “orphan” 
SDRs may be important therapeutic targets and others may represent “off-targets” if inhibited 
unintentionally by pharmaceuticals. Hence, “deorphanizing” enzymes is crucial to understand their 
physiological roles and to evaluate and understand adverse and beneficial drug effects. In this thesis the 
SDR DHRS7 was identified as a tumor suppressor and possible marker for breast and prostate cancer. 
DHRS7 protein was found to be decreased with increasing tumor grades in prostate cancer tissue 
samples. Furthermore, knockdown of DHRS7 increased the aggressiveness of cells in vitro. Microarray 
data suggested the involvement of EMT and/or the BRCA pathway in the DHRS7 mediated effects. In 
addition, evidence presented in this thesis suggests DHRS7 may also play a role in liver regeneration. To 
fully understand the mechanism and function of DHRS7 its substrate(s) need to be identified. Applying our 
steroid analytics the most common steroid hormones could be excluded as substrates of DHRS7 and 
further research is warranted to “deorphanize” this enzyme. An untargeted omics approach is currently 
followed for hypothesis generation. 
In conclusion, the results presented in this thesis significantly extend our knowledge in the field of SDRs. 
Firstly, we identified novel, potent, selective inhibitors for two well-characterized 11βHSDs. Secondly, the 
observed effects of amphetamine-related drugs on steroid hormone levels in the blood suggest that they 
activate the HPA axis and enhance steroid production rather than altering steroid levels by modifying 
11βHSD activities. Finally, this thesis describes a novel role for the “orphan” SDR DHRS7 as a tumor 
suppressor in breast and prostate cancer. This thesis underlines the importance of “deorphanizing” SDRs, 
which may play important roles in many metabolic and signaling pathways and may thus be involved in 
several diseases.  
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2. Preface 
This thesis is divided into three chapters comprising the projects I was involved in. In the first chapter, the 
characterization of several synthetic and natural compounds inhibiting 11β-hydroxysteroid 
dehydrogenases (11β-HSDs) is described.  Such inhibitors are of potential therapeutic interest; however, 
their potential for unwanted side-effects has to be carefully investigated and other members of the family 
of short-chain dehydrogenases (SDRs) including DHRS7 should be considered in the assessment. The 
first chapter contains two published studies, one where I share first authorship and one where I am co-
author. The second chapter describes a project in healthy humans, where the effects of 3, 4-
methylendioxymethamphetamine (MDMA) and methylphenidate (MPH) on circulating steroid levels were 
investigated. In this project I gained deeper insights into the method of liquid chromatography–mass 
spectrometry (LC-MS/MS) for the quantification of steroids in clinical samples. This method was later used 
to search for possible substrates of DHRS7. The second chapter contains a study published in the journal 
of Neuroendocrinology.  The final chapter focusses on my main project, the investigation of the “orphan” 
SDR DHRS7. The results of my experiments provide the first evidence for a role of DHRS7 as a tumor 
suppressor.  This chapter contains a paper submitted to the International Journal of Cancer.   
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3. Chapter 1: Characterization of novel inhibitors of 11β- 
Hydroxysteroid dehydrogenases 
Introduction 
The 11β-hydroxysteroid dehydrogenases (11β-HSDs) belong to the short-chain 
dehydrogenases/reductases (SDRs), one of the largest enzyme superfamilies, with members identified in 
all life forms. More than 70 different SDRs are found in humans [2]. Although sequence identity between 
SDRs is relatively low (15–30%), several motifs are typical for these enzymes, such as the cofactor 
binding motif TGxxxGxG and the active center motif YxxxK [3]. SDRs share common three-dimensional 
structures, such as the Rossmann-fold, a structural motif containing a parallel 7 stranded β-sheet 
surrounded on both sides by α-helices that forms the cofactor 
binding site and is located at the N-Terminus (Figure 1) [4]. SDRs 
have a co-factor preference for nicotinamide adenine dinucleotide 
(H) (NAD(H)) or nicotinamide adenine dinucleotide phosphate (H) 
(NADP(H)). SDRs catalyze the oxidation and reduction of a wide 
variety of substrates including sugars, steroids, retinoids, fatty acids 
and xenobiotics [5]. Several members of this protein family, for 
example 11β-HSD1 are not restricted to one substrate but exhibit 
multifunctionality [6]. 
Due to their broad spectrum of substrates and their pivotal role in the 
regulation of different metabolic and signaling pathways, 
dysfunctional SDR enzymes can lead to the progression of several 
diseases such as Alzheimer's disease, cancer and obesity-related 
medical conditions [7-9]. Therefore, drugs and xenobiotics targeting 
SDRs might result in adverse effects. However, some specific SDR members like 11β-HSD1 are 
considered to be promising pharmacological drug targets [10].   
11β-HSD1 is expressed in key metabolic tissues including skeletal muscle, liver and adipose tissue [11, 
12]. 11β-HSD1 is strongly associated with the development of obesity, type 2 diabetes, hypertension and 
the metabolic syndrome [13, 14]. Although the enzyme functions bidirectional, the main reaction catalyzed 
by 11β-HSD1 is the NADPH-dependent reduction of cortisone to the active steroid hormone cortisol. 
Cortisol is a glucocorticoid synthesized and released from the adrenal cortex in accordance with a strong 
circadian rhythm. Secretion of glucocorticoids is under the control of the hypothalamic pituitary adrenal 
(HPA) axis. After glucocorticoids enter the cell, by free diffusion through the cell membrane, they can be 
metabolized and the active form, cortisol, can bind to the ligand binding domain of the glucocorticoid 
Figure 1: classical SDR structure; 
Rossmann-fold motif is depicted 
with beta strands in blue and 
helices in red; additional domains 
and secondary structural elements 
are shown in grey [1]. 
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receptor (GR) (Figure 2). Binding of cortisol to GR leads to conformational changes, receptor dimerization 
and activation of the receptor complex. The “activated” receptor then interacts in the nucleus with critical 
regulatory sites of genes [15]. The transcription of genes controlling immune response, metabolism and 
development is triggered either directly by binding of the GR to the promotor region of a gene or indirectly 
by the interaction of the GR with other transcription factors [16]. 
 
 
Figure 2: Schematic representation of mechanisms of GR-dependent gene transcription. Glucocorticoids are 
free to cross the plasma membrane where they can be metabolized by 11β-HSD1/2. Upon binding with 
cortisol, the GR translocates into the nucleus and modulates gene transcription [modified after [14] using 
Servier Medical Art software (www.servier.com)] 
 
In the last decade, interconversion of active and inactive glucocorticoids by 11β-HSDs emerged as a key 
regulatory mechanism of glucocorticoid action [17]. Thus, studies showed that specific 11β-HSD1 
inhibitors decrease local cortisol availability and improve insulin sensitivity, glucose tolerance, lipid levels 
and atherosclerosis via indirect antagonism of the GR [18, 19]. At present, there are several clinical trials 
ongoing, using 11β-HSD1 inhibitors in patients with metabolic syndrome, type 2 diabetes and 
cardiovascular disease [20]. The need for selective isozyme inhibitors is important, since the inhibition of 
11β-HSD2 results in sodium and water retention, elevated blood pressure and hypokalemia [21]. 11β-
HSD2 is a NAD+-dependent dehydrogenase that acts unidirectional, catalyzing the oxidation of cortisol to 
its inactive metabolite cortisone. This isozyme is mainly expressed in mineralocorticoid target tissues such 
as the kidney and colon, where it prevents inappropriate activation of the mineralocorticoid receptor (MR) 
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by cortisol. Cortisol has been shown to possess binding affinities comparable to that of the physiologic 
mineralocorticoid aldosterone to the MR [22]. Compounds inhibiting 11β-HSDs non-selectively promote 
MR activation, which has been linked with the pathogenesis of cardiovascular disease in several clinical 
studies [23]. On the other hand, MR antagonists showed promising results in the treatment of chronic 
kidney disease and diabetic nephropathy [24, 25]. Although inhibition of 11β-HSD2 needs to be avoided in 
most cases, it was recently suggested that 11β-HSD2 inhibitors may be useful to treat chronic 
hemodialysis patients by increasing potassium loss as a result of cortisol-induced MR activation in the 
colon [26]. Furthermore, the inhibition of 11βHSD2 showed a suppression in Cyclooxygenase-2 (COX-2) 
driven prostaglandin E2 production and colorectal tumor growth without any obvious adverse side effects 
in human [27]. These studies support the hypothesis that 11β-HSD2 inhibition may be a promising 
therapeutic target, specifically with locally acting enteric inhibitors that are neither systemically absorbed 
nor influencing renal 11β-HSD2 [28]. 
The first study of this chapter examined the effect of the oleoresin mastic gum and its constituents, 
isolated from Pistacia lentiscus var. chia, on 11β-HSD1 and 2 activities performed in collaboration with Dr. 
A. Assimopoulou, Dr. D. Schuster and coworkers. Pistacia lentiscus is an evergreen tree of the 
Anacardiaceae family, which is common in the eastern Mediterranean area. The variety chia, commonly 
known as mastic tree, is uniquely cultivated in southern Chios, a Greek island in the Aegean [29]. The 
oleoresin of mastic consists of nearly 70 constituents and has been linked to numerous diverse biomedical 
and pharmacological characteristics, including destruction of bacteria and fungi, reduction of symptoms of 
autoimmune diseases like Crohn's disease and asthma, protection of the cardiovascular system, induction 
of apoptosis in human cancer cells and improvement of symptoms in patients with functional dyspepsia 
[30]. However, many of the potential medical and pharmaceutical properties of mastic gum have only been 
shown in vitro or in animal models. Studies performed in humans, testing mastic gum, are mostly 
subjective and have contradictory outcomes. Therefore, further research is required to evaluate the 
potential effects of mastic gum. Recently, mastic gum also showed antidiabetic effects in mice in vivo but 
the exact mechanism remains unknown [31]. However, peroxisome proliferator-activated receptor (PPAR) 
modulation was discussed as possible mechanism [32]. Glucocorticoid metabolism may also be a possible 
target of this plant extract.  Dr. A. Vuorinen applied a pharmacophore-based virtual screening to filter a 
natural product database for 11β-HSD1 selectivity. The two main constituents of mastic gum, the 
triterpenoids masticadienonic acid and isomasticadienonic acid were predicted to bind 11β-HSD1. To 
support these findings, I performed activity assays for 11β-HSD1 and 2 in cell lysates to test the effect of 
oleoresin, the acidic fraction and the purified triterpenic acids; masticadienonic acid and 
isomasticadienoinic acid. The major constituents of the acidic fraction includes; the triterpenic acids 
oleanonic acid, masticadienonic acid as well as isomasticadienoinic acid. 
The second study of this chapter focused on the effect of progesterone and a selection of its metabolites, 
on the activity of the MR and the 11β-HSDs, since they have been reported to bind to these enzymes [33, 
34]. This study was performed in collaboration with Prof. Dr. JC Vederas and coworkers. A previous study 
showed that the progesterone derivative, 11β-hydroxyprogesterone triggered the activation of MR in vitro 
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and inhibited 11β-HSD1 with an IC50 value of 65 nM in vitro [34]. However, 11β-hydroxyprogesterone was 
an equally potent inhibitor of 11β-HSD2 activity in whole cell preparations, with an IC50 value of 0.2 μM 
[35, 36]. In this study, I further evaluated the inhibiting potential of progesterone derivatives on 11β-HSD1 
as well as their specificity to inhibit the dehydrogenase reactions and assessed their ability to bind to the 
MR. Due to high lipophilicity, progesterone possesses low water solubility and hence low bioavailability. 
Therefore, chemical modifications need to be introduced to improve these parameters [37].  To overcome 
this problem aminosteroids and amino acid–steroid conjugates are commonly prepared [38]. Following the 
successful synthesis of several 11β-amino and amino acid progesterone derivatives by Dr. K. Pandya, I 
tested 17 compounds for their potential to inhibit 11β-HSD1 and 11β-HSD2, as well as for their ability to 
modulate MR transcriptional activity.  
Results and Discussion 
The aim of the first study described in this thesis was to investigate the effect of four different constituents 
of mastic gum on 11β-HSD1 and 2 in cell lysates in vitro.  To evaluate the selective inhibiting potential of 
the resin, acidic fraction, masticadienonic acid and isomasticadienonic acid on 11β-HSD1 and 11β-HSD2 
a screening was performed at a high concentration, prior to IC50 measurements (Figure 3).  
 
Figure 3: Conversion of radio labeled cortisone by 11β-HSD1 and cortisol by 11β-HSD2. DMSO served as 
vehicle control and glycyrrhetinic acid (1 µM) as positive control. Data of three independent experiments was 
normalized to vehicle control and expressed as mean ± SD. 
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 All constituents tested showed inhibiting potential and selectivity for 11β-HSD1 in HEK293 cell lysates, 
thereby supporting the hypothesis generated by the pharmacophore-based virtual screening model. 11β-
HSD2 was not inhibited by any plant constituent, illustrating the selectivity of the compounds. 
Following the screening, I determined the IC50 values for each of the tested constituents (Figure 4 in the 
publication).  The resin, which contains all the triterpenoids, showed the highest inhibitory potential with an 
IC50 of 1.33 µg/µL.  The plant constituents are known to have effects which improve human health [39]. 
The anti-inflammatory activity of mastic gum for example has been mainly attributed to triterpenoids [40]. 
Interestingly, purified isomasticadienonic acid gave an IC50 of 1.94 μM. This constituent was also 
reported to be the most active purified compound with respect to the anti-inflammatory action of mastic gum 
in vitro [40]. Compared to oleanonic acid, a main constituent of the acidic fraction of mastic gum, which 
has been shown to inhibit 11β-HSD1 with high nanomolar IC50 values, the inhibiting potential of 
masticadienonic acid and isomasticadienonic acid is rather low. In summary, I observed for all the tested 
mastic constituents selectivity for 11β-HSD1 over 11β-HSD2 in vitro with low micromolar IC50 values. 
 
 
Figure 4:  IC50 of 11β-HSD2 incubated with progesterone derivatives (Lysates of HEK293 cells expressing 
recombinant 11β-HSD2 were incubated 10 min at 37 °C in the presence of 50 nM cortisol and 500 µM NAD+, 
followed by determination of amount of product formed). Results represent mean ± SD and are derived from 
three independent experiments. 
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However, 11β-HSD1 inhibitors have already been developed by several pharmaceutical companies and 
most of the compounds have high selectivity for 11β-HSD1 over 11β-HSD2 in the low nanomolar range 
[41]. Clinical studies showed that 11β-HSD1 inhibitors are safe and novel agents for the treatment of type 
2 diabetes and metabolic syndrome. Nevertheless, the adverse effects of mastic gum should be evaluated 
before pharmaceutical use, since the plant extract has been linked to allergic contact dermatitis in humans 
and increased liver weight in rats [42, 43]. An evaluation of risk-benefit effect of mastic gum compared to 
other drugs needs to be carried out to validate its potential as a pharmaceutical product. Additionally, 
possible adverse effects, such as the effect of 11β-HSD1 inhibition on the innate immune response or the 
negative feedback to the HPA axis, will require careful monitoring during clinical development. In addition, 
the homology between 11β-HSD1 and other enzymes of the SDR family might lead to non-selective 
effects [44]. For example, inhibition of the 17β-HSDs may affect sex steroid metabolism and therefore 
cause abnormalities [45]. Non-Selective inhibition of “orphan” SDR DHRS7, identified as a tumor 
suppressor in this thesis, is also critical, since it may increase the aggressive potential of cells, which may 
aid cancer progression. Besides the side effects, the response of the patients is important for the use of 
11β-HSD1 inhibitors in therapy. In several phase II studies the response has been observed as 
heterogeneous and therefore requires the development of pharmacodynamic biomarkers to identify likely 
‘responders’ [45]. Nevertheless, the potential of mastix gum to inhibit 11β-HSD1 may in combination with 
other mechanisms, contribute to the antidiabetic and anti-inflammatory effects of mastic gum [30]. To 
evaluate new molecular mechanisms and the pharmacological synergy between several compounds 
associated with the effects of mastic gum further experiments need to be performed. In the second study, 
the effects of 11β-aminoprogesterone derivatives were evaluated in cell lysates in vitro. In contrast to the 
mastic gum project this study focused on the inhibition of 11β-HSD2 and MR transactivation. Six of the 
tested progesterone derivatives showed selective inhibition of 11β-HSD2 over 11β-HSD1 in a preliminary 
screening (Figure 2 in the publication). While all compounds showed low micromolar IC50 values, the 
highest inhibiting potential was obtained for compound 3, which showed an IC50 of 2.2 µM (Figure 4). 
Compared to glycyrrhetinic acid, which is a nonselective inhibitor for 11β-HSD isozymes but exhibits an 
IC50 of 30 nM for 11β-HSD2 in HEK293 lysates, the newly synthetized compounds have weak inhibiting 
potential, though possess greater binding to 11β-HSD2 over 11β-HSD1 [46]. 
This study forms a basis for the development of 11β-aminoprogesterone derivatives, which possess more 
selective effects on 11β-HSD2 effects compared to their lead compound progesterone and thus may have 
positive effects in hemodialysis patients suffering from hyperkalemia or in patients with colon cancer. 
Improvement of the inhibitory potential may be achieved by the modulation of side groups. To ensure the 
inhibition of 11β-HSD2 in patients and avoid possible side effects occurring with MR targeting in the 
kidney, it would be an asset if newly designed compounds act locally in the gastrointestinal tract. Further 
studies in vitro and in vivo need to be performed to accentuate the potential of 11β-aminoprogesterone 
derivatives. 
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 Publication: Selective inhibition of 11β-HSD1 by masticadienonic acid and 
isomasticadienonic acid – constituents of Pistacia lentiscus oleoresin as 
promising antidiabetic drugs 
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Abstract
!
In traditional medicine, the oleoresinous gum of
Pistacia lentiscus var. chia, so-called mastic gum,
has been used to treat multiple conditions such
as coughs, sore throats, eczema, dyslipidemia,
and diabetes. Mastic gum is rich in triterpenes,
which have been postulated to exert antidiabetic
effects and improve lipid metabolism. In fact,
there is evidence of oleanonic acid, a constituent
of mastic gum, acting as a peroxisome prolifera-
tor-activated receptor γ agonist, and mastic gum
being antidiabetic in mice in vivo. Despite these
findings, the exact antidiabetic mechanism of
mastic gum remains unknown. Glucocorticoids
play a key role in regulating glucose and fatty acid
metabolism, and inhibition of 11β-hydroxyste-
roid dehydrogenase 1 that converts inactive corti-
sone to active cortisol has been proposed as a
promising approach to combat metabolic distur-
bances including diabetes. In this study, a phar-
macophore-based virtual screening was applied
to filter a natural product database for possible
11β-hydroxysteroid dehydrogenase 1 inhibitors.
The hit list analysis was especially focused on the
triterpenoids present in Pistacia species. Multiple
triterpenoids, such as masticadienonic acid and
isomasticadienonic acid, main constituents of
mastic gum, were identified. Indeed, masticadie-
nonic acid and isomasticadienonic acid selec-
tively inhibited 11β-hydroxysteroid dehydrogen-
ase 1 over 11β-hydroxysteroid dehydrogenase 2
at low micromolar concentrations. These findings
suggest that inhibition of 11β-hydroxysteroid de-
hydrogenase 1 contributes to the antidiabetic ac-
tivity of mastic gum.
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l.Introduction
!
Pistacia lentiscus var. chia (Anacardiaceae family)
is a tree that grows exclusively on the Greek is-
land Chios. It is mainly exploited for its oleoresin-
uous gum, the so-called mastic gum [1]. This
oleoresin is harvested in a traditional way by lon-
gitudinal incisions from the tree as tears or drop-
lets, although an alternative technique called liq-
uid collection has also been applied. In the latter
method, the stimulating agent ethrel is used for
resin excretion after incision of the tree to in-crease the mastic gum productivity. The gum har-
vested by this liquid method is produced in fluid
form and has a characteristic odor [2]. In addition
to controling cholesterol levels and combating
diabetes, the oleoresin has been used for centu-
ries against coughs, sore throats, eczema, stom-
achaches, kidney stones, pain, and rheumatism
[3].
The medicinal effects of P. lentiscus are proposed
to be caused by the secondary metabolite triter-
penes that are found at high concentrations in
both the acidic and neutral fractions of PistaciaVuorinen A et al. Pistacia lentiscus Oleoresin:… Planta Med
Fig. 1 Main constituents of P. lentiscus oleoresin
(mastic gum).
Fig. 2 Interconversion of cortisone to cortisol and
vice versa by 11β-hydroxysteroid dehydrogenases.
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l.oleoresins. Generally, the triterpenes are derivatives from 11
skeletons: Δ12-oleanene, Δ18-oleanene, 28-nor-Δ17-oleanene,
Δ7-tirucallene, 24,25-dehydro-Δ7-tirucallene, Δ8-tirucallene,
24,25-dehydro-Δ8-tirucallene, dammarane, lupane, lupene, and
Δ12-lupene [2]. The concentrations of different triterpenes vary
with Pistacia species and the resin harvest method. The resin
from P. lentiscus var. chia was found to contain 36 triterpenes
when harvested in a traditional way and in the case of liquid har-
vesting, 26 different triterpenes were found [4]. The main con-
stituents in both harvest methods are isomasticadienonic acid,
masticadienonic acid, and 28-norolean-17-en-3-one (l" Fig. 1).
In traditional medicine, mastic gum has been used against diabe-
tes, a complex condition where the organism does not respond
normally to the absorbed glucose. This is caused either by de-
creased insulin production (type 1 diabetes) or by insulin resis-
tance, impaired glucose intake, and gluconeogenesis (type 2 dia-
betes), leading to elevated blood glucose levels [5]. ModernWest-
ern medicine combats diabetes by direct insulin injections, insu-
lin sensitizing therapy, or enhancing the insulin secretion. Except
for direct insulin injections, the treatment of diabetes involves
multiple targets that play a role in glucose intake, gluconeogene-
sis, insulin sensitivity, and insulin secretion [5]. Among these tar-
gets is PPARγ, which enhances insulin sensitivity and fatty acid
storage upon activation [6]. In fact, oleanonic acid, a constituent
of mastic gum, has been shown to activate PPARγ [7]. An in vivo
study in rats indicated that daily consumption of mastic gum re-
sulted in a 40% decrease of blood glucose levels in high-fat diet-
fed rats that also received streptozotoxin injection according to a
protocol that induced diabetes II [8]. In addition, the administra-
tion of mastic gum decreased blood glucose levels and improved
serum fatty acid levels in diabetic mice [9]. Nevertheless, it is
likely that these effects are not only mediated through PPARγ.
Thus, to understand the in vivo effects of mastic gum, the com-
pounds involved and the underlying mechanisms need to be ex-
plored.Vuorinen A et al. Pistacia lentiscus Oleoresin:… Planta MedOne possible explanation for the antidiabetic effects of mastic
gum could be an interference with glucocorticoid metabolism.
Glucocorticoids regulate carbohydrate and fat metabolism by de-
creasing glucose uptake and utilization, as well as increasing glu-
coneogenesis in the liver [10]. By affecting lipolysis and fat distri-
bution, glucocorticoids are associated with the development of
dyslipidemia that is often related to type 2 diabetes, metabolic
disorders, and Cushingʼs syndrome. Glucocorticoids act via GRs
and MRs, and their intracellular, pre-receptor concentrations are
dependent on 11β-HSDs (l" Fig. 2) [11]. 11β-HSD1 converts corti-
sone to its active hydroxyl derivative cortisol. This enzyme uses
NADPH as a cofactor and the limiting factor of its cortisone-re-
ducing activity is the coexpression with H6PDH that regenerates
NADPH from NADP+ [12,13]. Therefore, in vivo, 11β-HSD1 acts
predominantly as a reductase. In contrast, 11β-HSD2 is an NAD+-
dependent dehydrogenase responsible for the oxidative inactiva-
tion of cortisol to cortisone [14]. 11β-HSD1 is highly expressed in
the liver, adrenals, adipose tissue, and skeletal muscles [15],
whereas 11β-HSD2 is found in the kidneys, colon, and placenta
[11,16].
Since circulating cortisol levels (corticosterone in rodents) affect
glucose and lipid metabolism, 11β-HSD1 is considered a promis-
ing intervention point to treat type 2 diabetes and metabolic dis-
orders [17,18]. In fact, this hypothesis is supported by biological
data; the overexpression of 11β-HSD1 in adipose tissue in mice
has been shown to cause visceral obesity, hyperglycemia, insulin
resistance, and increased serum fatty acid and triglyceride levels
[19]. Additionally, high corticosterone concentrations found only
in the liver do not cause obesity or central adiposity, but instead
cause steatosis, dyslipidemia, hypertension, and mild insulin re-
sistance [20]. 11β-HSD1 knockout mice were shown to have an
increased adrenal corticosterone production as a result of the im-
paired hepatic regeneration of active glucocorticoids, and they
resisted obesity- or stress-related hyperglycemia [21]. Moreover,
11β-HSD1 inhibitors have been shown to improve several meta-
Fig. 3 Pharmacophore models for 11β-hydroxysteroid dehydrogenase 1 in-
hibition. The original model (A), intermediate refinedmodel (B), and the final
refined model that was used for virtual screening (C). The pharmacophore
features are color-coded: hydrophobic – cyan, hydrogen bond donor –ma-
genta, hydrogen bond acceptor – green, shape – gray. (Color figure available
online only.)
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l.bolic parameters as well as atherosclerosis in mice by decreasing
aortic lesions [17,22]. Thus, 11β-HSD1 inhibitors constitute a
promising way to treat metabolic syndrome and type 2 diabetes
in rodent models. However, when inhibiting 11β-HSD1, selectiv-
ity over 11β-HSD2 is important to avoid adverse effects such as
severe hypokalemia, hypertension, edema formation, and renal
enlargement, which are all consequences of cortisol-dependent
MR activation [23].
There is a large number of known 11β-HSD1 inhibitors, mostly
small synthetic chemicals [24–26]. In addition, compounds from
natural origin have been shown to inhibit 11β-HSD1. Most of
these natural compounds are triterpenes, such as corosolic acid,
ursolic acid, glycyrrhetinic acid, and its derivatives [27,28]. Be-
cause mastic gum is rich in triterpenes, the inhibition of 11β-
HSD1 could be one explanation for the observed antidiabetic ef-
fects of mastic gum. To test this hypothesis, a virtual screening
campaign to search for 11β-HSD1 inhibitors from natural origin
was launched. In virtual screening, a database of compounds is
filtered to match the query requirements, and it has been consid-
ered a suitable tool for setting biological testing priorities also in
the natural products field [29,30]. One common way to perform
virtual screening is the pharmacophore-based method. In this
method, pharmacophore models representing the 3D arrange-
ment of those electrostatic and steric functionalities that make
the small molecule active towards its target protein [31] are used
as a filter. Pharmacophore models consist of features such as hy-
drogen bond acceptor (HBA)/hydrogen bond donor (HBD), hy-
drophobic areas (H), aromatic rings (AR), positively ionizable (PI)
and negatively ionizable (NI) groups, as well as metal binding
areas (M). Exclusion volumes (XVOLs) – forbidden areas – or a
shape can be added to mimic the size and the shape of the bind-
ing pocket or active ligands. The result of a virtual screening is a
so-called hit list that contains those compounds which chemical
functionalities match with the features of the query pharmaco-
phore. These compounds are predicted to be active towards the
target.
To support drug development and to discover new 11β-HSD1 in-
hibitors, a pharmacophore model for 11β-HSD1 inhibition has
been developed and reported [32]. This pharmacophore model
consisted of six chemical features: four Hs, one HBA, one HBD,
and a shape (l" Fig. 3A). The model was theoretically and experi-
mentally successfully validated and used for virtual screening
campaigns. However, during the recent years, new 11β-HSD1 in-
hibitors have been rapidly reported, and the pharmacophore
model needed improvement to ensure the best performance.Therefore, it was refined according to the newly published 11β-
HSD1 inhibitors to better represent the current state of knowl-
edge. First, the HBD function of the original model was ex-
changed with an HBA, and the shape restriction was removed
(l" Fig. 3B). However, this model was not very restrictive, and
therefore, as a further refinement step, a new shape restriction
was added (l" Fig. 3C) [33]. This refinedmodel, whichwas named
model 4new in its original publication [33], was employed for the
virtual screening of a natural compound database to test the
theory of P. lentiscus oleoresin constituents as 11β-HSD1 inhib-
itors prior to in vitro testing.Results
!
In order to search for natural compounds with antidiabetic activ-
ity, especially focusing on the constituents of P. lentiscus, a phar-
macophore-based virtual screening of the DIOS natural product
database was performed. The DIOS database is an in-house data-
base comprising 9676 secondary metabolites from 800medicinal
plants described by Dioscorides in his De Materia Medica [34].
The refined 11β-HSD1 model (l" Fig. 3C) returned 305 hits from
the virtual screening. The hit list contained 155 terpenes, includ-
ing 96 triterpenes, among which 27 were from Pistacia species
and 8 were P. lentiscus constituents (l" Fig. 4). Other frequent
classeswere lipids and flavonoids with 30 and 28 compounds, re-
spectively. Mostly, the triterpenes present in Pistacia species
were derivatives of masticadienonic and isomasticadienonic ac-
ids. The focus of the biological evaluation was set on the whole
resin, its acidic fraction containing mainly the above triterpenes,
and on purified compounds. Among the eight virtual hits ob-
tained from the species P. lentiscus, almost all of them belong to
the acidic fraction that was isolated from P. lentiscus var. chia
oleoresin. The two main constituents masticadienonic acid and
isomasticadienonic acid were chosen for biological evaluation.
The other virtual hits, masticadienolic acid and oleanolic acid,
have previously been reported as constituents of P. lentiscus var.
chia [35]; however, they were not detected in the resin batch that
was used for biological evaluation [4] and could therefore not be
tested. The remaining four hits were excluded because these
were not constituents of the P. lentiscus var. chia, although they
were commonly found in P. lentiscus L.
After harvesting and isolating the substances of interest, their in-
hibitory activity against 11β-HSD1 and 11β-HSD2 was tested in
lysates of cells expressing the corresponding recombinant humanVuorinen A et al. Pistacia lentiscus Oleoresin:… Planta Med
Fig. 4 P. lentiscus constituents found by virtual screening.
Fig. 5 Activities of P. lentiscus var. chia oleoresin,
acidic fraction, masticadienonic, and isomastica-
dienonic acids in lysed cells expressing 11β-hy-
droxysteroid dehydrogenase 1.
Vuorinen A et al. Pistacia lentiscus Oleoresin:… Planta Med
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Fig. 6 Predicted bind-
ing orientations of mas-
ticadienonic and iso-
masticadienonic acids
in the 11β-hydroxyste-
roid dehydrogenase 1
ligand binding site.
Masticadienonic acid
(red) and isomastica-
dienonic acid (green)
occupy the same space
in the binding pocket
compared to the coc-
rystallized ligand carbe-
noxolone (gray) (A).
Masticadienonic acid
(B) was anchored to the
binding pocket with hy-
drophobic interactions,
hydrogen bonds with
Leu217, whereas iso-
masticadienonic acid
(C) forms an additional
hydrogen bond with
the cofactor NADPH.
Hydrophobic interac-
tions are shown as yel-
low spheres and hydro-
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l.enzyme. All four probes, the oleoresin, the acidic fraction of the
gum, masticadienonic acid, and isomasticadienonic acid dose-
dependently inhibited 11β-HSD1 (l" Fig. 5), but, importantly, not
11β-HSD2 (data not shown). As expected, the oleoresin that con-
tained all the triterpenes turned out to be a potent 11β-HSD1 in-
hibitor with an IC50 value of 1.33 µg/mL, whereas the acidic frac-
tion, containing all the acidic triterpenes, had an IC50 of 2.10 µg/
mL. Masticadienonic acid and isomasticadienonic acid had IC50
values of 2.51 µM and 1.94 µM, respectively. In contrast, the non-
selective reference compound glycyrrhetinic acid inhibited 11β-
HSD1 and 11β-HSD2 with IC50 values of 0.68 ± 0.17 µM and
0.26 ± 0.07 µM, respectively, in line with previously published da-
ta [28].
To evaluate how masticadienonic acid and isomasticadienonic
acid bind to 11β-HSD1 and to estimate their mechanism of ac-
tion, they were docked into the respective binding pocket. Both
of them aligned well with each other and with the cocrystallized
ligand carbenoxolone (l" Fig. 6A). They did not form hydrogen
bonds with the catalytic residues, but occupied the binding site,
thus preventing the natural ligand from binding. Masticadie-
nonic acid was anchored to the binding site with hydrophobic in-
teractions andwith a hydrogen bondwith the backbone nitrogen
of Leu217 (l" Fig. 6B). Isomasticadienonic acid was proposed to
bind similarly to the binding pocket, but it also formed a hydro-
gen bond with the cofactor NADPH (l" Fig. 6C).gen bonds as red ar-
rows. The catalytic triad
Ser-Tyr-Lys, the cofac-
tor, and Leu217 are de-
picted in ball-and-stick
style. (Color figure
available online only.)
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In this study, a pharmacophore-based virtual screening of the
natural compound database DIOS was performed. As a virtual
screening filter, a previously published and refined pharmaco-
phore model for 11β-HSD1 inhibitors was used. The model suc-
cessfully recognized triterpenes, from which the majority was
from Pistacia species. The biological evaluation of the mastic
gum oleoresin and its constituents supported the hypothesis of
11β-HSD1 being one of the targets involved in the antidiabetic
activity of mastic gum. To support the biological findings, binding
orientations for masticadienonic acid and isomasticadienonic ac-
id were predicted. The predicted binding modes were compared
with corosolic acid (docking studies reported by Rollinger et al.
[27]) and the cocrystallized ligand carbenoxolone. Isomasticadie-
nonic and masticadienonic acids did not have the similar flipped
binding orientation predicted for corosolic acid. However, their
binding orientations and observed hydrogen bonds with Leu217
and the cofactor as well as the hydrophobic interactions are com-
parable with those of carbenoxolone. Therefore, masticadienonic
and isomasticadienonic acids are suggested to act as competitive
11β-HSD1 inhibitors, like carbenoxolone.
The findings of this study show that the oleoresin of P. lentiscus
(mastic gum), and especially masticadienonic and isomasticadie-
nonic acids, target 11β-HSD1, which may contribute to a lowered
blood glucose and improved serum fatty acids concentrations
that have been observed in earlier reports on the treatment of di-
abetic mice with mastic gum [9]. Moreover, moronic acid, one of
the triterpenes present in mastic gum [4], has been shown to ex-
ert antihyperglycemic properties in rats and to be a weak 11β-
HSD1 inhibitor in vitro (22% enzyme inhibition at the concentra-
tion of 10 µM) [36]. Other triterpenes with a Δ12-oleanene skel-
eton, such as oleanolic acid, which was also found as a virtual hit,
and its derivatives, have been proven to inhibit 11β-HSD1 with
high nanomolar IC50 values [37]. However, the activity of olea-nonic acid, a mastic gum constituent, is to the best of our knowl-
edge unknown.
There are several studies reporting natural compounds as 11β-
HSD1 inhibitors with the potential to be antidiabetic drugs.
Nevertheless, most of them, like glycyrrhetinic acid and curcu-
min, also inhibit 11β-HSD2 and may therefore not be suitable for
diabetes treatment [38,39]. Other compounds like flavonone and
its derivatives selectively inhibited 11β-HSD1, however, they are
rather weak inhibitors [40].
Several constituents of mastic gum acting on the same or differ-
ent targets could provide an explanation for the antidiabetic ac-
tions of mastic gum, such as masticadienonic, isomasticadie-
nonic, and moronic acids inhibiting 11β-HSD1, as well as olea-
nonic acid activating PPARγ. However, of these compounds, mas-
ticadienonic and isomasticadienonic acids are the most potent,
experimentally confirmed 11β-HSD1 inhibiting constituents
frommastic gum. In addition, at a concentration of 200 µM, olea-
nonic acid caused a 13-fold activation of PPARγ, whereas masti-
cadienonic and isomasticadienonic acids inhibited 50% of the
11β-HSD1 activity at concentrations of about 2 µM. Based on the
previously performed quantification study using an GC‑MS tech-
nique, these two bioactive compounds (masticadienonic and iso-
masticadienonic acids) account for 3.4 and 8.9% w/w in mastic
gum oleoresin, respectively [4]. Thus, even at low mastic gum
concentrations, the pronounced 11β-HSD1 inhibition of these
two main constituents as well as probably further contributing
congeners may be the main reason for the oleoresinʼs antidia-
betic effects. However, it is currently not clear whether additionalVuorinen A et al. Pistacia lentiscus Oleoresin:… Planta Med
Original Paperstargets are also involved which warrant further studies on the
molecular mechanism of the constituents of this traditionally
used herbal remedy.
In addition to the explanation for the antidiabetic effects of mas-
tic gum, the findings of this study form an excellent basis for the
discovery of new 11β-HSD1 inhibitors from a natural origin. The
pharmacophore model has proven it is able to enrich active nat-
ural compounds from a large database by identifying masticadie-
nonic and isomasticadienonic acids as new selective 11β-HSD1
inhibitors from natural sources.D
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Virtual screening
For the virtual screening, the DIOS database was composed with
the Build 3D database tool of DiscoveryStudio 3.0 (2005–2010
Accelrys Software, Inc.). The database was generated with Best
settings and a maximum of 255 conformations per molecule.
The pharmacophore model for 11β-HSD1 inhibition was ob-
tained from our pharmacophore model collection. The detailed
pharmacophore generation and refinement were described by
Schuster et al. [32] and Vuorinen et al. [33]. Briefly, Schuster et
al. developed a ligand-based pharmacophore model for 11β-
HSD1 inhibitors. The model was trained to enrich the active sub-
stances from a set of active and inactive compounds, used for vir-
tual screening, and successfully experimentally validated. During
the last years, a vast number of new 11β-HSD1 inhibitors have
been developed, and the model needed refinement in order to
maintain a good predictive power. The final pharmacophore
model used in this present study is a refined version of the model
published by Schuster et al. The virtual screening of the DIOS da-
tabase was performed with the Search 3D database tool of Dis-
coveryStudio 3.0 (2005–2010 Accelrys Software, Inc.) with Best
settings.
Preparation of samples
P. lentiscus var. chia oleoresin collected traditionally (crude, large
tears) was kindly provided by the Mastic Gum Growers Associa-
tion (Chios, Greece). The acidic fraction (NaOH) of P. lentiscus var.
chia was isolated as described in [4] after fractionation of the
crude P. lentiscus var. chia oleoresin. Masticadienonic acid and
isomasticadienonic acid were isolated by semipreparative
HPLC‑DAD (Dionex summit – preparative HPLC system) from
the acidic fraction of P. lentiscus var. chia (as prepared above) as
described in [41]; their purity was determined by HPLC‑DAD also
as described in [41]. Their structures were identified by spectro-
scopic (1D and 2DNMR) and analytical methods (HPLC‑MS) (as
shown in [41]), and additionally by comparison with published
data [4]. All solvents used in this study were LC‑MS grade and
supplied by Merck.
Biological evaluation
Inhibition of 11β-HSD enzyme activity was performed as de-
scribed earlier [28]. HEK-293 cells stably expressing human 11β-
HSD1 or 11β-HSD2 were harvested by trypsination, followed by
centrifugation. The resulting cell pellets were frozen and stored
at − 80°C. For the experiments, cell pellets were suspended in
TS2 buffer (100mM NaCl, 1mM EGTA, 1mM EDTA, 1mMMgCl2,
250mM sucrose, 20mM Tris-HCl, pH 7.4), sonicated, and imme-
diately used for the activity assay. Cell lysates were incubated for
10min at 37°C in a final volume of 22 µL containing either ve-Vuorinen A et al. Pistacia lentiscus Oleoresin:… Planta Medhicle (0.2% methanol) or the corresponding inhibitor. Glycyrrhe-
tinic acid (Sigma-Aldrich, article G10105, 97% assay purity) was
used as a reference compound [28]. Inhibitors were diluted in
TS2 buffer from stock solutions (10mg/mL or 10mM in metha-
nol). To measure 11β-HSD1 activity, the reaction mixture con-
tained 200 nM [1,2-3H]cortisone and 500 µM NADPH. 11β-HSD2
activity was measured similarly at a final concentration of 50 nM
[1,2,6,7-3H] cortisol and 500 µM NAD+. Reactions were stopped
by adding an excess of unlabeled cortisone and cortisol (2mM
each, in methanol). Steroids were separated by TLC, followed by
scintillation counting and calculation of the substrate conversion
compared to the methanol control. Data were obtained from
three independent experiments.
Docking
Masticadienonic acid and isomasticadienonic acid were drawn
with ChemBioDraw Ultra 12.0 (1986–2010 CambridgeSoft), and
3D structures were obtained using PipelinePilot (2010 Accelrys
Software, Inc.). The X‑ray crystal structure of 11β-HSD1 was
downloaded from the PDB (www.pdb.org [42]). For 11β-HSD1,
the PDB entry 2 BEL [43] was chosen because it is cocrystallized
with carbenoxolone, a ligand that is structurally similar to the tri-
terpenoid mastic gum compounds. The docking was performed
using GOLD [44,45]. This program uses a genetic algorithm for
creating low-energy binding orientations for small molecules in-
to the binding pocket of a protein. The binding site was defined as
an 8 Å sphere, centered on the hydroxyl-oxygen of Ser170 (x
3.84; y 22.49; z 13.34). ChemPLP was selected as a scoring func-
tion, and the program was allowed to terminate the docking run
in case the three best-scored binding orientations were located
similarly in the binding site. To ensure acceptable ligand flexibil-
ity, the program was set to flip ring corners when exploring the
binding orientations. Atom types for the protein and for the lig-
and were defined by the program. These docking settings were
validated by redocking the original ligand, carbenoxolone, for a
correct reproduction of the bindingmode obtained by crystallog-
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11b-Hydroxyprogesterone is a well-known nonselective inhibitor of 11b-hydroxysteroid dehydrogenase
(11bHSD) types 1 and 2. It also activates the mineralocorticoid receptor (MR). Modulation of corticoste-
roid action by inhibition of 11bHSDs or blocking MR is currently under consideration for treatment of
electrolyte disturbances, metabolic diseases and chronic inﬂammatory disorders. We established condi-
tions to synthesize sterically demanding 11b-aminoprogesterone, which following subsequent nucleo-
philic or reductive amination, allowed extension of the amino group to prepare amino acid derivatives.
Biological testing revealed that some of the 11b-aminoprogesterone derivatives selectively inhibit
11bHSD2. Moreover, two compounds that did not signiﬁcantly inhibit 11bHSDs had antagonist properties
on MR. The 11b-aminoprogesterone derivatives form a basis for the further development of improved
modulators of corticosteroid action.
 2013 Elsevier Ltd. All rights reserved.H1. Introduction
Steroids play an important role in maintenance and regulation
of various physiological functions. Speciﬁcally, the corticosteroids
are essentially involved in the regulation of carbohydrate, lipid
and protein metabolism, inﬂammation, and maintenance of water
and electrolyte balance. Corticosteroids exert their effects mainly
through glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR). A chemical hallmark of the endogenous glucocorti-
coids is the existence of inactive 11-oxosteroids and active 11b-
hydroxysteroids that can be interconverted by 11b-hydroxysteroid
dehydrogenases (11bHSDs) (Fig. 1).1 Speciﬁcally, there are two iso-
forms, 11bHSD1 and 11bHSD2, that control tissue- and cell-speciﬁc
concentrations of active glucocorticoids. 11bHSD1 predominantly
catalyzes the reduction of oxosteroids to alcohols, while 11bHSD2
performs the reverse reaction.
Impaired corticosteroid action has been associated with cardio-
metabolic diseases such as hypertension, atherosclerosis, hyperlip-
idemia and diabetes as well as psychiatric disorders.2 Transgenic
mice overexpressing 11bHSD1 in adipose tissue develop all typicaldisturbances observed in metabolic syndrome.3 Mice overexpress-
ing 11bHSD1 speciﬁcally in the liver present with steatosis and
rather mild insulin resistance but without obesity.4 Based on these
and additional animal data and clinical observations, inhibition of
11bHSD1-mediated glucocorticoid activation emerged as a promis-
ing strategy to treat metabolic diseases, including type 2 diabetes,
hyperlipidemia, atherosclerosis and osteoporosis.
Since inhibition of 11bHSD2 in the kidney results in cortisol-in-
duced MR activation with sodium and water retention and hyper-
tension,5 11bHSD1 inhibitors used for treatment of metabolic
diseases need to be highly selective. Although inhibition of
11bHSD2 needs to be avoided for these applications, it was re-
cently suggested that 11bHSD2 inhibitors may be used to treat pa-
tients on hemodialysis in order to achieve potassium loss as a
result of cortisol-induced MR activation in the colon,6 and
several glycyrrhetinic acid derived 11bHSD2 inhibitors were
K. Pandya et al. / Bioorg. Med. Chem. 21 (2013) 6274–6281 6275reported.7–10 Due to frequent dialysis, sodium retention is limited
in these patients.
Some of the adverse cardio-metabolic effects of corticosteroids
are likely to be caused by increased activation of MR in cardiomyo-
cytes, adipocytes and macrophage.2 Excessive activation of MR by
aldosterone or cortisol induces detrimental cardiovascular effects,
and MR antagonists improved the morbidity and mortality of pa-
tients with myocardial infarction or heart failure.11–13 Further-
more, MR antagonists showed promising results in the treatment
of chronic kidney disease and diabetic nephropathy.14–16 Thus, sev-
eral pharmaceutical companies are currently developing novel MR
antagonists.
Progesterone and some of its metabolites have been reported to
bind to MR and inhibit 11bHSDs.17–19 In the present project, we
used 11a-hydroxyprogesterone as a starting point for the synthesis
of several 11b-aminoprogesterone derivatives with the goal to
identify potential 11bHSD inhibitors and MR antagonists. The lipo-
philicity of steroids has led chemists to introduce various chemical
modiﬁcations that can improve their water solubility and bioavail-
ability.20 Aminosteroids and amino acid–steroid conjugates are
commonly prepared to overcome these problems.21,22 In an effort
to obtain selective inhibitors of one of the 11bHSD isoforms, we
synthesized a small library of aminosteroid and amino acid–steroid
conjugates with the hopes of preparing inhibitors with improved
solubility and bioavailability. Based on previous inhibition studies
of 11b-hydroxyprogesterone (1a),23 we chose to introduce amino
and amino acid functionalities to the 11b-position of progesterone.
This class of molecules presents a synthetic challenge, as only
limited examples of 11b substituted progesterone derivatives ex-
ist.24–27 This is based on the steric demands that are introduced
by the rigid steroid backbone, as well as the angular methyl groups
attached to C10 and C13. Following the successful synthesis of
these 11b-amino and amino acid progesterone derivatives, they
were assessed for their potential to inhibit 11bHSD1 and 11bHSD2
as well as for their ability to modulate MR transcriptional activity.
2. Results and discussion
2.1. Synthesis
To access the sterically hindered 11b-aminoprogesterone back-
bone, we started from commercially available 11a-hydroxyproges-
terone (1b). Attempts to introduce the amino functionality via a
number of SN2-type displacement reactions were unsuccessful.
These include displacement via a Mitsunobu reaction with a
DNs-protected glycine nucleophile and the Mitsunobu reaction
with sodium azide as a nucleophile. In each of these cases the de-
sired 11b-substituted product was not observed, and the major
products isolated were a mixture of elimination products (these
compounds were not fully puriﬁed or characterized). Finally, we
followed the modiﬁed Mitsunobu protocol of Loibner and Zbiral28
to synthesize 11b-azidoprogesterone (Scheme 1). Treatment of
PPh3, diethyl azodicarboxylate and phenol with freshly prepared
hydrazoic acid29 and 11a-hydroxyprogesterone (1b) gave azido
product 2 in 42% yield. After several attempts at the reduction ofN3
O
HO
O
O
2
a
1a (11-β)
1b (11-α)
11
H H H
H H
Scheme 1. Synthesis of 11b-aminoprogesterone. (a) PPh3, diethyl azodicarboxylate,2, it was found that use of a cobalt–boride reduction system30,31
was optimal. Reduction of the azido species to provide 11b-amino-
progesterone (3) was achieved when 2 was reﬂuxed in a CoCl2–
NaBH4 mixture. It is important to note these conditions did not re-
duce the ketones at C3 or C20. Conﬁrmation of the 11b-amino sub-
stitution was obtained by X-ray crystallographic analysis
(Supplementary information). It should be noted that this repre-
sents an improved method to obtain this skeleton relative to that
previously reported.25,26
To add functionality to the amino steroid, we synthesized a ser-
ies of conjugates, as shown in Scheme 2. The glycine-functional-
ized derivative 5 was prepared by reaction of 3 with t-butyl
bromoacetate, followed by acidic hydrolysis of the t-butyl ester.
Alternatively, when 3 was treated with o-nosyl chloride, sulfony-
lated derivative 6 was obtained. Finally, we prepared the 3-(ethyl
2-hydroximino-propionate) derivative 7 by direct displacement
with the corresponding bromide 13.32
We propose that amino acid conjugates of steroids can provide
an important handle that can be further functionalized with a vari-
ety of pharmacophores, or to improve water solubility. While
derivatives 5 and 7 can provide this functionality, we also hoped
to prepare derivatives where the steroid served as a ‘side-chain’
to an a-amino acid. We attempted to prepare these derivatives
using protected a-amino acids bearing a leaving group at the b-po-
sition. In cases where the electrophile was not activated (b-bromo-
alanine), no product was observed. Also, 11b-aminoprogesterone
did not alkylate activated aziridines, which have been used in the
synthesis of lanthionine derivatives.33,34
These results led us to the conclusion that activated, sterically
unencumbered electrophiles, such as those used in the synthesis
of 4–7, are required to overcome the steric demand that the 11b-
aminoprogesterone skeleton provides.
To avoid the challenges of alkylation of 3, we decided to use a
reductive amination approach to increase the diversity of 11b-
aminoprogesterone (Scheme 3). When 3 was treated with enantio-
merically pure Garner’s aldehyde, in the presence of methanol, ace-
tic acid and NaCNBH3, the protected amino–alcohol functionalized
derivatives 8a or 8bwere obtained in 60% yield.35 It was found that
when this reaction was run for longer times (greater than 3–4 h),
epimerization at 20 was observed.
While cooler temperatures and shorter reaction times avoided
this problem the diastereomeric products could be separated fol-
lowing deprotection. The acetonide and Boc protecting groups of
8a or 8b were hydrolyzed in a warm solution of TFA and water
to give amino alcohols 9a and 9b.
To convert these amino alcohols to amino acids, we ﬁrst re-pro-
tected the amino group with Boc using standard conditions to yield
10a or 10b. Oxidation of these protected amino alcohols was suc-
cessfully achieved using Jones oxidation conditions. At this point,
any diastereomeric products that may have been generated during
the reductive amination could be readily separated by silica gel
chromatography. The ﬁnal amino acid products, which are in es-
sence c-N-alkylated 2,3-diaminopropionate (Dap) derivatives,
were obtained by TFA cleavage of the Boc protective group to give
amino acids 12a or 12b.O
H2N
O
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3
b
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H
phenol, THF, followed by HN3 and 1b (42%); (b) CoCl26H2O, NaBH4, H2O (62%).
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Scheme 2. Synthesis of amine substituted 11b-aminoprogesterone derivatives. (a)
t-Butyl bromoacetate, Bu4NI, K2CO3, MeCN (75%); (b) TFA, CH2Cl2 (89%); (c) o-NsCl,
pyridine, CH2Cl2 (61%); (d) 13, Bu4NI, K2CO3, MeCN (33%).
Table 1
Inhibition of 11bHSD1 and 11bHSD2 by progesterone derivatives
Compound IC50 [lM] (mean ± SD)
11bHSD1 11bHSD2
1a 1.16 ± 0.21 0.49 ± 0.06
1b 0.63 ± 0.13 0.40 ± 0.08
3 n.d. 2.20 ± 0.12
4 n.d. 2.41 ± 0.45
5 n.d. 2.69 ± 0.14
7 0.64 ± 0.21 1.05 ± 0.26
8b n.d. 5.85 ± 1.32
10b n.d. 4.21 ± 1.57
12b n.d. 6.76 ± 2.00
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Previous studies showed that 1a is a potent nonselective inhib-
itor of both 11bHSD enzymes.23,36 Morris et al. reported a more
pronounced inhibition of 11bHSD2 compared with 11bHSD1 dehy-
drogenase activity.23 Interestingly, using rat Leydig cells they ob-
served no inhibition of 11bHSD1 reductase activity. Galignana
et al. provided evidence that 1a is a substrate for both 11bHSD
enzymes.36
In the present study, we determined the inhibitory activity of 1a
and 1b and of derivatives of the latter against cortisone reduction
by human recombinant 11bHSD1 and cortisol oxidation by human
recombinant 11bHSD2 (Fig. 1, Table 1). Both 1a and 1b potently
inhibited 11bHSD1 reductase activity with IC50 of 1.16 ± 0.21 and
0.63 ± 0.13 lM, respectively, and 11bHSD2 dehydrogenase activity
with IC50 of 0.49 ± 0.06 and 0.40 ± 0.08 lM (Table 1). The novel
derivatives of 1b were then ﬁrst screened for 11bHSD inhibitionH2N
O
O
HN
O
N
O
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O
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c d
3 8a (2'R)8b (2'S)
2'
10a (2'R)
10b (2'S)
11
11
2'
H H H H
H H
H H
H
Scheme 3. Synthesis of c-substituted amino acid derivatives of 11b-aminoprogesterone
50 C; (c) Boc2O, NaHCO3, MeCN, H2O (78%, two steps); (d) Jones oxidant, acetone (39%at a concentration of 10 lM, and IC50 values were determined for
compounds showing more than 70% inhibition (Fig. 2).
Compound 7 with the 3-(ethyl 2-hydroximino propionate) side
chain was the only potent 11bHSD1 inhibitor with an IC50 of
0.64 ± 0.21 lM. However, 7 was not selective and also potently
inhibited 11bHSD2 with an IC50 of 1.05 ± 0.26 lM, thus resembling
the effect of the parental compound 1b.
In contrast to 11bHSD1, several of the 11b-amino derivatives
preferentially inhibited 11bHSD2, that is 3–5, 8b, 10b and 12b, in
the low micromolar range. Interestingly, the S stereoisomers of
compounds 8, 10 and 12 retained higher inhibitory activity com-
pared with the R forms. In summary, activity against 11bHSD2
can be retained with modiﬁcations at position 11 on the steroid
backbone. However, compared to 1a and the parental compound
1b these 11b-amino derivatives were less active. Nevertheless,
they provide a basis for the development of more potent
compounds.
In a next step, 1a and the 11b-aminosteroid derivatives were
tested for direct effects on MR transactivation activity using HEK-
293 cells expressing human MR and a galactosidase reporter gene
under the control of the MR sensitive MMTV promoter. The refer-
ence compound 1a, which has been reported earlier to activate MR
in transfected COS-7 cells with an EC50 of about 50 nM,18 showed
weak agonist activity in transfected HEK-293 cells with an EC50
of 14 ± 5 lM and, as observed previously in the COS-7 cell system,
did not act as antagonist.
Among the 11b-aminosteroid derivatives three compounds
were active. Compound 12a activated MR with an EC50 of
4.1 ± 1.2 lM but did not act as antagonist, whereas compounds 2
and 6 inhibited aldosterone-induced MR activation with IC50 ofO
HN
O
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. (a) (R)- or (S)-Garner’s aldehyde, MeOH, AcOH, then NaCNBH3 (60%); (b) TFA, H2O
); (e) TFA, CH2Cl2 (quant).
Figure 2. Preliminary inhibition screen of 11bHSD1 and 11bHSD2 by progesterone
derivatives at 10 lM. Lysates of HEK-293 cells expressing recombinant human
11bHSD1 or 11bHSD2 were incubated for 10 min at 37 C in the presence of 200 nM
cortisone and 500 lM NADPH to measure 11bHSD1 reductase activity or 50 nM
cortisol and 500 lM NAD+ to measure 11bHSD2 dehydrogenase activity, followed
by determination of the amount of product formed. Results (mean ± SD) are from
three independent experiments.
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nist. The reason for the differences in the sensitivity of COS-7 and
HEK-293 cells for MR activation remains unknown but may be ex-
plained by differences in the experimental procedure and/or the
ability of progesterone and its derivatives to enter the cell. Never-
theless, MR modulation by the three aminoprogesterone deriva-
tives 2, 6 and 12a was observed at lower concentrations than
that by the parental compound 1a, which has been shown to stim-
ulate sodium absorption in renal cortical collecting duct cells.18
Thus, future studies are needed to explore the use of these amino-
progesterone derivatives as a basis for the development of suitable
MR blockers and to investigate their biological effects.
3. Conclusion
Despite the steric limitations that are imposed on the 11b-posi-
tion of progesterone, we were able to develop a concise synthesis
of 11b-aminoprogesterone (3) starting from readily available
11a-hydroxyprogesterone (1b). We demonstrated that alkylation
of the newly introduced amino functionality is challenging, and
only activated unbulky electrophiles were useful. Reductive ami-
nation, however did prove to be amenable to extending the func-
tionality of the amine group, and allowed for the synthesis of
amino acid derivatives 12a and 12b. These amino acid derivatives
provide a convenient handle that can be further elaborated in the
search for second generation 11bHSD2 inhibitors and MR antago-
nists. Our results indicate that some of the substituted 11b-amino-
progesterone derivatives prepared display the ability to
preferentially inhibit 11bHSD2. Furthermore, we identiﬁed two
compounds with antagonist properties against the MR (2 and 6).
The biological effect of these compounds needs to be further inves-
tigated in suitable cell and animal models.4. Experimental details
4.1. Chemistry
All reactions were performed in oven-dried glassware, under a
stream of argon. Solvents were purchased from Fisher and used di-
rectly, unless otherwise noted. When required, solvents were dried
as follows: MeOH was distilled over CaH2; Et2O and THF were dis-tilled over sodium in the presence of benzophenone as indicator;
CH2Cl2 was distilled over CaH2. Silica gel was purchased from Sili-
cycle (240–400 mesh). Reactions were monitored on silica-coated
plates with a ﬂuorescence indicator. All NMR spectra were re-
corded on Varian Unity or Inova spectrometers, at the indicated
frequencies at room temperature. High-resolution mass spectrom-
etry was recorded on an Agilent 6220 oaTOF, with electrospray
ionization. Reagents were purchased from Sigma–Aldrich, Alfa–Ae-
sar or 3B Scientiﬁc Corporation (11b-hydroxyprogesterone) and
used without further puriﬁcation.
4.1.1. 11b-Azidoprogesterone (2)
The title compound is synthesized by an adapted procedure.28
Diethyl azodicarboxylate (0.80 mL, 4.6 mmol) is added drop-wise
to a stirred solution of (oven-dried) triphenylphosphine (1.2 g,
4.6 mmol) and phenol (0.03 g, 0.3 mmol) in anhydrous THF
(2.4 mL) under argon at room temperature. Stirring is continued
for 2 min, then hydrazoic acid37 (3.85 mL of 2.4 M solution in ben-
zene, 9.2 mmol) is added, followed by 11a-hydroxyprogesterone
(1b, 0.5 g, 1.53 mmol), and the reaction mixture is reﬂuxed for
20 min. A color change from pink to dark brown indicates comple-
tion of the reaction. After reduced pressure evaporation of solvent,
the crude product is chromatographed twice through silica gel (1st
column: CH2Cl2–ethyl ether, 9.5:0.5 to 9:1; second column: ethyl
ether–hexane 5:5 to 8:2) to yield 11b-azidoprogesterone (2,
0.23 g, 42%) as colorless solid. 1H NMR (400 MHz, CDCl3) d: 5.67
(d, J = 1.7 Hz, 1H), 4.17–4.15 (m, 1H), 2.51–2.35 (m, 5H), 2.24–
2.18 (m, 2H), 2.18–2.09 (m, 4H), 2.05–1.93 (m, 1H), 1.91–1.75
(m, 2H), 1.74–1.65 (m, 2H), 1.41 (s, 3H), 1.39–1.23 (m, 2H), 1.17–
0.96 (m, 3H), 0.90 (s, 3H). 13C NMR (100 MHz, CDCl3) d: 208.7,
199.3, 171.4, 122.4, 63.5, 57.6, 57.4, 55.1, 42.5, 42.4, 39.0, 35.0,
33.6, 32.3, 31.7, 31.5, 31.2, 24.1, 22.6, 20.4, 14.4. HRMS (ESI) C21-
H29N3O2Na+ m/z: 378.2152 (expected), 378.2142 (found). FTIR
(MeOH thin ﬁlm) cm1: 3244, 3015, 2987, 2091, 1710, 1676,
1479. ½aD: +274 (c 0.87, CH2Cl2).
4.1.2. 11b-Aminoprogesterone (3)
To a suspension of azide 2 (1.9 g, 5.4 mmol) and CoCl26H2O
(3.8 g, 16.1 mmol) in water (10 mL) at room temperature, a
solution of NaBH4 (0.92 g, 24.1 mmol) in H2O (25 mL) is added
drop-wise (to subside an excessive foaming) with stirring. The
appearance of a black precipitate indicates the formation of a
cobalt boride species. The mixture is then stirred at reﬂux for
3.5 h. Upon completion of the reaction, the solution is allowed to
cool back to room temperature, which is then diluted with ethyl
acetate (30 mL). The resulting biphasic mixture is ﬁltered through
Celite and the aqueous layer is separated. The aqueous phase is ex-
tracted several times, ﬁrst with ethyl acetate (3  30 mL) and then
with CH2Cl2 (3  30 mL). The combined organic phases are dried
(Na2SO4) and concentrated under reduced pressure, and further
puriﬁed on silica gel by ﬂash column chromatography (100% ethyl
acetate followed by CH2Cl2–MeOH, 9.5:0.5) to give the pure amine
3 (1.1 g, 62%) as a colorless solid. 1H NMR (500 MHz, CDCl3) d: 5.67
(d, J = 1.7 Hz, 1H), 3.62 (br s, 1H), 2.51–2.34 (m, 5H), 2.26–2.21 (m,
1H), 2.20–2.09 (m, 5H), 2.07–2.00 (m, 1H), 1.97–1.88 (m, 2H),
1.79–1.68 (m, 2H), 1.44 (s, 3H), 1.35–1.28 (m, 2H), 1.15–1.03 (m,
3H), 0.92 (s, 3H). 13C NMR (125 MHz, CDCl3) d: 209.0, 199.3,
172.2, 122.2, 64.4, 58.4, 56.2, 48.7, 43.1, 39.2, 35.0, 33.9, 32.9,
32.0, 31.4, 31.1, 29.8, 24.4, 22.6, 21.6, 16.6. HRMS (ESI) C21H31NO2-
H+ m/z: 330.2428 (expected), 330.2426 (found). FTIR (MeOH thin
ﬁlm) cm1: 3381, 3323, 2928, 2874, 1701, 1667, 1446, 1388 ½aD:
+208 (c 0.93, CH2Cl2). MP: 142–145 C.
4.1.3. t-Butyl 11b-aminoprogesteronyl acetate (4)
To a mixture of amine 3 (0.100 g, 0.3 mmol), t-butyl bromoace-
tate (88 lL, 0.6 mmol), tetrabutyl ammonium iodide and 4 Å MS
6278 K. Pandya et al. / Bioorg. Med. Chem. 21 (2013) 6274–6281(0.222 g, 0.6 mmol) in acetonitrile (5 mL) is added K2CO3 (0.166 g,
1.2 mmol) under argon at room temperature. This mixture is then
stirred at reﬂux for 9 h. The resulting mixture is ﬁltered through
Celite and the solvent is removed under reduced pressure. The res-
idue is dissolved in CH2Cl2 (10 mL) and extracted several times
with water (2  5 mL) followed by brine (1  5 mL). The organic
phase is dried (Na2SO4), concentrated under reduced pressure,
and further puriﬁed by silica gel ﬂash column chromatography
(ethyl acetate–hexane, 1:1) to give the pure title compound 4
(0.101 g, 75%) as an off-white solid. 1H NMR (600 MHz, CDCl3) d:
5.67 (s, 1H), 3.42 (d, J = 16.8 Hz, 1H), 3.29–3.10 (m, 2H), 2.52–
2.35 (m, 5H), 2.25–2.20 (m, 1H), 2.19–2.15 (m, 1H), 2.15–2.13
(m, 4H), 2.08–2.03 (m, 1H), 1.99–1.90 (m, 1H), 1.90–1.85 (m, 1H),
1.79–1.73 (m, 1H), 1.72–1.66 (m, 1H), 1.56 (s, 3H), 1.48 (s, 9H),
1.35–1.28 (m, 1H), 1.18 (dd, J = 11.4, 4.5 Hz, 1H), 1.14–1.02 (m,
3H), 0.92 (s, 3H). 13C NMR (125 MHz, CDCl3) d: 209.1, 199.6,
172.5, 171.8, 121.8, 81.4, 64.2, 58.5, 56.1, 55.0, 50.6, 43.3, 40.7,
39.2, 34.6, 34.0, 33.2, 32.0, 31.7, 31.5, 28.1, 24.4, 22.7, 21.8, 15.2.
HRMS (ESI) C27H41NO4H+ m/z: 444.3108 (expected), 444.3115
(found). FTIR (MeOH thin ﬁlm) cm1: 3032, 2934, 1731, 1703,
1671, 1367, 1234, 1158. ½aD: +137 (c 2.00, CH2Cl2).
4.1.4. 11b-Aminoprogesteronyl acetic acid TFA salt (5)
A solution of ester 4 (0.100 g, 0.23 mmol) in CH2Cl2 (2 mL) is
treated with excess triﬂuoroacetic acid (4 mL), and stirred at room
temperature for 6 h. After completion of the reaction, the solvent is
evaporated under reduced pressure and the resulting residue is
dried on high vacuum to yield the title amino acid 5 (0.101 g,
89%) as a ﬂuffy white solid. 1H NMR (500 MHz, CD3OD) d: 5.73
(d, J = 1.5 Hz, 1H), 4.08–4.01 (m, 3H), 2.64–2.50 (m, 4H), 2.42 (dt,
J = 16.7, 4.8 Hz, 1H), 2.39–2.32 (m, 1H), 2.28 (dt, J = 13.5, 5.0 Hz,
1H), 2.16 (s, 3H), 2.16–1.94 (m, 3H), 1.95–1.82 (m, 2H), 1.81 (dd,
J = 15.5, 5.0 Hz, 1H), 1.72 (dd, J = 11.8, 4.2 Hz, 1H), 1.58 (s, 3H),
1.43–1. 26 (m, 3H), 1.23–1.14 (m, 1H), 0.89 (s, 3H). 13C NMR
(125 MHz, CDCl3) d: 211.3, 200.9, 172.8, 170.0, 123.0, 64.2, 58.4,
57.5, 55.5, 42.3, 39.4, 39.1, 35.2, 34.2, 33.6, 32.4, 32.3, 31.0, 27.7,
24.8, 23.9, 22.0, 14.6. HRMS (ESI) C23H33NO4H+ m/z: 388.2482 (ex-
pected), 388.2483 (found). FTIR (MeOH thin ﬁlm) cm1: 3197,
2962, 1699, 1678, 1422, 1199. ½aD: +112 (c 1.44, H2O).
4.1.5. 11b-N-ortho-Nitrobenzenesulfonyl-aminoprogesterone
(6)
Amine 3 (0.2 g, 0.6 mmol) is mixed with o-nitrobenzenesulfonyl
chloride (1.33 g, 6 mmol) and pyridine (0.48 mL, 6.0 mmol) in CH2-
Cl2 (5 mL) and then stirred at reﬂux for 12 h. The resulting mixture
is diluted further with additional CH2Cl2 (5 mL) and then extracted
with water (2  5 mL) and brine (1  5 mL). The organic phase is
dried (Na2SO4), concentrated under reduced pressure, and further
puriﬁed on silica gel by ﬂash column chromatography (CH2Cl2 fol-
lowed by ethyl acetate–CH2Cl2, 2:8) to give pure title compound 6
(0.19 g, 61%) as a light yellow solid. 1H NMR (500 MHz, CDCl3) d:
8.19–8.13 (m, 1H), 7.93–7.87 (m, 1H), 7.83–7.73 (m, 2H), 5.68 (d,
J = 1.6 Hz, 1H), 5.48 (d, J = 10.4 Hz, 1H), 4.46 (dtd, J = 10.0, 4.7,
2.3 Hz, 1H), 2.51–2.35 (m, 4H), 2.30–2.20 (m, 2H), 2.09–1.96 (m,
3H), 1.96–1.80 (m, 2H), 1.77 (s, 3H), 1.76–1.63 (m, 2H), 1.49 (s,
3H), 1.48–1.43 (m, 1H), 1.31–1.19 (m, 2H), 1.15–0.99 (m, 2H), 0.53
(s, 3H). 13C NMR (125 MHz, CDCl3) d: 207.8, 199.2, 170.4, 147.8,
136.2, 133.7, 133.4, 129.6, 125.7, 122.7, 63.8, 57.3, 55.2, 51.4, 44.4,
41.9, 39.1, 34.8, 33.9, 32.7, 31.8, 31.7, 30.7, 24.3, 22.6, 21.0, 16.1.
HRMS (ESI) C27H34N2O6SNa+ m/z: 537.2030 (expected), 537.2028
(found). FTIR (MeOH thin ﬁlm) cm1: 3388, 3092, 2942, 2881,
1700, 1667, 1542, 1450, 1355, 1166. ½aD: +275.6 (c 1.13, CH2Cl2).
4.1.6. Ethyl 2-(hydroxyimino)-3-bromopropanoate (13)
The title compound was synthesized as per the literature proce-
dure.32 Brieﬂy, a stirred solution of ethyl bromopyruvate (3.6 mL,28.5 mmol) in CHCl3 (85 mL) and CH3OH (57 mL), is treated with
hydroxylamine hydrochloride (2.00 g, 28.5 mmol) at room temper-
ature. The mixture is stirred overnight at room temperature and
then concentrated to dryness. The residue is dissolved in CH2Cl2
(40 mL), washed with 0.1 N HC1 (20 mL) and brine (20 mL), and
dried over Na2SO4. Evaporation of the solvent gives crystalline
material, which is recrystallized (CH2Cl2–hexane) to yield the de-
sired product (3.96 g, 68%) as white needles. 1H NMR (500 MHz,
CDCl3) d: 9.33 (s, 1H), 4.38 (q, J = 7.2 Hz, 2H), 4.27 (s, 2H), 1.38 (t,
J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) d: 161.7, 147.9, 62.5,
30.1, 14.3. HRMS (ESI) C5H8BrNO3Na+ m/z: 231.9580 (expected),
231.9579 (found). FTIR (MeOH thin ﬁlm) cm1: 3445 (br), 3275,
3057, 2987, 1724, 1472, 1326, 1225, 1184, 1035. Mp: 77–78 C.
4.1.7. 11b-N-3-(O-Ethyl-2-hydroxyimino-propanoyl)-
aminoprogesterone (7)
To a mixture of amine 3 (0.05 g, 0.15 mmol), and oxime 13
(0.065 g, 0.3 mmol), in acetonitrile (1 mL) is added tetrabutyl
ammonium iodide (0.110 g, 0.3 mmol), K2CO3 (0.085 g, 0.6 mmol)
and 4 Å MS under argon at room temperature. The mixture is stir-
red at reﬂux for 12 h, and then ﬁltered through Celite. The ﬁltrate is
evaporated under reduced pressure, and the residue is dissolved in
CH2Cl2 (2 mL) and extracted with water (2  2 mL) followed by
brine (1  2 mL). The organic phase is dried (Na2SO4), concentrated
under reduced pressure, and further puriﬁed by silica gel column
chromatography (ethyl acetate–CH2Cl2, 1:1) to give pure title com-
pound 7 (0.025 g, 33%) as a light yellow solid. 1H NMR (500 MHz,
CDCl3) d: 8.97 (s, 1H), 5.66 (d, J = 1.6 Hz, 1H), 4.31 (q, J = 7.1 Hz,
2H), 3.81 (d, J = 12.9 Hz, 1H), 3.63 (d, J = 13.0 Hz, 1H), 3.19 (s,
1H), 2.54 (dd, J = 13.8, 2.2 Hz, 1H), 2.50–2.29 (m, 5H), 2.24–2.18
(m, 1H), 2.19 (td, J = 4.6, 3.7, 2.1 Hz, 1H), 2.15 (s, 3H), 2.15–2.05
(m, 1H), 2.06–1.97 (m, 1H), 1.91–1.79 (m, 2H), 1.79–1.61 (m,
2H), 1.42 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.33–1.22 (m, 2H), 1.15
(dd, J = 11.5, 4.7 Hz, 1H), 1.14–1.00 (m, 2H), 0.89 (s, 3H). 13C NMR
(125 MHz, CDCl3) d: 209.2, 199.8, 172.6, 163.6, 152.5, 121.9, 64.3,
62.2, 58.4, 56.1, 55.4, 43.2, 40.9, 39.4, 34.5, 34.1, 33.2, 32.0, 31.8,
31.5, 29.9, 24.5, 22.6, 21.6, 15.4, 14.4. HRMS (ESI) C26H38N2O5H+
m/z: 459.2853 (expected), 459.2853 (found). FTIR (MeOH thin
ﬁlm) cm1: 3300, 3058, 2934, 1703, 1668, 1449, 1357, 1189,
1015. ½aD: +152 (c 0.75, CH2Cl2).
4.1.8. 11b-N-(3-(N-Tertbutyloxycarbonyl-N,O-acetonide-1-
hydroxy-2(R)-amino-propyl))-aminoprogesterone (8a)
This is prepared by adaptation of a known protocol.35 The fol-
lowing is a representative example; both diastereoisomers 8a
and 8b are generated following the same protocol. To a solution
of 3 (330 mg, 1 mmol) in dry MeOH (11 mL), containing acetic acid
(1% v/v), is added (S)-Garner’s aldehyde (230 mg, 1 mmol), and the
mixture is stirred at room temperature under an atmosphere of ar-
gon for 45 min. The resultant imine is reduced by the addition of
NaCNBH3 (80 mg, 1.25 mmol) in two portions over 30 min. This
is stirred at room temperature for another 2 h, at which point the
reaction is quenched with water (5 mL). The organic solvent is
evaporated, more water is added (5 mL), and the aqueous layer is
extracted with CH2Cl2 (3  15 mL). The combined organic extracts
are dried over Na2SO4, evaporated and the residue is puriﬁed by
silica gel chromatography (CH2Cl2–MeOH, 96:4). The title product
is obtained as a white foam (325 mg, 60%). 1H NMR (500 MHz,
CDCl3) d: 5.66 (s, 1H), 4.08–3.92 (m, 2H), 3.91–3.82 (m, 1H),
3.22–3.11 (m, 1H), 3.09–2.91 (m, 2H), 2.66–2.41 (m, 5H), 2.27–
2.09 (m, 5H), 2.08–2.02 (m, 2H), 1.93–1.80 (m, 2H), 1.79–1.64
(m, 2H), 1.60 (s, 3H), 1.51 (br s, 15H), 1.35–1.24 (m, 2H), 1.19
(dd, J = 11.5, 4.5 Hz, 1H), 1.71–1.01 (m, 2H), 0.84 (s, 3H). 13C NMR
(125 MHz, CD3OD) d: 208.9, 199.5, 172.4, 152.6, 121.8, 93.9, 80.8,
66.4, 64.2, 58.1, 57.2, 55.1, 55.0, 49.5, 48.9, 43.2, 39.9, 39.3, 34.5,
33.9, 33.1, 31.8, 31.7, 31.5, 28.3, 24.3, 22.6, 21.6, 15.5. HRMS (ESI)
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(MeOH thin ﬁlm) cm1: 3053, 2974, 2934, 2878, 1699, 1671,
1617, 1389, 1174, 1086. ½aD: +138 (c 0.74, CH2Cl2).
4.1.9. 11b-N-(3-(N-Tertbutyloxycarbonyl-N,O-acetonide-1-
hydroxy-2(S)-amino-propyl))-aminoprogesterone (8b)
1H NMR (500 MHz, CDCl3) d: 5.67 (s, 1H), 4.01–3.86 (m, 3H),
3.91–3.82 (m, 1H), 3.15 (br s, 1H), 3.11–3.02 (m, 2H), 2.58–2.30
(m, 5H), 2.30–2.19 (m, 2H), 2.15 (s, 3H), 2.10–1.98 (m, 2H), 1.96–
1.80 (m, 4H), 1.75 (s, 3H), 1.60 (s, 6H), 1.50 (br s, 9H), 1.40–1.21
(m, 2H), 1.20–1.17 (m, 1H), 1.17–1.00 (m, 2H), 0.87 (s, 3H). 13C
NMR (125 MHz, CD3OH) d: 208.8, 199.7, 169.4, 155.9, 122.7, 95.4,
83.0, 66.8, 64.1, 63.0, 58.2, 56.7, 55.9, 50.9, 43.1, 41.4, 40.6, 39.4,
34.5, 33.6, 33.2, 31.8, 31.4, 30.9, 28.2, 24.3, 22.6, 21.6, 15.5. HRMS
(ESI) C32H50N2O5Na+ m/z: 565.3612 (expected), 565.3605 (found).
FTIR (MeOH thin ﬁlm) cm1: 3056, 2972, 2935, 2879, 1699, 1671,
1389, 1365, 1207, 1172. ½aD: +90 (c 0.6, CH2Cl2).
4.1.10. 11b-N-(3-(1-Hydroxy-2(R)-amino-propyl))-
aminoprogesterone TFA salt (9a)
The following is a representative example; both diastereoiso-
mers 9a and 9b are generated following the same protocol. The
fully protected amino alcohol appended aminoprogesterone 8a
(250 mg, 0.46 mmol) is stirred in a mixture of triﬂuoroacetic acid
and water (6 mL, 5:1 mixture) at 50 C for 16 h. The solvents are
evaporated on a high-vacuum rotary evaporator, and then co-evap-
orated with water (3  10 mL), and dried on high vacuum, to afford
the desired product as a white triﬂuoroacetate salt. This product
was used without further puriﬁcation. Analytical samples and
those used for assay were further puriﬁed by HPLC. 1H NMR
(600 MHz, D2O) d: 5.83 (s, 1H), 4.22–4.16 (m, 1H), 4.16–4.11 (m,
1H), 3.99–3.93 (m, 2H), 3.93–3.88 (m, 1H), 3.64–3.56 (m, 1H),
2.73 (t, J = 9.2 Hz, 1H), 2.70–2.64 (m, 1H), 2.61–2.51 (m, 2H), 2.46
(dt, J = 17.0, 5.0 Hz, 1H), 2.37 (ddd, J = 14.8, 4.8, 2.6 Hz, 1H), 2.24
(s, 3H), 2.19–2.09 (m, 2H), 2.09–1.98 (m, 3H), 1.95–1.81 (m, 4H),
1.43 (s, 3H), 1.42–1.32 (m, 2H), 1.27–1.16 (m, 1H), 0.89 (s, 3H).
13C NMR (125 MHz, D2O) d: 216.0, 203.4, 175.2, 129.1, 121.2,
62.8, 61.5, 57.6, 56.8, 53.7, 48.3, 46.8, 41.3, 38.0, 36.9, 33.1, 32.5,
31.8, 31.1, 30.7, 23.2, 22.6, 20.2, 13.3. HRMS (ESI) C24H38N2O3H+
m/z: 403.2955 (expected), 403.2948 (found). FTIR (MeOH thin
ﬁlm) cm1: 3101, 2949, 2564, 1715, 1426, 1212, 1161. ½aD: +91.5
(c 1.8, H2O).
4.1.11. 11b-N-(3-(1-Hydroxy-2(S)-amino-propyl))-
aminoprogesterone TFA salt (9b)
1H NMR (600 MHz, D2O) d: 5.83 (d, J = 1.6 Hz, 1H), 4.18–4.15 (m,
2H), 4.07–4.00 (m, 1H), 3.98 (m, 1H), 3.89 (dd, J = 13.9, 6.2 Hz, 1H),
3.81–3.75 (m, 1H), 2.77–2.64 (m, 2H), 2.62–2.51 (m, 2H), 2.46 (dt,
J = 17.2, 5.1 Hz, 1H), 2.39–2.34 (m, 1H), 2.24 (s, 3H), 2.22–2.12 (m,
2H), 2.10–1.98 (m, 3H), 1.97–1.82 (m, 4H), 1.45 (s, 3H), 1.44–1.31
(m, 2H), 1.28–1.16 (m, 1H), 0.88 (s, 3H). 13C NMR (125 MHz, D2O)
d: 216.1, 203.7, 175.4, 129.2, 121.2, 62.9, 62.1, 57.5, 56.7, 53.7, 48.5,
46.3, 41.4, 37.9, 36.5, 33.1, 32.5, 31.8, 31.1, 30.7, 23.3, 22.5, 20.3,
13.1. HRMS (ESI) C24H38N2O3H+ m/z: 403.2955 (expected),
403.2948 (found). FTIR (MeOH thin ﬁlm) cm1: 3087, 2960, 2570,
1703, 1435, 1210, 1168. ½aD: +89 (c 0.62, CH2Cl2).
4.1.12. 11b-N-(3-(1-Hydroxy-2(R)-tertbutyloxycarbonyl-amino-
propyl))-aminoprogesterone (10a)
The following is a representative example; both diastereoiso-
mers 10a and 10b are generated following the same protocol.
The deprotected amino alcohol 9a (0.46 mmol) is dissolved in a
water–acetonitrile mixture (6 mL, 1:2 mixture), to which is added
NaHCO3 (116 mg, 1.4 mmol) and di-t-butyl-dicarbonate (105 mg,
0.48 mmol). The mixture is stirred at room temperature for 2 h,
at which point the starting material is completely consumed asevidenced by TLC analysis (CH2Cl2–MeOH, 95:5). The solution is
basiﬁed with NaOH (three drops of a 3 M solution), and extracted
with ethyl acetate (3  30 mL). The combined organic extracts
were dried over Na2SO4, concentrated and puriﬁed by silica gel
chromatography (CH2Cl2–MeOH, 95:5), to yield the desired prod-
uct (181 mg, 78% over two steps). 1H NMR (600 MHz, CDCl3) d:
5.69 (s, 3H), 5.14–5.02 (br s, 1H), 3.78–3.64 (m, 3H), 3.18–3.11
(br s, 1H), 3.00–2.91 (m, 1H), 2.96 (dd, 1H, J = 11.0, 3.7 Hz), 2.75–
2.65 (m, 1H), 2.52–2.43 (m, 3H), 2.40–2.30 (m, 1H), 2.26–2.21
(m, 1H), 2.19–2.12 (m, 4H), 2.12–2.02 (m, 3H), 1.94–1.82 (m,
3H), 1.81–1.69 (m, 2H), 1.61–1.56 (m, 1H), 1.52 (s, 3H), 1.48–
1.43 (m, 9H), 1.36–1.25 (m, 3H), 1.26–1.20 (m, 2H), 0.88 (s, 3H).
13C NMR (125 MHz, CDCl3) d: 209.1, 199.4, 172.1, 156.2, 122.1,
79.9, 65.7, 64.2, 58.3, 55.7, 52.1, 49.9, 43.2, 40.3, 39.3, 34.7, 34.0,
33.2, 31.9, 31.8, 31.6, 29.9, 28.5, 24.5, 22.8, 22.0, 15.5. HRMS (ESI)
C29H46N2O5H+ m/z: 503.3479 (expected), 503.3470 (found). IR
(MeOH cast ﬁlm) cm1: 3385.4, 2933.3, 1702.2, 1667.7, 1616.1,
1523.0, 1452.8, 1365.1, 1171.4, 1031.8, 700.4. ½aD: +135.6 (c
0.90, MeOH).
4.1.13. 11b-N-(3-(1-Hydroxy-2(S)-tertbutyloxycarbonyl-amino-
propyl))-aminoprogesterone (10b)
1H NMR (600 MHz, CDCl3) d: 5.66 (s, 1H), 4.99 (br s, 1H), 3.72
(dd, 2H, J = 4.1, 1.9 Hz), 3.65–3.49 (m, 1H), 3.17–3.13 (m, 1H),
3.10–3.04 (m, 1H), 2.52–2.39 (m, 4H), 2.38–2.32 (m, 1H), 2.24–
2.19 (m, 1H), 2.16–2.11 (m, 4H), 2.11–2.06 (m, 1H), 2.05–1.99
(m, 1H), 1.91–1.88 (m, 1H), 1.87–1.80 (m, 1H), 1.79–1.65 (m,
2H), 1.59–1.53 (m, 3H), 1.46 (s, 3H), 1.44–1.40 (m, 9H), 1.30–1.23
(m, 2H), 1.22–1.18 (m, 1H), 1.11–1.03 (m, 2H), 0.84 (s, 3H). 13C
NMR (125 MHz, CDCl3) d: 209.0, 199.4, 172.1, 156.5, 122.1, 80.0,
64.2, 58.4, 56.0, 55.8, 52.9, 49.7, 43.2, 40.4, 39.3, 34.8, 34.0, 33.2,
31.9, 31.8, 31.6, 29.9, 28.5, 24.4, 22.8, 21.8, 15.5. HRMS (ESI) C29-
H46N2O5H+ m/z: 503.3479 (expected), 503.3471 (found) IR (MeOH
cast ﬁlm) cm1: 3375.4, 2931.5, 1701.8, 1668.4, 1616.0, 1522.7,
1452.3, 1390.5, 1364.9, 1171.3, 1030.3, 703.2. ½aD: +120.9 (c
0.86, MeOH).
4.1.14. 11b-N-(3-(1-Carboxy-2(R)-tertbutyloxycarbonyl-amino-
propyl))-aminoprogesterone (11a)
The following is a representative example; both diastereoiso-
mers 11a and 11b are generated following the same protocol.
The Jones reagent (2 M ﬁnal concentration) is prepared freshly by
dissolution of CrO3 (100 mg, 1 mmol) in water (0.5 mL) followed
by the addition of concentrated H2SO4 (0.085 mL, 1.5 mmol). The
Boc-protected amino alcohol 10a (127 mg, 0.25 mmol) is stirred
at room temperature in HPLC-grade acetone (2.5 mL). Oxidation
is achieved by the slow addition of freshly prepared Jones reagent
(0.26 mL of a 2 M solution, 0.53 mmol), over 5 min, followed by
stirring at room temperature for a further 1.5 h. The progress of
the reaction is followed by TLC analysis (CH2Cl2–MeOH, 8:2). Once
the reaction is deemed complete excess Jones reagent is quenched
with iPrOH (1 mL), and the entire mixture is evaporated. The resi-
due is suspended in water (20 mL) and extracted with CH2Cl2
(2  15 mL) followed by ethyl acetate (2  15 mL). The combined
organic extracts are dried over Na2SO4, evaporated and puriﬁed
by silica gel chromatography (CH2Cl2–MeOH, 4:1), to yield the
product as a pure white solid (50 mg, 39%). 1H NMR (600 MHz,
CD3OD) d: 5.64 (s, 1H), 4.19–4.09 (m, 1H), 3.75–3.64 (m, 1H),
3.49–3.41 (m, 1H), 3.03–2.94 (m, 1H), 2.64 (dd, 1H, J = 15.0,
1.9 Hz), 2.60–2.45 (m, 3H), 2.40–2.24 (m, 3H), 2.17–2.06 (m, 3H),
2.00–1.89 (m, 2H), 1.89–1.76 (m, 2H), 1.63–1.58 (m, 1H), 1.60–
1.49 (m, 4H), 1.49–1.40 (m, 9H), 1.40–1.31 (m, 1H), 1.31–1.22
(m, 2H), 1.19–1.09 (m, 1H), 0.90 (s, 3H). 13C NMR (125 MHz, CD3-
OD) d: 210.0, 200.2, 174.2, 172.7, 156.4, 121.2, 79.5, 63.0, 57.3,
55.3, 54.6, 48.5, 41.5, 38.4, 37.6, 33.4, 33.0, 32.5, 31.1, 31.0, 29.7,
27.3, 23.5, 22.3, 19.8, 13.0. HRMS C29H44N2O6H+ (ESI) m/z:
6280 K. Pandya et al. / Bioorg. Med. Chem. 21 (2013) 6274–6281517.3272 (expected), 517.3264 (found) IR (MeOH cast ﬁlm) cm1:
3390.1, 2936.2, 1705.0, 1671.5, 1484.2, 1454.5, 1365.7, 1167.2,
1058.5, 1029.2, 871.6. ½aD: +80.0 (c 1.10, MeOH).
4.1.15. 11b-N-(3-(1-Carboxy-2(S)-tertbutyloxycarbonyl-amino-
propyl))-aminoprogesterone (11b)
1H NMR (600 MHz, CD3OD) d: 5.66 (s, 1H), 4.18–4.10 (m, 1H),
3.76–3.68 (m, 1H), 3.26 (d, 1H, J = 6.2 Hz), 2.81 (app d, 1H,
J = 13.9 Hz), 2.62 (app t, 1H, J = 9.1 Hz), 2.60–2.41 (m, 2H), 2.39–
2.23 (m, 1H), 2.19 (s, 3H), 2.15–2.04 (m, 3H), 1.98–1.86 (m, 3H),
1.86–1.76 (m, 1H), 1.76–1.64 (m, 1H), 1.65–1.59 (m, 1H), 1.51 (s,
3H), 1.45–1.40 (m, 9H), 1.38–1.22 (m, 3H), 1.20–1.08 (m, 1H),
0.80 (s, 3H). 13C NMR (125 MHz, CD3OD) d: 210.0, 200.5, 178.1,
173.3, 156.6, 121.0, 79.5, 63.3, 57.8, 54.9, 53.8, 48.2, 42.1, 38.6,
37.9, 33.7, 33.1, 33.0, 31.2, 30.1, 29.0, 27.3, 23.6, 21.9, 20.4, 13.4.
HRMS (ESI) C29H44N2O6H+ m/z: 517.3272 (expected), 517.3268
(found). IR (MeOH cast ﬁlm) cm1: 3413.3, 2935.2, 1702.6,
1671.2, 1482.2, 1392.7, 1366.4, 1244.6, 1165.5, 1029.1, 867.8.
½aD: +131.0 (c 1.10, MeOH).
4.1.16. 11b-N-(3-(1-Carboxy-2(R)-amino-propyl))-
aminoprogesterone TFA salt (12a)
The following is a representative example; both diastereoiso-
mers 12a and 12b are generated following the same protocol.
The Boc-protected amino acid derivative 11a (11 mg, 0.02 mmol)
is stirred at room temperature in a CH2Cl2–TFA mixture (0.5 mL,
3:1 mixture) for 30 min. The solvent is evaporated, followed by
co-evaporation with water (3  1 mL), to yield the amino acid
12a as a TFA salt (quant). 1H NMR (500 MHz, D2O) d: 5.79 (br s,
1H), 4.08 (dd, 1H, J = 12.5, 4.0 Hz), 4.05–4.01 (m, 1H), 3.79 (dd,
1H, J = 11.7, 4.0 Hz), 3.41 (app t, 1H, J = 12.2 Hz), 2.73–2.66 (m,
1H), 2.62–2.49 (m, 3H), 2.43 (dt, 1H, J = 17.3, 5.0 Hz), 2.36–2.30
(m, 1H), 2.21–2.16 (m, 4H), 2.14–2.09 (m, 1H), 2.05–1.96 (m,
3H), 1.91–1.77 (m, 4H), 1.48 (app s, 3H), 1.40–1.30 (m, 2H),
1.24–1.13 (m, 1H), 0.85 (app s, 3H). 13C NMR (125 MHz, D2O) d:
216.2, 203.9, 175.7. 171.7, 120.9, 62.9, 56.7, 56.6, 53.3, 47.5, 45.5,
41.4, 38.1, 36.5, 32.8, 32.7, 32.0, 31.1, 30.7, 30.7, 23.3, 22.5, 20.1,
13.1. HRMS (ESI) C24H36N2O4H+ m/z: 417.2748 (expected),
417.2741 (found) IR (MeOH cast ﬁlm) cm1: 2945.7, 1676.9,
1422.8, 1362.3, 1294.5, 1202.9, 1134.6, 1027.8, 836.7, 721.4. ½aD:
+56.6 (c 0.8, MeOH).
4.1.17. 11b-N-(3-(1-Carboxy-2(S)-amino-propyl))-
aminoprogesterone TFA salt (12b)
1H NMR (500 MHz, D2O) d: 5.80 (app s, 1H), 4.18 (dd, 1H,
J = 12.1, 4.0 Hz), 4.17 (m, 1H), 3.78 (dd, 1H, J = 12.8. 4.0 Hz), 3.62
(app t, 1H, J = 12.5 Hz), 2.69 (app t, 1H, J = 9.0 Hz), 2.67–2.60 (m,
1H), 2.58–2.47 (m, 2H), 2.40 (dt, 1H, J = 17.3, 5.0 Hz), 2.35–2.29
(m, 1H), 2.30–2.16 (m, 4H), 2.15–2.08 (m, 1H), 2.03–1.91 (m,
3H), 1.91–1.77 (m, 4H), 1.45 (app s, 3H), 1.40–1.30 (m, 2H),
1.25–1.11 (m, 1H) 0.81 (app s, 3H). 13C NMR (125 MHz, D2O) d:
216.1, 203.9, 175.4, 171.5, 121.2, 62.9, 57.0, 53.9, 53.7, 46.0, 43.7,
41.4, 38.2, 37.0, 33.1, 32.6, 31.8, 31.2, 30.8, 30.6, 23.2, 22.5,
20.4,13.3. HRMS (ESI) C24H36N2O4H+ m/z:: 417.2748 (expected),
417.2741 (found) IR (MeOH cast ﬁlm) cm1: 2957.8, 2881.1,
1676.5, 1431.0, 1360.6, 1203.7, 1137.5, 835.8, 799.2, 721.8. ½aD:
+114.1 (c 0.80, MeOH).
4.2. Biology
All experiments were performed with intact HEK-293 cells or
homogenates of cells expressing recombinant human proteins.
Construction of expression plasmids of 11b-HSD1 and 11b-HSD2
and of MR and reporter gene have been described earlier.38,39
[1,2-3H]-cortisone was purchased from American Radiolabeled
Chemicals (St. Louis, MO), [1,2,6,7-3H]-cortisol from Perkin Elmer(Waltham, MA, USA), cell culture media from Invitrogen (Carlsbad,
CA), aldosterone from Steraloids (Wilton, NH, USA) and all other
chemicals from Sigma–Aldrich Chemie GmbH (Buchs, Switzerland)
of the highest grade available.
4.2.1. 11bHSD enzyme activity
Inhibition of 11bHSD enzyme activity was measured as de-
scribed earlier.10 Brieﬂy, HEK-293 cells stably expressing human
11bHSD1 or 11bHSD2 were harvested by centrifugation and cell
pellets were frozen and stored at 80 C. Cell pellets were sus-
pended in TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA,
1 mM MgCl2, 250 mM sucrose, 20 mM Tris–HCl, pH 7.4), sonicated
and immediately used for activity assay. Cell lysates were incu-
bated for 10 min at 37 C in a ﬁnal volume of 22 lL, containing
either vehicle (0.2% DMSO) or the corresponding inhibitor. Inhibi-
tors were diluted in TS2 buffer from stock solutions (10 mM in
DMSO). To measure 11bHSD1 activity, the reaction mixture con-
tained 200 nM [1,2-3H]cortisone and 500 lM NADPH. 11bHSD2
activity was measured similarly at a ﬁnal concentration of 50 nM
[1,2,6,7-3H] cortisol and 500 lM NAD+. Reactions were stopped
after 10 min by adding an excess of unlabeled cortisone and corti-
sol (2 mM each, in methanol). Steroids were separated by TLC, fol-
lowed by scintillation counting and calculation of substrate
conversion. Data were obtained from three independent
experiments.
4.2.2. MR transactivation activity
The effect of compounds on the transcriptional activity of MR
was measured as described earlier.40 Brieﬂy, 150,000 HEK-293
cells/well of a poly-L-lysine coated 24-well plate were incubated
for 24 h, followed by transfection using calcium phosphate precip-
itation with pMMTV-lacZ b-galactosidase reporter (0.20 lg/well),
pCMV-LUC luciferase transfection control (0.04 lg/well) and plas-
mid for human recombinant MR (0.35 lg/well). The medium was
changed 6 h post-transfection and cells were incubated for another
18 h. Cells were washed twice with charcoal-treated DMEM con-
taining 10% FBS and incubated with various concentrations of com-
pounds in the absence of presence of 10 nM aldosterone and for
24 h. Cells were washed once with PBS and lysed with 50 lL lysis
buffer of the Tropix kit (Applied Biosystems, Foster City, CA) sup-
plemented with 0.5 mM dithiothreitol. Lysed samples were frozen
at 80 C prior to analysis of b-galactosidase activity using the Tro-
pix kit and luciferase activity using a luciferine-solution. Data were
normalized to the ratio of b-galactosidase to luciferase activity of
the vehicle control and were obtained from three independent
experiments.
4.2.3. Calculations and statistical analysis
Enzyme kinetics was analyzed by nonlinear regression using
the four parameter logistic curve ﬁtting. All data (mean ± SD) were
obtained from at least three independent experiments and signiﬁ-
cance was assigned using the ratio t-test in the GraphPad Prism 5
software.
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4. Chapter 2: Effects of 3,4-methylenedioxymethamphetamine and 
methylphenidate on circulating steroids in healthy humans 
Introduction 
The illicit, recreational drug 3,4-methylenedioxymethamphetamine (MDMA) or “ecstasy” is a powerful 
central nervous system stimulant, mostly used by dance clubbers, which can generate feelings of 
euphoria, energy surge, elevated mood, enhanced bonding with others and psychedelic effects [47]. 
However, MDMA abuse also has many, though rare, adverse effects, such as liver damage, extended 
depressed mood, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, 
arrhythmias and death caused by dehydration [48]. Nevertheless, the recreational drug was suggested as 
treatment for post-traumatic stress disorder (PTSD) [49]. However, because of the possible side effects, 
pharmaceutical use of MDMA is questionable [50]. MDMA is a methamphetamine derivative with many 
similarities to the parent compound. It has a particular affinity for the serotonin transporter and can release 
up to 80% of available serotonin, but like methamphetamine, it also stimulates the release of dopamine, 
norepinephrine and other neurotransmitters [51]. Many studies show that MDMA triggers changes in 
hypothalamic–pituitary–adrenal (HPA) axis, resulting in the increased release of adrenocorticotropic 
hormone (ACTH) and glucocorticoids, such as the hormone cortisol. Several studies in humans supported 
this hypothesis by showing increased levels of plasma cortisol following MDMA administration [52-54]. In a 
controlled study under laboratory conditions in healthy volunteers, an acute MDMA use increased cortisol 
levels by 50-100 % [53]. Several investigators tested the changes in cortisol levels in dance clubbers 
before and after MDMA use and found up to an 800% increase in cortisol levels [54]. Since glucocorticoids 
are involved in a wide range of psychobiological functions including memory, sleep, appetite, impulsivity, 
neuronal damage, and hippocampal activity, the suggested changes in HPA axis activity may be involved 
in many of the diverse effects of recreational ecstasy [53, 55]. The effects of MDMA on other steroid 
hormones has also been studied, but mostly in small cohorts of human subjects or animal studies and 
some of the results are contradictive. MDMA intake was reported to suppress the hypothalamic-pituitary-
gonadal (HPG) reproductive axis of male rats, resulting in, amongst others a decrease in testosterone 
levels [56]. However, a study performed in dance clubbers showed increased levels of the androgen 
testosterone [52]. Furthermore plasma dehydroepiandrosterone (DHEA), a precursor for androgens as 
well as estrogens, was found to be increased in experienced volunteers (regular MDMA users) after 
ecstasy intake [57]. The mineralocorticoid aldosterone was also shown to be increased in rats after acute 
administration [58]. However, the effects of MDMA on a wider range of corticosteroids have not yet been 
studied in humans. To better understand the effects of MDMA on the brain there is a need to measure the 
steroid hormones in human plasma following MDMA administration.  
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In contrast to MDMA, methylphenidate (MPH), a piperidine derivative structurally related to 
amphetamines, exerts its psychomotor stimulant effects via dopamine and norepinephrine but not through 
serotonin. MPH is used in the clinic for the treatment of attention-deficit/hyperactivity disorder (ADHD), the 
most common behavioral disorder during childhood and adolescence. However, MPH is also misused as 
a cognitive enhancer primarily among university students [59]. The beneficial effects of MPH on ADHD 
patients include the reduction of impulsivity and the improvement of disruptive behavior, sustained 
attention, short-term memory and social responsiveness [60]. Several human studies reveal that MPH 
treatment influence the neuroendocrine systems, thus affect the levels of DHEA, testosterone and cortisol 
[59, 61, 62]. This suggests that the therapeutic effects of MPH in ADHD treatment may be through 
changes in steroid levels. DHEA and DHEA-S are precursors for sex hormones; however, they also exert 
multiple effects on the central nervous system (CNS), affecting emotion and mood, neural plasticity, 
neuroprotection, sleep, inhibiting aggressive-impulsive behavior, improving attention and memory. 
Previously, significant inverse correlations between clinical symptomatology and levels of DHEA in 
humans with ADHD were indicated. The beneficial effects of MPH were suggested to be linked with 
increasing DHEA levels [60, 63]. However, the global effects of MPHs on the steroidal system remain 
unknown. Additionally, several studies show the influence of MPH in human development is critical. 
Chronic exposure to MPH during development showed changes in behavior as well as in steroid hormone 
plasma levels in developing rats [64, 65]. MPH treatment was also linked with puberty delay in male non-
human primates [66]. These results highlight the need for further research, to improve understanding of 
the effects of stimulants on the developing nervous system and the potential lasting effects resulting from 
drug exposure in early life phases. Steroid hormones may play a key role in the therapeutic and adverse 
effects of MPH. 
Since MDMA and MPH are widely misused drugs and pharmacodynamic interactions of both are likely, 
the comparison between the combined intake versus a single drug administration could give insights into 
mechanism of the beneficial as well as the unwanted side effects. Additionally, the combination of both 
drugs in a single study may be of clinical importance for assessing the risks of combined psychostimulant 
misuse. Given that serotonin release plays a role in MDMA, but not in the MPH mechanism of action, the 
comparison of both drugs might provide further information as to their underlying mechanisms. Since both, 
MDMA and MPH share an enhancing effect on norepinephrine neurotransmission, resulting in 
sympathomimetic and psychostimulant effects, and they are otherwise indirect serotonergic or 
dopaminergic agonists, it makes them promising pharmacological molecules to evaluate the role of 
serotonin and dopamine as activators of the HPA axis. In a study performed in healthy volunteers MPH 
and MDMA shared some subjective amphetamine-type effects; however, MDMA increased positive mood 
more than MPH and MPH enhanced activity and concentration more than MDMA. Besides, the combined 
use of MPH and MDMA did not show an increase in psychoactive effects compared with either drug alone, 
but potentially enhanced cardiovascular and adverse effects [67]. 
The second project of this thesis focused on the measurement of eleven steroid hormones in plasma 
samples of healthy volunteers after a single dose intake of MDMA, MPH or a combination of both (Figure 
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5) in collaboration with Dr. M. Liechti and coworkers. The steroid panel consisted of hormones from the 
mineralocorticoid, glucocorticoid as well as androgen family. During the study performed by Dr. C Hysek, 
16 subjects (8 men, 8 women) were treated with MDMA (125 mg), MPH (60 mg), MDMA + MPH and 
placebo on 4 separate days using a double-blind, cross-over study design. Plasma samples were taken 1 
hour prior and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 24 h following the administration of the drugs 
or placebo. I supported the study by extracting, measuring and quantitating the following steroids: cortisol, 
cortisone, corticosterone, 11-dehydrocorticosterone, aldosterone, 11-deoxycorticosterone (DOC), 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione and 
testosterone.  
 
 
Figure 5: Steroidogenesis of mineralocorticoids, glucocorticoids and androgens. Highlighted steroids were 
measured with LC-MS/MS (modified after KEGG [68] ). 
 
Low-dose steroids may provide insights into the function and effects of psychoactive drugs. However, the 
extremely low levels of some steroids in plasma and the insufficient sensitivity/selectivity of current 
analytical methods depict a significant challenge for the evaluation of steroid plasma levels. Therefore, a 
method for an ultrasensitive quantification of steroids in plasma samples was developed. The basis of the 
analyses performed in this study was an ultra-pressure liquid chromatography tandem mass spectrometry 
(UPLC-MS/MS) method developed and validated with the help of Dr. C. Penno. This was achieved by the 
combination of a selective solid-phase extraction (SPE) with a highly sensitive UPLC-MS/MS analysis. To 
validate the quality of the newly developed method we determined the extraction efficiency with five 
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replicates of untreated pooled human plasma, which were extracted twice consecutively. Extraction 
efficiency was determined by comparing the amount of steroid extracted in both procedures. Values of 
lower limit quantification (LLOQ) were obtained by assessing the signal to noise (SNR) ratio at lower 
calibration range. A signal equal or higher than five times that of the baseline was considered the LLOQ, 
with accuracy between 80 and 120% of the true value and coefficient of variation of 20%.  Identical criteria 
were used to determine the SNR of a given sample. To determine intra-day precision and accuracy, 
quality assessment of the method was performed with untreated human plasma samples (quality control 1 
(QC1)) spiked with known concentrations of steroids (QC2 and QC3) using 5 replicates, respectively ( 
Table 1). To summarize our sample extraction and UPLC-MS/MS method generated reliable and 
reproducible results. The only exception was DHEAS, which showed a recovery rate of only approximately 
50% following extraction. Due to the low extraction recovery and the fact that the measured DHEAS 
values were low, these values should only be used for qualitative comparison. 
 
        Precision (coefficient of variation %) 
Steroid hormone Extraction Efficiency (%) LLOQ (nM) SNR  
QC1 
(Endogenous) 
QC2  (spiked 
with +50% of 
endogenous) 
QC3  (spiked 
with +100% of 
endogenous) 
Cortisol 88 ± 1 0.2 11 ± 2 4 4.4 3 
Cortisone 92 ± 2 0.2 10 ± 3 4 4.4 3 
Corticosterone 90 ± 2 0.2 10 ± 1 7.4 6 4.8 
11-
Dehydrocorticosterone 85 ± 2 0.06 12 ±  2 15.5 8.5 7.6 
Aldosterone 86 ± 4 0.2 6 ± 2 11.2 5.6 18 
DOC 88 ± 2 0.2 6 ± 2 8.7 6.4 10.7 
Androstenedione 96 ± 7 0.2 21 ± 3 7 10.5 7.3 
Testosterone 97 ± 4 0.3 25 ± 4 6.7 4 6.9 
DHEA 98 ± 4 1 7 ± 2 14 4.6 8.9 
DHEAS 49 ± 2 3 8 ± 3 1.8 7.8 7.9 
 
Table 1: Method qualification LC-MS/MS 12 steroids measurement including assessed extraction efficiency, 
LLOQ, SNR as well as precision 
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Results and Discussion 
Following rigorous quality control and development of the UPLC-MS/MS method, the measurement of the 
steroid hormones cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, aldosterone, DOC, DHEA, 
DHEAS, androstenedione and testosterone were performed. MDMA significantly increased the plasma 
concentrations of cortisol by over 60% compared to control, which is comparable to what was reported 
earlier [54]. The dramatic differences between plasma cortisol levels following MDMA intake reported in 
dance clubbers versus the clinically assessed volunteers could be a consequence of environmental as 
well as physical factors such as temperature, crowding and prolonged dancing, which may also influence 
the psychobiological effects of MDMA [55]. Another important co-factor is the regular use of MDMA 
compared with healthy volunteers screened and identified as drug naive. Additionally, the possible use of 
other psychoactive drugs by dance clubbers, including alcohol, amphetamine, cannabis, cocaine and 
nicotine could play a role in the more pronounced change of cortisol levels. Circadian rhythm, sleeping 
habits and stress of the volunteers may also play a role in the differences observed [69]. Furthermore, 
corticosterone, 11 dehydrocorticosterone, and DOC plasma levels increased, supporting the hypothesis 
that MDMA can influence changes in the HPA axis, thus resulting in increased release of glucocorticoids. 
On the other hand, the glucocorticoid cortisone showed no change. Notably, MDMA increased both the 
sum of cortisol + cortisone levels and cortisol/cortisone ratio, suggesting an increase in HPA axis 
stimulation and possibly reduced or saturated 11β-HSD2 enzyme function. The 11β-HSD2 enzyme 
catalyzes the reduction of the active glucocorticoid cortisol to the inactive form cortisone [70]. MDMA also 
moderately increased aldosterone levels compared with placebo. Interestingly, significant positive 
correlations were found between the MDMA-induced peak elevation of DOC, a mineralocorticoid 
precursor, and aldosterone and the peak increase in systolic blood pressure (R s = 0.38 and 0.40, 
respectively, both p < 0.05, n = 30), which supports a role for of MDMA in mineralocorticoid action [67]. On 
the other hand, MDMA did not alter the levels of DHEA, DHEAS, androstenedione or testosterone. 
Compared to placebo, MPH did not affect any of the steroid concentrations and it neither synergized nor 
inhibited the effects of MDMA on circulating steroids. In the context of recreational drug use, steroid 
hormones such as cortisol or DHEA may contribute to or modulate substance-induced acute psychotropic 
and reinforcing effects [71]. For example, MDMA-induced increases in plasma cortisol levels have 
previously been shown to correlate with subjective “drug liking” in response to MDMA in a laboratory study 
[57]. Stress-induced increases in cortisol were also correlated with positive mood responses to other 
recreational drugs [72]. In summary, the serotonin releaser MDMA has acute effects on circulating 
steroids. These effects are not observed after stimulation of the dopamine and norepinephrine systems as 
with MPH. The present findings support the view that serotonin rather than dopamine and norepinephrine 
mediates the acute pharmacologically induced stimulation of the HPA axis in absence of other stressors.   
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repeatedly measured up to 24 h using liquid chromatogra-
phy-tandem mass spectroscopy. MDMA significantly in-
creased the plasma concentrations of cortisol, corticoste-
rone, 11-dehydrocorticosterone, and 11-deoxycorticoste-
rone and also tended to moderately increase aldosterone 
levels compared with placebo. MDMA also increased the 
sum of cortisol + cortisone and the cortisol/cortisone ratio, 
consistent with an increase in glucocorticoid production. 
MDMA did not alter the levels of cortisone, DHEA, DHEAS, 
androstenedione, or testosterone. Methylphenidate did not 
affect any of the steroid concentrations, and it did not 
change the effects of MDMA on circulating steroids. In sum-
mary, the serotonin releaser MDMA has acute effects on cir-
culating steroids. These effects are not observed after stim-
ulation of the dopamine and norepinephrine systems with 
methylphenidate. The present findings support the view 
that serotonin rather than dopamine and norepinephrine 
mediates the acute pharmacologically induced stimulation 
of the hypothalamic-pituitary-adrenal axis in the absence of 
other stressors.  © 2014 S. Karger AG, Basel 
 Key Words 
 MDMA · Methylphenidate · Steroid · Cortisol · Aldosterone · 
Testosterone  
 Abstract 
 3,4-Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) 
and methylphenidate are widely used psychoactive sub-
stances. MDMA primarily enhances serotonergic neuro-
transmission, and methylphenidate increases dopamine 
but has no serotonergic effects. Both drugs also increase 
norepinephrine, resulting in sympathomimetic properties. 
Here we studied the effects of MDMA and methylphenidate 
on 24-hour plasma steroid profiles. 16 healthy subjects (8 
men, 8 women) were treated with single doses of MDMA 
(125 mg), methylphenidate (60 mg), MDMA + methylpheni-
date, and placebo on 4 separate days using a cross-over 
study design. Cortisol, cortisone, corticosterone, 11-dehy-
drocorticosterone, aldosterone, 11-deoxycorticosterone, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone 
sulfate (DHEAS), androstenedione, and testosterone were 
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 Introduction 
 Many recreational drugs activate the hypothalamic-
pituitary-adrenal (HPA) axis to release adrenocortico-
tropic hormone (ACTH) and corticosteroids  [1] . The 
neurochemical mechanisms involved in HPA axis acti-
vation depend on the particular drug and mostly involve 
corticotropin-releasing factor stimulation in the hypo-
thalamus  [1–3] . HPA axis activation by cocaine and am-
phetamine and its derivatives is thought to be mediated 
by increases in brain monoamines, including dopamine 
(DA), norepinephrine (NE), and serotonin (5-hydroxy-
tryptamine, 5-HT)  [1] . Few studies have examined 
which of these monoamines contribute the most to HPA 
axis activation in animals  [1] , and even less data are 
available for humans. For example, cocaine inhibits the 
uptake of all three monoamines (DA, NE, and 5-HT), 
and all three may be involved in cocaine-induced HPA 
axis activation. Dopaminergic and adrenergic receptor 
antagonists reduced the corticosterone response to co-
caine in rodents  [4–6] . Additionally, the blockade of 
5-HT receptors also decreased the ACTH response to 
cocaine in rats  [5] .
 3,4-Methylenedioxymethamphetamine (MDMA; ‘ec-
stasy’) primarily releases 5-HT in the brain via the sero-
tonin transporter (SERT) and NE via the NE transporter 
(NET)  [7] . Methylphenidate is an amphetamine deriva-
tive used for the treatment of attention-deficit/hyperac-
tivity disorder and misused as a cognitive enhancer and 
recreationally. In contrast to MDMA, methylphenidate 
only elevates the levels of DA and NE by inhibiting the 
DA transporter and NET  [8] . Thus, both MDMA and 
methylphenidate share an enhancing effect on NE neuro-
transmission, resulting in sympathomimetic and psycho-
stimulant effects  [9] , but they are otherwise indirect sero-
tonergic or dopaminergic agonists, making them phar-
macological tools to evaluate the role of 5-HT and DA as 
activators of the HPA axis.
 Several studies evaluated the stimulant effects of 
MDMA on the HPA axis in humans [for reviews, see  10, 
11] . Plasma cortisol has been shown to be increased after 
MDMA administration in many human laboratory 
studies  [12–15] and in recreational ecstasy users follow-
ing MDMA administration in a club setting  [16, 17] . 
Small laboratory studies also previously reported 
 MDMA-induced increases in ACTH  [18] and dehydro-
epiandrosterone (DHEA)  [12] . A trend toward an in-
crease in testosterone was also found in subjects who 
used MDMA at a dance club  [16] . However, the effects 
of MDMA on a wider range of corticosteroids have not 
yet been studied in humans. Therefore, we evaluated the 
acute effects of predominantly 5-HT activation using 
MDMA or predominantly DA activation using methyl-
phenidate or MDMA + methylphenidate on changes in 
the plasma concentration of a series of steroids over 24 h 
in healthy subjects. Specifically, we measured the plas-
ma levels of glucocorticoids (cortisol, cortisone, corti-
costerone, and 11-dehydrocorticosterone), mineralo-
corticoids (aldosterone and 11-deoxycorticosterone), 
and androgens (DHEA, DHEA sulfate (DHEAS), an-
drostenedione, and testosterone). Cortisol is the main 
active glucocorticoid and a major stress hormone. It is 
converted to the inactive metabolite cortisone. Corti-
costerone is also a potent activator of glucocorticoid and 
mineralocorticoid receptors, but it is present at 10- to 
20-times lower concentrations than cortisol in humans. 
11-Deoxycorticosterone is a precursor of corticosterone 
and aldosterone and exhibits mineralocorticoid activity 
 [19] . Mineralocorticoids increase renal sodium absorp-
tion and blood pressure. Androgens may modulate the 
addictive effects of drugs of abuse  [12, 20, 21] . We hy-
pothesized that methylphenidate and MDMA would 
differentially affect the plasma levels of these steroids 
based on their different pharmacological profiles.
 Methods 
 Study Design 
 The study used a double-blind, placebo-controlled, cross-over 
design with four experimental test sessions (placebo-placebo, 
methylphenidate-placebo, placebo-MDMA, and methylpheni-
date-MDMA) performed in counterbalanced order according to a 
Latin square randomization scheme. All of the subjects received all 
of the study treatments in a within-subjects study design. The 
washout periods between sessions were at least 10 days. The study 
was conducted in accordance with the Declaration of Helsinki and 
International Conference on Harmonization Guidelines in Good 
Clinical Practice and approved by the local Ethics Committee and 
Swiss Agency for Therapeutic Products (Swissmedic). The study 
was registered at ClinicalTrials.gov: http://clinicaltrials.gov/ct2/
show/NCT01465685. All of the subjects provided written in-
formed consent.
 Participants 
 Sixteen healthy subjects (8 men and 8 women; mean ± SD age 
24.8 ± 2.6 years) were recruited from the University of Basel cam-
pus. The exclusion criteria were acute or chronic physical illness, 
psychiatric disorders, smoking, and a lifetime history of using il-
licit drugs more than 5 times, with the exception of past cannabis 
use. The use of any illicit drugs, including cannabis, within the past 
2 months or during the study period was prohibited. We per-
formed urine drug tests at screening and before each test session 
using Triage ® 8 (Biosite, San Diego, Calif., USA). Female partici-
pants were investigated during the follicular phase of their men-
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strual cycle (days 2–14) to account for cyclic changes in the reac-
tivity to amphetamines. A detailed description of the participants 
has been previously published  [9] .
 Study Procedures 
 Methylphenidate (60 mg, Ritalin ® ; Novartis, Bern, Switzerland) 
or placebo was administered orally at 08: 00 h. MDMA (125 mg, 
racemic MDMA hydrochloride; Lipomed, Arlesheim, Switzerland) 
or placebo was administered orally at 09: 00 h. A standardized lunch 
was served at 12: 00 h, and the subjects were sent home at 18: 00 h. 
The day following each test session, the participants returned to the 
research ward at 09: 00 h for the collection of the 24-hour blood 
sample.  The subjects did not engage in any physical activity and 
were resting in hospital beds during the test session. Blood samples 
for the analysis of plasma steroid hormone levels (cortisol, corti-
sone, corticosterone, 11-dehydrocorticosterone, 11-deoxycortico-
sterone, aldosterone, DHEA, DHEA-S, androstenedione, and tes-
tosterone) were collected 1 h prior to MDMA or placebo adminis-
tration and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 24 h 
following the administration of MDMA or placebo. The psychotro-
pic and autonomic effects of MDMA and methylphenidate from 
the present study have been presented elsewhere  [9] .
 Steroid Quantification 
 A detailed description of the materials, procedure, and 
 method  validation is included in the see online supplementary 
 material (for  all online suppl. material, see www.karger.com/
doi/10.1159/000364879). Briefly, plasma samples (1 ml) were 
mixed with 200 μl precipitation solution (0.8  M zinc sulfate in wa-
ter/methanol and deuterium-labeled aldosterone, cortisol, corti-
costerone, and testosterone as internal standards), diluted with 
water to 2 ml and centrifuged again. The supernatants were sub-
jected to Oasis HBL SPE cartridges for purification. The samples 
were reconstituted in 25 μl methanol. Steroids were separated and 
quantified by ultra-pressure liquid chromatography-tandem mass 
spectroscopy (UPLC-MS/MS) using an Agilent 1290 UPLC cou-
pled to an Agilent 6490 triple quadrupole MS equipped with an 
electrospray ionization source (Agilent Technologies, Basel, 
 Switzerland). The separation of analytes was achieved using a re-
verse-phase column (ACQUITY UPLC TM BEH C 18 , 1.7 μm, 2.1, 
150 mm; Waters, Wexford, Ireland). Mass Hunter software (Agi-
lent Technologies) was used for data acquisition and analysis. For 
method validation, see online supplementary material. 
 Statistical Analyses 
 Peak concentration (C max ) values were determined for all 
 repeated measures. Repeated-measures analyses of variance 
( ANOVAs) with the within-subject factors MDMA (MDMA vs. 
placebo) and methylphenidate (methylphenidate vs. placebo), fol-
lowed by the Tukey post hoc tests based on significant main effects 
of interactions in the ANOVA were used to assess differences in 
the effect of the different treatment conditions. Associations were 
assessed using Spearman’s rank correlations. One subject was ex-
cluded from the correlational analyses because of missing values. 
Because the effects of MDMA were similar regardless of whether 
MDMA was administered alone or combined with methylpheni-
date, the data were pooled for the correlational analyses (n = 30). 
The significance level was set to p = 0.05. The statistical analysis 
was performed using R project statistical packages (R Foundation 
for Statistical Computing, Vienna, Austria).
 Results 
 The peak levels of plasma steroid hormone concentra-
tions and statistics are shown in  table 1 . MDMA signifi-
cantly increased the plasma levels of the glucocorticoids 
cortisol, corticosterone, and 11-dehydrocorticosterone 
and mineralocorticoid 11-deoxycorticosterone compared 
with placebo ( fig. 1 a, c–e) but not the glucocorticoid cor-
tisone ( fig.  1 b). MDMA also significantly increased the 
sum of cortisol + cortisone and cortisol/cortisone ratio 
( table 1 ). The sum of corticosterone + 11-dehydrocortico-
sterone was also significantly elevated (data not shown), 
further supporting the increase in glucocorticoid produc-
tion. The levels of the mineralocorticoid aldosterone were 
increased by MDMA (significant main effect) but this ef-
fect was only significant for the MDMA + methylpheni-
date condition compared with placebo ( fig. 1 f). MDMA 
did not significantly alter the circulating levels of the an-
drogens DHEA, DHEAS, androstenedione, or testoster-
one ( fig. 2 a–e). For unknown reasons the absolute values 
obtained for DHEAS were lower than expected, allowing 
qualitative comparison only. Methylphenidate did not af-
fect any of the measured glucocorticoid, mineralocorti-
coid, or androgen hormones compared with placebo 
( fig. 1 ,  2 ). Administration of MDMA + methylphenidate 
led to similar hormonal responses compared with MDMA 
alone ( fig. 1 ,  2 ), with the exception of a more robust and 
significant increase in aldosterone. There were no interac-
tive effects of MDMA and methylphenidate on steroid 
levels. As expected, testosterone levels were lower in wom-
en than in men. No sex differences were observed in the 
effects of the drugs on steroid levels. However, significant 
positive correlations were found between the MDMA-in-
duced peak elevation of 11-deoxycorticosterone and aldo-
sterone and the peak increase in systolic blood pressure 
(R s  = 0.38 and 0.40, respectively, both p < 0.05, n = 30)  [9] . 
None of the steroid levels (peak or area under the concen-
tration-time curve changes from baseline) correlated with 
the simultaneously recorded psychotropic effects of 
MDMA including ‘good drug effects’, ‘drug liking’, ‘drug 
high’, ‘happy’, and ‘stimulated’ that have been reported 
previously  [9] . The time from MDMA administration to 
C max for cortisol, corticosterone, 11-dehydrocorticoster-
one, 11-deoxycorticosterone, and aldosterone was 2.1 ± 
0.8, 1.8 ± 0.6, 2.0 ± 0.6, 1.5 ± 0.5 h and 2.1 ± 1.5 h (mean ± 
SD), respectively. The time to C max for MDMA was 2.4 ± 
0.4 h  [9] . The MDMA-induced acute increases in circulat-
ing steroids generally disappeared within 6 h after drug 
administration. The plasma levels of cortisol, determined 
by UPLC-MS/MS (present findings) or radioimmunoas-
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say  [9] , at the 2 h time point after MDMA administration 
were significantly correlated across all measurements 
(R s  = 0.77, p < 0.001, respectively, n = 64).
 Discussion 
 The present study provides insights into the acute ef-
fects of two sympathomimetic drugs or pharmacological 
stressors on the plasma levels of a series of steroids in 
healthy humans. MDMA increased the plasma levels of 
the glucocorticoid cortisol. MDMA also increased the 
plasma levels of corticosterone and the inactive steroid 
11-dehydrocorticosterone, which is known to change in 
parallel with cortisol  [22] . Although circulating concen-
trations of corticosterone are lower than those of cortisol, 
a significantly increased ratio of corticosterone to cortisol 
was observed in the brain as a result of differential trans-
port by the P-glycoprotein at the blood-brain barrier  [23] . 
MDMA had no effect on the inactive cortisol metabolite 
cortisone, which is produced by 11β-hydroxysteroid de-
hydrogenase (11β-HSD) type 2, mainly in the kidney, and 
the reverse reaction is catalyzed by 11β-HSD1  [24] . Nota-
bly, MDMA increased both the sum of cortisol + cortisone 
levels and cortisol/cortisone ratio, suggesting an increase 
in HPA axis stimulation and possibly reduced or saturated 
11β-HSD2 enzyme function  [25] . A high cortisol/corti-
sone ratio has also been observed after acute ACTH ad-
ministration and in patients with chronic ACTH hyperse-
cretion  [25] . In contrast, a low cortisol/cortisone ratio 
characterizes adrenal insufficiency  [26] . MDMA also in-
creased the levels of the mineralocorticoids 11-deoxycor-
ticosterone and aldosterone, an effect that reached signif-
icance for the latter only when MDMA was co-adminis-
tered with methylphenidate. The mineralocorticoids, 
including aldosterone and 11-deoxycorticosterone, phys-
iologically increase renal sodium absorption and blood 
pressure. We observed a significant  association between 
MDMA-induced increases in mineralocorticoids and in-
creases in systolic blood pressure. However, MDMA does 
not alter plasma sodium levels or plasma osmolality as 
shown in a previous study  [27] . This finding would be well 
explained by the fact that MDMA also increases plasma 
arginine vasopressin  [27, 28] , which increases water reten-
tion and therefore has similar effects on blood pressure as 
aldosterone but opposite effects on plasma sodium levels. 
In fact, MDMA tended to increase urine osmolality  [27] . 
In the present study, MDMA did not affect the concentra-
tions of the androgens DHEA, DHEAS, androstenedione, 
or testosterone. Methylphenidate alone did not increase 
 Table 1.  Absolute peak plasma steroid concentrations and statistics
Placebo-
placebo
(mean ± SE)
Placebo-
MDMA
(mean ± SE)
Methylphenidate-
placebo
(mean ± SE)
Methylphenidate-
MDMA
(mean ± SE)
MDMA Methylphenidate Methylpheni date × 
MDMA
  F1,16 p value F1,16 p value F1,16 p value
Glucocorticoids
Cortisol, nM 463±53 770±45*** 556±54 765±43*** 43.47 <0.001 3.05 0.10 2.39 0.14
Cortisone, nM 36.7±1.8 40.9±2.7 43.4±3.0 42.6±2.2 0.34 0.57 3.65 0.08 1.39 0.26
Corticosterone, nM 8.4±1.5 29.7±2.4*** 12.8±2.4### 26.1±3.6*** 46.35 <0.001 0.05 0.82 2.54 0.13
11-Dehydrocorticosterone, nM 2.0±0.3 5.1±0.4*** 2.9±0.4### 5.2±0.5*** 45.49 <0.001 4.75 0.05 1.65 0.22
Cortisol + cortisone 499±52 796±45*** 582±54### 802±43*** 43.47 <0.001 3.05 0.10 1.46 0.25
Cortisol/cortisone ratio 15.8±1.7 24.8±1.5*** 16.6±1.5### 23.21±1.46*** 26.77 <0.001 0.29 0.60 1.24 0.28
Mineralocorticoids
Aldosterone, nM 0.16±0.04 0.25±0.06 0.17±0.04 0.33±0.11* 5.56 0.03 1.02 0.33 1.14 0.30
11-Deoxycorticosterone, nM 0.21±0.06 0.42±0.08** 0.26±0.07# 0.44±0.08*** 14.57 0.002 0.86 0.37 0.16 0.69
Androgens
DHEA, nM 24.7±6.6 24.6±3.5 19.7±2.4 23.7±3.4 0.69 0.42 0.95 0.35 0.27 0.61
DHEAS, nM 787±75 1.036±103 954±140 1,032±98 2.81 0.11 1.74 0.21 1.28 0.28
Androstenedione, nM 6.0±1.1 7.5±1.0 6.4±0.8 7.3±0.9 3.69 0.07 0.13 0.73 0.78 0.39
Testosterone in women, nM 0.59±0.25 0.55±0.14 0.45±0.19 0.57±0.10 0.07a 0.80 0.65a 0.45 0.45a 0.53
Testosterone in men, nM 11.8±4.4 13.0±3.9 14.0±4.3 13.0±4.0 0.00a 0.97 2.35a 0.17 3.03a 0.13
 Values are peak concentrations (mean ± SEM) of 16 subjects. * For p < 0.05, ** for p < 0.01, and *** for p < 0.001 compared to placebo-placebo. # For 
p < 0.05, and ### for p < 0.001 compared to placebo-MDMA (Tukey post hoc tests based on significant main effects in the ANOVAs).
a F1,7 (8 instead of 16 subjects).
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 Fig. 1.  a–f Effects of MDMA and methylphenidate on plasma con-
centration-time profiles of glucocorticoids and mineralocorti-
coids. The values are expressed as mean ± SEM in 16 subjects. 
MDMA was administered at t = 0 h. Methylphenidate was admin-
istered at t = –1 h. MDMA significantly increased the plasma con-
centrations of cortisol ( a ), corticosterone ( c ), 11-dehydrocortico-
sterone ( d ), and weak mineralocorticoid 11-deoxycorticosterone 
( e ) but not the non-bioactive glucocorticoid cortisone ( b ). MDMA 
also tended to moderately increase the plasma levels of the miner-
alocorticoid aldosterone ( f ). Similar changes in plasma steroid lev-
els were induced regardless of whether MDMA was administered 
alone or combined with methylphenidate ( a–f ). In contrast to 
MDMA, methylphenidate did not alter the plasma levels of any of 
the steroids ( a–f ). CYP = Cytochrome P450. 
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 Fig. 2. Effects of MDMA and methylphenidate on plasma concen-
tration-time profiles of androgens. The values are expressed as the 
mean ± SEM in 16 subjects (8 subjects for testosterone). MDMA 
was administered at t = 0 h. Methylphenidate was administered at 
t = –1 h. MDMA did not significantly alter the plasma concentra-
tions of DHEA ( a ), DHEAS ( b ), androstenedione ( c ), or testos-
terone in men ( d ) or women ( e ). Similar changes in plasma an-
drogen levels were induced regardless of whether MDMA was ad-
ministered alone or combined with methylphenidate ( a–e ). 
Similarly, methylphenidate did not alter the plasma levels of any 
of the androgens ( a–e ). 17β-HSD = 17β-Hydroxysteroid dehy-
drogenase. 
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the concentrations of any of the steroids measured. Co-
administration of MDMA + methylphenidate produced a 
similar hormonal response to MDMA alone.
 Several previous laboratory studies have documented 
similar and maximal 2-fold (50–100%) increases in plas-
ma cortisol levels in response to comparable doses of 
MDMA  [12–15] . In contrast, 2- to 8-fold increases in cor-
tisol levels were observed in dance clubbers who used 
MDMA while physically active  [16, 17, 29] . Moderate 
MDMA-induced elevations of DHEA were seen in a pre-
vious laboratory study  [12] . The effects of MDMA on all 
of the other steroids reported herein have not been previ-
ously described in a placebo-controlled setting. A non-
significant trend toward an increase in plasma testoster-
one levels has been reported in healthy subjects who used 
MDMA at a dance club  [16] . In contrast, we did not ob-
serve any effects of MDMA on testosterone levels in our 
placebo-controlled study.
 Methylphenidate at an oral dose of 60 mg did not affect 
steroid levels in the present study. Similarly, oral methyl-
phenidate at a dose of 20 mg did not alter plasma cortisol 
levels in healthy subjects  [30, 31] . In contrast, intravenous 
methylphenidate at doses of 10 mg (0.12–0.15 mg/kg) or 
0.3 mg/kg significantly increased cortisol levels in healthy 
subjects  [32] . Related catecholaminergic substances, such 
as amphetamine and methamphetamine, have also been 
shown to elevate cortisol levels in some studies  [33–36] 
but not others  [14] . A single dose of the NET inhibitor 
reboxetine also increased cortisol levels  [37] , particularly 
in subjects who scored high on subclinical depression 
 [38] . Chronic treatment with methylphenidate increased 
the levels of DHEA and DHEAS but not cortisol in chil-
dren with attention-deficit/hyperactivity disorder  [39] . 
There are several possible explanations why methylphe-
nidate at a relatively high single oral dose of 60 mg  [40, 
41] did not affect steroid levels in the present study. For 
example, cortisol levels are typically highest in the morn-
ing, which is when methylphenidate was administered in 
our study. In contrast, in studies that reported significant 
increases in cortisol, methylphenidate was administered 
in the evening, when cortisol levels are typically low  [32] . 
Additionally, physical activity may have enhanced the re-
sponse to stimulant drugs in some previous studies  [29] , 
whereas our subjects were resting. Finally, a significant 
response was observed with intravenous but not oral ad-
ministration, possibly because of faster changes associ-
ated with the mode of drug exposure.
 Pharmacologically, MDMA activates the 5-HT system, 
and methylphenidate does not  [7] . MDMA but not meth-
ylphenidate increased plasma prolactin levels  [9] , which is 
a clinical marker of serotonergic activity  [42] . The present 
study, therefore, indicates that 5-HT plays a crucial role in 
mediating activation of the HPA axis. In rats, the MDMA-
induced release of ACTH or corticosterone has been 
shown to involve 5-HT release and 5-HT 1 and 5-HT 2 re-
ceptor stimulation  [43, 44] . We previously showed that 
MDMA-induced increases in plasma cortisol in humans 
were blocked by the SERT/NET inhibitor duloxetine  [13] , 
which blocks the interaction of MDMA with the SERT 
and NET and the resulting MDMA-induced transporter-
mediated release of 5-HT and NE  [7] , but were not blocked 
by the NET inhibitor reboxetine  [13] , which only blocks 
the MDMA-induced release of NE  [45] .
 Additionally, MDMA and the 5-HT releaser meta-
chlorophenylpiperazine increased plasma cortisol levels, 
whereas amphetamine, which activates catecholamines 
more similarly to methylphenidate, did not  [14] . Selective 
activation of the 5-HT system by acute administration of 
the SERT inhibitor citalopram also increased plasma and 
salivary cortisol levels  [46] . Six-day treatment with citalo-
pram but not the NET inhibitor reboxetine also increased 
waking salivary cortisol levels  [47] . Finally, significant as-
sociations have been reported between polymorphisms in 
the genes that encode the SERT and HPA axis reactivity 
 [48] . Thus, these findings indicate a role for 5-HT in the 
mediation of MDMA-induced HPA axis stimulation in 
humans but little or no role for NE. Additionally, MDMA 
releases 5-HT from peripheral non-neuronal tissues di-
rectly into the blood plasma  [49] and 5-HT has been 
shown to directly stimulate aldosterone secretion by glo-
merulosa cells  [50] .
 One important issue is the clinical relevance of  MDMA’s 
effects on corticosteroids. Steroids are involved in a wide 
range of central and peripheral physiological functions re-
lated to mood, cognition, adaptation to stress, immune 
function, and others. In the context of recreational drug 
use, cortisol, DHEA, and testosterone may contribute to 
or modulate substance-induced acute psychotropic and 
reinforcing effects  [12, 20, 21] . For example, MDMA-in-
duced increases in plasma cortisol levels have previously 
been shown to correlate with subjective drug liking in re-
sponse to MDMA in a laboratory study  [12] . Stress-in-
duced increases in cortisol were also correlated with posi-
tive mood responses to amphetamine  [51] . Nonetheless, 
we found no associations between plasma steroid levels 
and any of the previously reported psychotropic effects of 
MDMA in the present study  [9] or in our previous work 
 [13] . It is possible that we missed a true association be-
cause of the small study size. It is also possible that the 
subjective and some endocrine responses were maximal 
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and therefore similar in most subjects (low between-sub-
ject variability). For example, such a lack of between-sub-
jects correlations has previously been documented for 
correlations between MDMA plasma levels and autonom-
ic effects  [52] . The pleasurable effects of amphetamine and 
methamphetamine in humans also did not change when 
cortisol levels were increased pharmacologically  [53] or 
lowered by metyrapone administration prior to metham-
phetamine administration  [33] . As noted above, MDMA-
induced elevations of mineralocorticoids may also con-
tribute to regulation of the hypertensive effects of MDMA. 
Corticosteroids may also facilitate the development of hy-
perthermia associated with amphetamines, a potentially 
fatal complication of recreational ecstasy use  [54, 55] . In 
rats, adrenalectomy or administration of a glucocorticoid 
receptor antagonist suppressed methamphetamine- and 
MDMA-induced increases in body temperature  [56–58] . 
Human data are lacking, but MDMA-induced elevations 
of steroids may contribute to the clinical toxicity of ec-
stasy  [16, 29] . Finally, repeated HPA axis stimulation by 
MDMA may contribute to chronic toxicity  [11, 17, 29] , 
including the deficits in neurocognitive function de-
scribed in heavy ecstasy users  [59] .
 The present study has several limitations. First, we used 
only single doses of the drugs. However, the selected dos-
es were high and produced pronounced and comparable 
sympathomimetic and drug-typical psychotropic effects 
 [9] . Second, we did not assess corticotropin-releasing fac-
tor or ACTH levels to describe the drugs’ effects on other 
mediators within the HPA axis. Instead, we provided the 
full profiles of ten steroids. Specifically, we included corti-
costerone, which is the biologically relevant glucocorti-
coid in rodents, the mineralocorticoid aldosterone, and 
androgens, which may play a role in mood regulation.
 In conclusion, the MDMA- but not methylphenidate-
induced effects on plasma steroids are consistent with a 
role for 5-HT in drug-induced HPA axis stimulation in 
the absence of other (psychosocial) stressors. Remaining 
to be investigated are whether and how the different ste-
roids contribute to the acute and chronic effects of these 
psychoactive drugs.
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5. Chapter 3: The role of the short-chain dehydrogenase/reductase 
(SDR) DHRS7 in prostate and breast cancer 
Introduction 
The SDRs are a class of enzymes known to be involved in metabolic functions and their impaired 
expression and activities have been associated with metabolic disorders, degenerative diseases and 
cancer [7]. Amongst others, the major physiological function of SDR enzymes, namely their ability to 
control the cellular availability of hormone receptor ligand, makes some members interesting therapeutic 
drug targets. 11β-HSD1 inhibition, for example, shows promise in the treatment of metabolic syndrome, 
atherosclerosis and osteoporosis [73]. On the other hand, inhibition of 17β-HSDs, which control sex 
hormone metabolism, may be important targets in breast and prostate cancer treatment [8, 74]. 
Uncharacterized SDRs may be potential candidates to treat monogenic and multifactorial diseases 
including cancer. The identification and subsequent functional characterization of new SDRs may help 
identifying novel targets for drug development [75]. There is evidence that several “orphan” enzymes may 
be involved in cancer processes, such as the “orphan” prostate SDR 1 (PSDR1) (also called retinol 
dehydrogenase 11 and known under the nomenclature name SDR7C1). PSDR1 is an androgen receptor 
regulated member of the SDR family, which was found to be highly expressed in healthy and neoplastic 
prostate tissue compared to tumor tissue, suggesting it may play a role in pathogenesis of prostate cancer 
(PCa)  [76]. SDRO, also known under the nomenclature name SDR9C7, is another novel SDR.  The 
expression of SDRO was closely correlated with metastasis and it was suggested to be a prognostic 
marker for cancer patients [77]. Furthermore, “orphan” 11βHSD3 (SCDR10B) showed increased 
expression in human cancerous lung compared to healthy lung tissue, suggesting a possible role in 
cancer progression [78]. Even though many “orphan” SDRs seem to play a role in complex cancer 
processes, the endogenous mechanisms of action remains unknown and one of the major challenges 
facing researchers is to identify and characterize the endogenous substrates of these enzymes [79]. 
Dehydrogenase/Reductase SDR Family Member 7 (DHRS7) (also known as retSDR4 and under the 
nomenclature name SDR34C1), is an “orphan” SDR expressed in various tissues including the liver, 
kidney, skeletal muscle and prostate [80, 81]. To date, little is known about DHRS7’s catalytic activity. 
However, a recent publication by Stambergova et al. showed that DHRS7 metabolizes endogenous 
substrates with a steroid structure (estrone, cortisone, 4-androstene-3,17-dion) and exogenous 
substances bearing a carbonyl group (1,2-naphtoquinone, 9,10-phenantrenequinone, 
benzoquinone, nitrosamine 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone) in vitro, using NADP(H) as a 
cofactor with preference [82]. In another study, DHRS7 showed increased mRNA expression levels in 
goose hepatocytes treated with free fatty acid mixtures, indicating a possible role in the metabolism of 
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these compounds [83]. Interestingly, microarray data of a recent study showed elevated DHRS7 
expression in wild type mice fed a low fat, high caloric diet compared to a normal diet, an observation 
abolished in the stearoyl-CoA desaturase-1 (SCD1) knockout animals [84]. This data suggests that SCD1 
might be involved in DHRS7 regulation and since SCD1 is a key regulator of fatty acid metabolism, this 
finding suggests also a possible role of DHRS7 in fatty acid metabolism.  Previously it was reported that 
mRNA expression levels of DHRS7 increased in rats following a 2/3 hepatectomy, indicating a possible 
function of this “orphan” enzyme in liver regeneration, entailing cell proliferation and differentiation 
processes [85]. Supporting the hypothesis of DHRS7 having a possible role in cell proliferation and 
differentiation, microarray expression data from three independent studies on human PCa tissue showed 
that DHRS7 levels are altered in this tumor [86-88]. A recent study in a novel hollow fibre mouse model 
setup, using the LNCaP PCa cells, showed that DHRS7 mRNA levels were significantly altered as the 
tumor develops into castration resistant prostate cancer (CRPC) [89]. DHRS7 may therefore play a role in 
this disease by sustaining de novo androgen synthesis and/or metabolism in CRPC, eventually leading to 
the reactivation of androgen receptor (AR), thus promoting cancer progression, even in the absence of 
testicular androgens [89]. Interpretation of this data leads to the assumption that DHRS7 may play a role 
in PCa progression. 
 
Sites Estimated new cases Estimated deaths % of new cases 
Prostate 233000 29480 12.7 
Lung 116000 86930 74.9 
Urinary bladder 56390 11170 23.1 
Colon 48450 26270 59.9 
Skin (Melanoma) 43890 6470 11.5 
Kidney 39140 8900 22.7 
Non-Hodgekin Lymphoma 38270 10470 27.4 
Liver 24600 15870 64.5 
Pancreas 23530 20170 85.7 
Rectum 23380   0.0 
 
Table 2: US statistics of cancer in male 2014. Modified after: Siegel et al., Cancer statistics 2014 [90] 
 
PCa is one of the most common malignancies worldwide and the second leading cause of cancer-related 
death among males in Europe and the United States (Table 2). Clinically, PCa manifests as a 
heterogeneous multifocal disease with rising incidence [90, 91]. The mechanisms underlying the initiation 
and progression of PCa are complex. Initial, pre-malignant lesions, which are attributed to genetic 
alterations in one or more cells, arise.  The accumulation of genetic alterations in pre-malignant cells 
drives them into malignant growth and into the production of a primary tumor. Cells in a primary tumor 
express heterogeneous phenotypic and biological characteristics, which are caused by the differences in 
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the genes altered. Therefore, some highly metastatic cells, possessing invasive and metastatic ability, 
might occur. Such cells selectively are able to produce a metastatic tumor in a distant organ (Figure 6) 
[92].  
In addition to environmental factors, age and familial inheritance, steroid hormone receptor signaling is 
mainly involved in all stages of prostate carcinogenesis. The early development of PCa, as well as the 
progression to CRPC can be driven by AR signaling pathway. Hence, the progression of PCa to CRPC 
can be initiated by several mechanisms, including hypersensitivity of the AR signaling pathway to 
androgens, enrichment or accumulation of androgen-insensitive stem cells, and the activation of 
intratumoral steroidogenesis. In addition to the AR, specific genes and signaling pathways such as Wnt/β-
catenin signaling, proto-oncogenes MET and MYC, vascular endothelial growth factor receptor (VEGFR) 
signaling, phosphatase and tensin homolog (PTEN), ERBB2 encoding human epidermal growth factor 
receptor 2 (HER2), B-cell CLL/lymphoma 2 (BCL2) and many others have been suggested to play a role 
in PCas development and progression [93-95]. Furthermore, evidence suggested that the process of 
epithelial to mesenchymal transition (EMT) plays a pivotal role in the development of metastatic CRPC. 
EMT is a process by which epithelial cells lose their characteristics and acquire mesenchymal properties, 
which allows cancer cells to detach from the tumor mass and translocate to other tissues. At the molecular 
level, EMT is characterized by the loss of the epithelial cell adhesion molecule E-cadherin (CDH1), which 
enables cells to increase motility and invasiveness through the disruption of intercellular contacts [96, 97]. 
 
 
Figure 6: PCa progression. Modified after: Abate-Shen et al.; Molecular genetics of prostate cancer [98] 
 
Although the survival rate of PCa is high due to recent advances in current therapeutic and screening 
methods, many patients still develop post-operative disease relapse and endure significant treatment-
associated complications. The current standard for the treatment of PCa is either medical or surgical 
castration.  However, after castration, PCa can progress to CRPC and patients may develop metastases 
in lymph nodes, liver and bone. To provide better strategies for the prevention and treatment of PCa it is 
important to further investigate the molecular mechanisms underlying the initiation and progression of the 
disease [99, 100]. 
Given that DHRS7s may play a role in PCa, we carried out tissue microarray (TMA) and immuno detection 
of DHRS7 in clinical human prostate tissue samples of different tumor stages in collaboration with Prof. 
Dr. L. Terracciano and co-workers. To expand on the findings in the clinical samples, I conducted an in 
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vitro study to evaluate the functional effects of the enzymes in cancer progression. To determine the 
effects of DHRS7 on the metastatic potential of cells in vitro, I evaluated cell proliferation, migration and 
adhesion after siRNA mediated knockdown of DHRS7 in three prostate cell lines, namely LNCaP, BPH1 
and PC3. Additionally, I performed a microarray in LNCaP cells treated with siRNA against DHRS7 to 
identify pathways involved in DHRS7 action.  
In addition to PCa, I also investigated the role of DHRS7s in breast cancer (BC). BC is also a 
heterogeneous disease and presents a leading cause of cancer death in females worldwide. [90] The 
development of BC involves the progression through an intermediate complex process, beginning with 
ductal hyperproliferation, followed by development of a local carcinoma and finally metastases [101]. 
Comparable to PCa, steroid signaling, specifically the estrogen receptor (ER) pathway, plays a critical role 
in the development of BC and its progression and continuing exposure to endogenous or exogenous 
estrogen is a well characterized cause of BC. For this reason, the use of selective estrogen receptor 
modulators, such as tamoxifen, is the most common treatment for BC. However, the efficacy of tamoxifen 
is limited by intrinsic and acquired resistance, since it requires functional ER signaling to work [102]. 
Possible mechanisms for endocrine resistance include the deregulation of the ER pathway itself, 
comprising loss of ER expression, post-translational modification of ER and the deregulation of ER co-
activators. Besides altered estrogen signaling, other mechanisms also influence tumor cell proliferation 
and survival and can therefore cause resistance. For instance, increased receptor tyrosine kinase 
signaling also leads to the activation of various intracellular pathways involved in signaling transduction, 
proliferation and cell survival. Alterations in cell cycle and apoptosis, as well as epigenetic modification 
and altered expression of specific microRNAs are other possible mechanisms leading to BC progression 
[103]. EMT, which increases motility, invasiveness and metastatic capabilities of BC cells is suggested to 
be a mechanism for endocrine therapy resistance and cancer progression [104]. 
Given the high degree of diversity between and within tumors as well as among patients suffering from BC 
the determination of the risk of disease progression and therapeutic resistance is challenging. Molecular 
classification, using immunohistochemistry to characterize the hormone receptor expression of the tumors 
and other cell markers has become useful for diagnosis and treatment of BC. Three major subtypes can 
be distinguished within BC: luminal A (ER+ and/or PR+; HER2−) or B (ER+ and/or PR+; HER2+), the 
HER-2 amplified (ER−, PR−, and HER2+), and the basal-like (ER−, PR−, and HER2−) also called triple-
negative cancer (TNBC). The characteristics and risk factors of each of these subtypes are different, such 
as their response and resistance to treatment, the risk of disease progression or the propensity to spread 
metastatic cells to a particular organ [105]. Thus, when compared with other BC subtypes, TNBC is an 
aggressive neoplasia strongly associated with distant recurrence, metastases and death. Hence, 
understanding and characterizing biomarkers, including their role in cancer progression and drug 
resistance as well as their use for diagnosis and treatment is important for BC treatment [106]. My recent 
findings in PCa and evidence of altered DHRS7 expression from several microarrays in different stages of 
BC suggests that DHRS7 may also play a role in BC progression [107-109]. To identify DHRS7s role in 
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BC I first selected a panel of cell lines based on the enzymes mRNA and protein levels. Subsequently, I 
performed proliferation and migration assay in ZR-75-1 cells.  
Previous studies showed an increase in DHRS7 gene expression in regenerating rat liver following 2/3 
hepatectomy [85]. Additionally, the assessment of microarray data derived from pathology group in 
patients suffering from hepatocellular carcinoma (HCC) also showed altered DHRS7 levels [85]. Taking 
these results into account, I hypothesized that DHRS7 may play a role in liver regeneration. We obtained 
mouse liver samples from regenerating liver following 2/3 hepatectomy from Prof. Dr. Dufour. Additional 
work on molecular regulation of DHRS7 by factors involved in liver regeneration has been examined by 
the master student P. Marbet whom I supervised [110]. 
To date, several steroid hormones and xenobiotics have been tested by me, to see if they are metabolized 
by DHRS7 using different in vitro setups such as activity assays in cells expressing recombinant DHRS7.  
The first results presented in the third chapter of my thesis provide evidence that the “orphan” enzyme 
DHRS7 acts as a tumor suppressor and that its loss of function promotes PCa and BC cell 
aggressiveness. Additionally, I characterized, using qPCR and transactivation methods, the molecular 
regulation of DHRS7 by sex steroids in LNCaP cells.  
Finally, based on data from several microarrays, I tested if diet plays a role in the expression of DHRS7 in 
high fat versus low fat fed animals [111-113]. 
Results and Discussion 
The role of DHRS7 in prostate cancer  
The first study on DHRS7 conducted in this thesis focused on the role of DHRS7 in different PCa grades. 
In collaboration with Prof. Dr. L. Terraccianos Molecular Pathology, University of Basel, DHRS7 protein 
levels were analysed by immunohistochemistry in a large collection of human prostate specimens using 
TMA (Figure 1A in the submitted manuscript). This analysis determined DHRS7 to be highly expressed in 
normal prostate and samples scored as benign (Figure 1B in the submitted manuscript). Conversely, most 
of the PCa specimens showed lower levels of DHRS7 protein expression. Importantly, this study reports 
for the first time, that DHRS7 protein levels are decreased in human PCa tissues and negatively correlate 
with Gleason levels. However, Kaplan-Meier analysis did not show a significant association between 
DHRS7 expression and the survival of PCa patients (Figure 1C in the submitted manuscript). Other 
important tumor suppressor genes, like p53, also fail to serve as prognostic markers for survival although 
their partial loss of expression in PCa is correlated with increased tumor aggressiveness. This may be due 
to heterogeneity within the tumor and small TMA cohorts with low statistical power [114]. Therefore, it 
remains to be established whether low DHRS7 levels serve as a possible biomarker to predict a poor 
prognosis of PCa patients. To support the TMA findings, the impact of DHRS7 on prostate cancer cell 
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aggressiveness was tested in vitro. I identified three cell lines expressing DHRS7 on an endogenous level. 
MRNA and protein levels of DHRS7 in the selected cell lines, namely LNCaP, BPH1 and PC3, were highly 
diverse (Figure 7A and Figure 2 in the submitted manuscript). From the panel of cell lines, LNCaP showed 
the highest expression of DHRS7 on the protein and mRNA level. A recent study suggested highly 
elevated DHRS7 levels in the LNCaP cell line in a novel hollow fibre mouse model setup [89]. LNCaP is a 
PCa cell line established from a metastatic lesion of human prostatic adenocarcinoma. High specific 
expression of ARs and ERs and its hormone responsiveness rank among the main characteristics of this 
cell line; thus 5α-dihydrotestosterone modulates cell growth and stimulates acid phosphatase production 
in LNCaP in vitro. The mean population doubling time of these androgen-dependent cells is approximately 
60 hours [115].  In contrast, BPH1, an immortalized but non-transformed human prostate epithelial cell line 
displayed the lowest amount of DHRS7 protein expression close to the limit of detection using 
immunoblotting. This cell line expresses a relatively low mRNA level in qPCR analysis when compared to 
the other cell lines. BPH1 cells do not express AR or the secretory markers, prostate specific antigen 
(PSA) and prostatic acid phosphatase [116]. Another cell line, PC3, showed a lower endogenous 
expression of DHRS7 protein compared to the LNCaP cells. PC3 cells are derived from human lumbar 
vertebral metastasis. Similar to BPH1, PC3 cells do not express AR and PSA. The doubling time of PC3 
cells is approximately 33 hours, the lowest of all the tested models [117]. Additionally, I assessed the 
endogenous expression of DHRS7 in DU145 cells, another PCa cell line commonly used in other studies. 
Neither the mRNA nor protein levels of DHRS7 could be detected in this cell model. 
 
 
Figure 7: (A) Endogenous expression of DHRS7 mRNA in different prostate cell lines, (B) main characteristics 
of the prostate cell models (modified after Sobel et al. [117]) 
 
Following the selection of the prostate cell model panel, I characterized the effects of siRNA-mediated 
DHRS7 knockdown. First I selected one DHRS7 targeted siRNA from a panel of four. The selected 
molecule clearly showed lower expression of DHRS7 mRNA levels compared to the other siRNAs after 72 
hours of knockdown in the LNCaP cells (Supplementary Figure 1 in the submitted manuscript). To exclude 
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off-target siRNA mediated effects, the proliferation experiments in the LNCaP cells were performed using 
an additional siRNA molecule targeting DHRS7 (Supplementary Figure 2 in the submitted manuscript). 
Subsequently, proliferation, migration and adhesion assays in LNCaP, BPH1 and PC3 cells were 
performed. XCelligence measurement as well as Ki-67 immunostaining showed increased cell proliferation 
in LNCaP cells but not in BPH1 and PC3 cells following DHRS7 knockdown (Figure 2 in the submitted 
manuscript). The significantly lower endogenous expression of DHRS7 in BPH1 and PC3 cells compared 
to LNCaP cells is one possible explanation for the different growth response in these cell models. 
Furthermore, LNCaP cells differ extensively in their characteristics from the other models, as androgen-
dependent proliferation might promote DHRS7 knockdown effects. The basal proliferation rate of LNCaP 
cells is additionally much lower (approximately 60 h doubling time) compared to the doubling time of PC3 
and BPH1 cells (approximately 30-45 hrs), hence might account for the more pronounced proliferation 
effects in LNCaP cells. The heterogeneity of the cell models used in this study and the fact that many 
other studies reported differences in growth response in different prostate cell lines like the LNCaP and 
PC3 explain the variable results [118-120]. Migration and adhesion were found to be altered in all three 
cell lines after siRNA controlled knockdown of DHRS7 (Figure 4 in the submitted manuscript). However, in 
a transwell migration setup, LNCaP cells showed the most pronounced increase in migrating cells when 
compared to the two other models. Again, the low endogenous expression of DHRS7 in BPH1 and PC3 
cells as well as the variance in characteristics of the cell models might account for the observed 
differences. Nevertheless, adhesion was affected to a similar degree in all the cell lines. 
To understand the mechanisms underlying the effects of DHRS7 depletion and to further support the 
previous findings, I performed a microarray study using cells treated with siRNA targeting DHRS7 and 
compared the gene expression with that of cells transfected with a non-targeted RNA control. Given the 
high endogenous expression level and the most pronounced changes after DHRS7 knockdown, LNCaP 
cells were chosen for this experiment. Several genes involved in cell proliferation and adhesion pathways 
were found to be altered in DHRS7 depleted LNCaP cells. Specifically, expression of genes belonging to 
the BRCA1/2 pathway as well as the major EMT regulator CDH1 decreased following DHRS7 knockdown 
(Figure 5 in the submitted manuscript). Loss of CDH1 promotes the transition of epithelial cells to the 
mesenchymal state (EMT), which is linked to PCa progression [121]. Decreased CDH1 expression could 
additionally be linked to the observed increase in migration and altered adhesion in the prostate cell lines 
[122, 123].  
Another possible mechanism for the DHRS7-mediated regulation of PCa progression could involve the 
BRCA1/2 pathway, which is a key player in repairing DNA double-strand breaks or directing cells into 
apoptosis if DNA cannot be repaired. BRCA1 and BRCA2, are both breast and prostate tumor 
suppressors and their loss is associated with enhanced cell proliferation and cancer progression [124, 
125]. Other genes belonging to the BRCA pathway changed expression following DHRS7 knockdown, 
including BRCA1 associated ring domain protein 1 (BARD1), BRCA1 interacting protein C-terminal 
helicase 1 (BRIP), cell cycle checkpoint kinase 1/2 (CHEK1/2), fanconi anemia complementation group D2 
protein, isoform 1 (FANCD2) and DNA repair protein, S.cerevisiae homolog (RAD51). There are 
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numerous DNA repair pathways directed by the BRCA pathway to specific types of DNA damage (Figure 
8). Following DNA damage, activation of BRCA1 occurs via phosphorylation directly or indirectly through 
CHEK2. BRCA1 then can activate several pathways involved in different repair mechanisms. For 
example, homologous recombination repair is directed by interaction of BRCA1 and BRCA2 with RAD51 
and FANCD2. Moreover, BRCA1 can activate BRIP1, which is also able to trigger homologous 
recombinational repair [126]. Another repair mechanism includes the interaction of BRCA1 with BARD1, 
which forms a heterodimeric ubiquitin E3 ligase complex that is required for the accumulation of ubiquitin 
conjugates at sites of DNA damage and for silencing at DNA satellite repeat regions [127]. Detected 
down-regulation of these genes was found in the microarray analysis, which leads to the assumption that 
DHRS7 may play a role in the BRCA pathway. However, the changes in the BRCA pathway genes were 
most pronounced 72 hours following the knockdown and might therefore be secondary effects. 
Consequently, the microarray helped to generate new hypothesis, but the identification of the mechanism 
of DHRS7 and its role in cancer progression warrants further research. 
 
 
Figure 8: Microarray results: BRCA1 pathway. Boxplot represents median, 75th confidence interval and 
whiskers represent 95th of three independent replicates 
 
In conclusion, the results of this study provide the first evidence that DHRS7 may be a tumor suppressor 
and that its loss of function promotes PCa cell aggressiveness. Further studies are required to 
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characterize the function of DHRS7 and to uncover its regulation. Additional evidence for the tumor-
suppressive role of DHRS7 may help to evaluate this enzyme as a novel therapeutic PCa target and/or as 
a diagnostic biomarker.  
The role of DHRS7 in breast cancer  
 
The findings regarding the role of DHRS7 in PCa and the effects on the BRCA1/2 pathway that also play a 
crucial role in breast cancer, led me to examine the role of DHRS7 in BC in vitro. First, it was necessary to 
identify cell models endogenously expressing DHRS7 on the mRNA and protein level. All tested BC cell 
lines, namely MDA-MB-231, MDA-MB-453, HCC1569, T47D, MCF7, ZR-75-1, SUM159 and MDA-MB-468 
expressed comparable DHRS7 mRNA levels, but the protein levels did not correlate (Figure 9). This may 
be explained by the substantial role for regulatory processes, which occur after mRNA is transcribed 
including post-transcriptional, translational modifications and protein degradation regulation in controlling 
steady-state protein abundances [128]. Compared to LNCaP cells, the protein expression of DHRS7 in all 
the examined BC cell lines is much lower. The cell line SUM159 showed only background levels of protein 
expression. Since BC is highly heterogeneous, the different cell lines used in this study differ not only in 
DHRS7 expression but also vary in their properties (Table 3) [129]. 
 
 
 
Figure 9: Endogenous mRNA and protein expression of DHRS7 in different BC cell lines. LNCaP served as a 
positive and HEK as a negative control 
 
Almost all of the examined cell lines were established from malignant effusions and thus are derived from 
patients with an advanced stage of the disease. Nevertheless, each BC cell line possessed distinct 
differences in their morphological characteristics and ploidy, immunohistochemical expression of the ERs, 
progesterone receptors (PR), and ERBB2 amplification. Hence their proliferation behavior as well as their 
migration and invasive potential are different. Cell lines, for example MDA-MB-231 and SUM159 with 
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stellate morphology for example are reported to be highly metastatic and invasive, therefore may share 
similar characteristics to the PCa cell line PC3 and may no longer respond to effects mediated by DHRS7 
knockdown [130]. Since variable proliferation effects were shown in the prostate cells, the heterogeneity of 
the BC cell lines may similarly lead to variable results.  Because of their slow growth rate ZR-75-1 cells 
were used as the first model in this study. Other cell lines, with moderate growth rates that could be valid 
to tested for siRNA mediated knockdown effects of DHRS7 are the hormone-dependent MCF7 and T47D 
as well as the ERBB2 amplifying MDA-MB-453 and the basal-like cell line MDA-MB-468. ZR-75-1 cultures 
were derived from a malignant ascetic effusion of a 63-year-old female [131].  
 
Morphology Cell line ER PR ERBB2 amp 
Mutation 
status Tumor type 
Tumor 
source 
Tumor 
classification 
 
Doubling 
time 
[hrs] 
Mass 
HCC1569 neg  neg pos  PTEN, TP53 metaplastic carcinoma primary 
ERBB2 
amplified 40 
MCF7 pos pos pos CDKN2A, PIK3CA 
invasive ductal 
carcinoma 
metastasis 
(pleural 
effusion) 
Luminal 38 
T47D pos pos neg PIK3CA, TP53 
invasive ductal 
carcinoma 
metastasis 
(pleural 
effusion) 
Luminal 50 
Grape like 
MDA-MB-
468 neg  neg  neg 
MADH4, 
PTEN, RB1, 
TP53 
adenocarcinoma 
metastasis 
(pleural 
effusion) 
Basal-like 47 
MDA-MB-
453 neg  neg pos 
CDH1, 
PIK3CA adenocarcinoma 
metastasis 
(pleural 
effusion) 
ERBB2 
amplified 50 
ZR-75-1 pos pos pos N/A invasive ductal carcinoma 
metastasis 
(ascites) Luminal 80  
Stellate 
MDA-MB-
231 neg  neg neg 
BRAF, 
CDKN2A, 
KRAS, TP53 
adenocarcinoma 
metastasis 
(pleural 
effusion) 
Basal-like 24 
SUM159 neg  neg pos N/A anaplastic carcinoma primary 
ERBB2 
amplified 20 
         
 
Table 3: Relevant characteristics of malignant breast cell lines used are organized by morphology and 
summarized here. ER, PR, ERBB2 amplification status, primary tumor type, tissue source and tumor 
classification (modified after Kenny et al.) 
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Figure 10: Migration of ZR-75-1 cells after knockdown of DHRS7 assessed by the transwell migration assay. 
Cells transfected with siRNA against DHRS7 or scrambled non-targeted control siRNA were seeded on 
transwell inserts at 24 h post-transfection, followed by crystal violet staining after another 24 h. Stained cells 
in 5 fields scanned at 10x magnification setting were analysed using ImageJ. Representative pictures of 
migration assays are shown. Data represents mean ± SD from three independent experiments conducted in 
triplicate. Statistical analysis was performed using the Student’s t-test; *p ≤ 0.0001 compared to the non-
targeted control. 
 
They have a very high cell-doubling time of approximately 80 hours and their growth can be stimulated by 
estrogen and inhibited by tamoxifen [131]. The MCF7 cells originate from pleural effusion of a patient with 
metastatic mammary carcinoma [132]. This cell line has characteristics of a differentiated mammary 
epithelium, including the expression of cytoplasmic ER and the capability of forming domes. Its growth is 
moderate with a doubling time of approximately 38 hours [132]. T47D also express a functional ER 
response [133]. Doubling time of this model is about 50 hours. The MDA-MB-453 BC cell line was 
obtained from a malignant pleural effusion of a 48-year-
old female and has been suggested as a model for the 
molecular apocrine breast subtype since it exhibits as 
characteristic apocrine carcinoma steroid receptor profile: 
ER-α-negative, PR-negative and AR-positive. Increased 
proliferation in response to androgens is the key feature 
of MDA-MB-453, which can be blocked by anti-
androgens, such as flutamid. Her-2/neu activity has been 
well documented in this model, as well as the existence 
of a functional cross-talk between AR and Her-2/neu, 
involving the MAPK/ERK1/2 pathway. These features 
also tend to characterize a substantial proportion of 
Figure 11: proliferation of ZR-75-1 cells after 
DHRS7 knockdown with siRNA. (n=1) 
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invasive apocrine carcinomas of the breast. Doubling time of MDA-MB-453 cells is approximately 50 hours 
[134]. The cell line MDA-MB-468 originates from the same female patient, but belongs to the basal-like 
group and exhibits a doubling time of 47 hours.  
Following the characterization of BC cell models, the first experiments using siRNA to knockdown DHRS7 
were carried out in ZR-75-1 cells. Comparable to the prostate cell lines in the first study described in this 
thesis, this BC model showed an increase in the migration rate following 24 hour DHRS7 knockdown 
(Figure 10). Additionally, preliminary xCelligence data shows an increase in the cell proliferation in the ZR-
75-1 cells following DHRS7 knockdown (Figure 11). These first results give a hint that DHRS7 not only 
plays a role in prostate, but also in BC progression. However, disclosing the role of DHRS7 in breast 
cancer warrants further research in the ZR-75-1 cells as well as other BC cell lines. To expand this study 
in the future, in addition to the assays we used in the PCa project, I would like to establish methods to 
assess cancer progression such as an invasion assay and the use of -omics methodologies such as 
proteomics as well as interactomics to study the mechanism of DHRS7 action in cancer progression on 
molecular level. 
The role of DHRS7 in liver regeneration, metabolism and its regulation on molecular level  
In addition, to the role of DHRS7 in cancer, the “orphan” enzyme was previously linked to liver 
regeneration. In an earlier publication the mRNA expression of DHRS7  was shown to be elevate in rats 
following a 2/3 hepatectomy, indicating that DHRS7 may play a functional role in liver regeneration [85]. 
To further investigate these findings, I obtained liver tissue samples from 9 mice as a kind gift from Prof. 
Dr. JF. Dufour and co-workers from the Inselspital in Bern. The samples consisted of regenerating liver 
taken 24, 72 and 120 hours following 2/3 hepatectomy. Tissue obtained from the same animals during the 
hepatectomy surgery at time point 0 was used as a 
control. The qPCR analysis showed no significant 
differences in DHRS7 gene expression in regenerating 
liver following hepatectomy compared to control (Figure 
12). In contrast, I observed a trend for a reduction in 
DHRS7 mRNA levels following hepatectomy. 
Interspecies differences may be a possible explanation 
for this finding, since other publications also highlight 
interspecies phenotypic discrepancies, for example, 
stem cell-mediated liver regeneration was different 
between rats and mice. Therefore it is important to take 
into account the differences of individual species when 
extrapolating data [135]. Furthermore, the two studies 
followed different experimental protocols. The control 
samples I assessed were derived from the same animal 
at time point 0 during the 2/3 hepatectomy surgery, 
Figure 12:DHRS7 gene expression in mice24, 72 
and 120 h following 2/3 hepatectomy compared 
to control 
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whereas Wang et al. performed an operation control in additional animals [85, 136]. Other studies also 
show variable results in the liver under different stresses and pathologies [112, 137, 138]. To further 
investigate the role of DHRS7 in liver regeneration, DNA expression levels of patients exposed to different 
causes, leading to liver damage, were analyzed. Microarray data derived from patients suffering from 
hepatocellular carcinoma (HCC), performed in Prof. Dr. L. Terracianos group showed decreased levels of 
DHRS7 mRNA in HCC caused by Hepatitis C Virus (HCV) (Figure 13). Previous data generated in our lab 
by Dr. A. Meyer showed elevated DHRS7 mRNA following ethanol (4% in drinking water) administration to 
rats for three month (data not shown).  
Microarray data from a recent publication showed patients with alcoholic hepatitis had elevated gene 
expression compared to normal tissue [137]. However, comparisons between species as well as between 
cause and stage of liver damage, seems to be complex, since specific pathways might be triggered and 
therefore DHRS7 might be regulated in different ways [139, 140]. The levels of DHRS7 are clearly altered 
in the liver under specific conditions and warrant further research to understand its role. 
To determine the possible mechanisms underlying transcriptional regulation of DHRS7 following liver 
damage, the impact of several factors involved in hepatocyte proliferation during liver regeneration has 
been assessed in different hepatic cell lines by the master student P. Marbet, under my supervision. None 
of the tested factors, namely epidermal growth factor, tumor necrosis factor alpha, insulin and 
transforming growth factor beta 1 impacted significantly on DHRS7 mRNA levels in any of the evaluated 
cell lines [110].  
Besides, defining the role of 
DHRS7 in different disease 
states, I also focussed on 
characterizing the enzymes 
metabolic properties and gene 
regulation. Therefore, 
experiments were designed to 
attempt to “deorphanize” 
DHRS7 by finding its possible 
substrates. I used LC-MS/MS 
as well as assessing the gene 
expression of DHRS7 following 
steroid hormone treatments in 
vitro. To date, the substrate(s) 
of DHRS7 remain unknown. 
Although a recent study 
suggested that DHRS7 might 
catalyze the reduction of 
several steroid hormones such 
Figure 13:DHRS7 mRNA expression in human liver of patients suffering 
from HCC cause by alcohol (EtOH), Hepatits B or C virus (HBV, HBC) or 
combinations compared to normal liver. The data is derived from 
microarray data 
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as cortisone, 4-androstene-3, 17-dione and xenobiotics like 1, 2-naphtoquinone, 9,10-
phenantrenequinone, this evidence  was derived from indirect activity measurements of NADP and needs 
to be verified [82]. Treating HEK-293 cells expressing recombinant human DHRS7 with radiolabeled 
substrates, cortisone/cortisol and 4-androstenedione/testosterone, I was unable to detect any activity 
(Figure 14). I also performed LC-MS/MS measurements (method described in the second project of this 
thesis) with HEK-293 cells transfected with DHRS7 and assessed the metabolism of 12 steroid hormones, 
namely cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, aldosterone, DOC, DHEA, DHEAS, 
androstenedione and testosterone compared to HEK-293 cells transfected with pcDNA3 as a control. 
None of these steroid hormones could be confirmed as a substrate of DHRS7 (data not shown). In 
addition to the steroid hormones, several xenobiotics, such as bupropion, climbazol, metyrapone, 
menadione, triadimefon and triadimenol and metabolites of arachidonic acids including 5-HETE, 5-oxo-
ETE, 12 HETE, 12-oxo-ETE, 15 HETE and 15-oxo-ETE were also assessed for their potential as possible 
substrates for DHRS7. Again none of the tested compounds was metabolized after incubation with HEK-
293 cells expressing recombinant DHRS7 (data not shown). However, further experiments using the 
LNCaP cells knocked-down DHRS7 need to be performed to ensure that the previous findings have not 
been biased by transient expression of DHRS7 in HEK-293 cells with resulting inactivity of the enzyme or 
absence of interaction partners. Furthermore, it remains to be investigated whether DHRS7 might play a 
role in the production of androgens via the backdoor pathway or whether it indirectly stimulates androgen-
dependent cancer cell proliferation. Therefore experiments using “untargeted” steroidomics are ongoing. 
 
 
Figure 14: Activity assay in intact cells. HEK cells transfected with pcDNA3 or DHRS7 were incubated with 
radiolabeled androstenedione or cortisone and conversion was measured. Results display mean±SD of three 
independent replicates. 
 
The regulation of DHRS7 gene expression in LNCaP cells treated with steroid hormones has been 
analyzed (Figure 15A). Treatment of LNCaP cells with testosterone and estradiol elevated expression of 
DHRS7 mRNA after 48 and 72 h, respectively. However, the results in these experiments were highly 
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variable and therefore no significance was found, possibly depending on cell characteristics such as 
growth, passage and viability. Evaluation of regulatory effects of steroid hormones on DHRS7 protein 
levels warrants therefore additional assessment by immunoblotting. Furthermore, the effect of DHRS7 
expression on AR transactivation was examined (Figure 15B). HEK-293 cells expressing recombinant 
DHRS7 as well as a reporter gene under control of AR were treated with either vehicle control (DMSO 
0.01%), testosterone (10 nM) or the combination of testosterone (10 nM) with the AR antagonist Flutamide 
(1 µM) for 24 h. Testosterone increased the expression of the reporter gene via activation of AR, whereby 
the antagonist Flutamide was able to reverse this effect. The expression of DHRS7 did not affect the 
observed effects when compared to pcDNA3 transfection control. 
 
 
Figure 15: DHRS7 gene expression regulated by testosterone and estradiol and AR transactivation. (A) 
DHRS7 mRNA expression in LNCaP cells after treatment with 10 nM testosterone (T) and 10 nM estradiol (E) 
for 48 and 72 h. (B) AR transactivation in HEK-293 expressing DHRS7 and pcDNA3 as a control.  Data 
represents mean ± SD from three independent experiments. Statistical analysis was performed using the 
Student’s t-test; *p ≤ 0.0001 compared to the control. 
 
Recent studies indicated altered expression of DHRS7 gene expression in animals receiving low and high 
fat diets compared to controls [111-113]. Thus, special diets might influence DHRS7 on the molecular 
level. To test this hypothesis DHRS7 mRNA expression was assessed in rat liver samples from animals 
fed with either a high fat or standard chow diet obtained from Prof. Dr. JP. Montani, University of Fribourg. 
DHRS7 gene expression was found to be decreased in rats fed with a high fat diet when compared to a 
standard chow control. In addition, microarray data of a previous study showed that DHRS7 gene 
expression was decreased in wild type mice obtaining a high fat diet. In comparison, this effect was 
abolished in the SCD1 knockout animals, suggesting this enzyme may play a role in the regulation of 
DHRS7 following high fat diet [84]. Interestingly a recent study performed in obese women found the 
opposite trend, increased DHRS7 levels during a short term low fat, hypocaloric diet [138]. Further 
research needs to be performed to disclose the function and regulation of DHRS7 during different nutrition 
availabilities in animals and humans.  
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In summary, the work described in this thesis 
suggests that DHRS7 functions as a tumor 
suppressor. DHRS7 protein was found to be 
decreased with human prostate cancer progression in 
a TMA. Knockdown of the “orphan” enzyme led to 
increased cell proliferation and migration as well as 
decreased cell adhesion in several prostate and 
breast cancer cell lines in vitro. Microarray data 
suggested EMT and/ or BRCA pathway as possible 
mechanisms for DHRS7 effects. Furthermore, a 
possible role of DHRS7 in liver regeneration was 
identified. The substrate of DHRS7 still remains 
unknown. However, some steroid hormones can be 
excluded as possible substrates based on the results 
of this thesis. Regulation of DHRS7 gene expression 
may be influenced by sex steroid hormones such as 
testosterone or estradiol and by different diets and 
toxicants such as alcohol. Further research needs to be performed to define the function and regulation of 
DHRS7. In addition to following up on some of the targeted hypothesis generated with the help of the 
results in this thesis, untargeted omics approaches, such as metabolomics, (phospho)proteomics and 
interactomics, could be used to help support our current hypothesis and generate new ideas. 
Outlook 
More than 70 SDRs have been identified in the human genome so far and almost half of them are not at 
all characterized. Thus, characterization of “orphan” SDRs may be beneficial, since they may serve as 
novel diagnostic tools or therapeutic targets in several diseases, including cancer. “Orphan” SDRs share 
substantial structural similarity with others, characterized SDRs, such as 11βHSD1. Pharmaceutical 
inhibitors of 11βHSD1 may cause adverse effects by cross-reacting with other SDRs, including “orphan” 
SDRs. Therefore, the characterization of “orphan” enzymes is not only crucial for the assessment of their 
physiological roles, but also for the evaluation and understanding of potential adverse drug effects. This 
thesis characterized DHRS7 as a potential tumor suppressor and possible marker for breast and prostate 
cancer. Therefore, pharmaceuticals cross-reacting with DHRS7 may cause highly undesirable off-target 
effects, since they potentially promote cancer. In future experiments, a screening method to assess 
DHRS7 activity should be developed in order to study the physiological role of this enzyme and to use it 
as counter screen to avoid adverse effects. Furthermore, DHRS7 may serve as a useful tumor marker, 
since we found altered expression of the protein in early grades of prostate tumors. However, to 
understand the mechanism and function of DHRS7 its substrate(s) need to be identified. An untargeted 
metabolomics approach or a large compound screening could be used to help to “deorphanize” DHRS7. 
Figure 16: Gene expression of DHRS7 in liver in 
rats receiving high or low fat diet. Data displays 5 
animals in each group. Statistical analysis was 
performed using the Mann-Whitney U test *p ≤ 
0.0001 compared to high fat diet rats. 
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In addition, structural modelling in combination with compound library screening may aid the identification 
of DHRS7 substrate(s).  
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ABSTRACT 
 
Several microarray studies of prostate cancer (PCa) samples have suggested altered expression of 
the ‘orphan’ enzyme short-chain dehydrogenase/reductase DHRS7 (retSDR4, SDR34C1). However, 
the role of DHRS7 in prostate cancer is largely unknown and the impact of DHRS7 modulation on 
cancer cell properties has not yet been studied. Here, we investigated DHRS7 expression in normal 
human prostate and PCa tissue samples at different tumor grade using tissue-microarray (TMA) and 
immuno-visualization. Moreover, we characterized the effects of siRNA-mediated DHRS7 knockdown 
on the properties of three distinct human prostate cell lines. We found that DHRS7 protein expression 
decreases alongside tumor grade, as judged by the Gleason level, in PCa tissue samples. 
Additionally, siRNA-mediated knockdown of DHRS7 expression in the human prostate cancer cell 
lines LNCaP, BPH1 and PC3 significantly increased cell proliferation in LNCaP cells as well as cell 
migration in all of the investigated cell lines. Furthermore, cell adhesion was decreased upon DHRS7 
knockdown in all three cell lines. To begin to understand the mechanisms underlying the effects of 
DHRS7 depletion, we performed a microarray study with samples from LNCaP cells treated with 
DHRS7-specific siRNA. Several genes involved in cell proliferation and adhesion pathways were 
found to be altered in DHRS7 depleted LNCaP cells. Additionally, genes of the BRCA1/2 pathway and 
the epithelial to mesenchymal transition regulator E-cadherin were altered following DHRS7 
knockdown. Based on these results, further research is needed to evaluate the potential role of 
DHRS7 as a tumor suppressor and whether its loss-of-function promotes PCa progression and 
metastasis. 
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INTRODUCTION 
 
Prostate cancer (PCa) is one of the most common malignancies worldwide, with its incidence 
continually rising. It is also the second leading cause of cancer-related death among men. 
1
 Clinically, 
PCa manifests as a heterogeneous, multifocal disease. 
2, 3
 The mechanisms underlying the initiation 
and progression of PCa are complex. Initially, pre-malignant lesions, which are attributed to genetic 
alterations in one or more cells, arise. Subsequently, genetic alterations can occur in one or a few of 
the pre-malignant cells, resulting in changes of signaling pathways and resulting in malignant growth 
and the formation of a primary tumor. Cells in a primary tumor are heterogeneous regarding their 
phenotypic and biological characteristics, caused by the differences in the genes that were affected, 
thus making therapeutic interventions challenging.  
Besides environmental factors, age and familial inherited susceptibility factors, steroid hormone 
receptor signaling plays a pivotal role in all stages of prostate carcinogenesis. The androgen receptor 
(AR) signaling pathway is thought to promote the early development of PCa, and it also has an 
important role in the development of castration resistant prostate cancer (CRPC), which fails to 
respond to hormone deprivation therapies. Several mechanisms have been suggested to cause the 
progression of PCa to CRPC, including hypersensitivity of the AR signaling pathway to androgens, 
enrichment or accumulation of androgen-insensitive stem cells, and activation of intratumoral 
steroidogenesis. 
4
 Furthermore, there is evidence for a pivotal role of the process of epithelial-
mesenchymal transition (EMT) in the development of metastatic CRPC. 
5
  
In its initial stages, PCa is often curable; however, despite recent advances in current therapeutic 
methods, many patients develop post-operative disease relapse and suffer from significant treatment-
associated complications. The current standard for the treatment of PCa is either medical or surgical 
castration. Nevertheless, following castration, PCa can progress to CRPC and patients may develop 
metastases in various organs such as lymph nodes, liver and bone. 
6, 7
 Besides the androgen-
dependent growth stimulation, a comprehensive understanding of the molecular mechanisms 
underlying PCa progression is largely incomplete, with further research warranted. Thus, it is important 
to investigate new players in prostate cancer to understand disease progression and develop 
improved strategies for the prevention and therapy.  
In this context, analyses of the transcriptome of PCa samples can provide hints to genes involved in 
cancer development and progression. Microarray expression data from three independent studies on 
human prostate cancer tissues suggested that the levels of the short-chain dehydrogenase/reductase 
(SDR) enzyme DHRS7 (also known as retSDR4 and under the nomenclature name SDR34C1) 
8
 are 
frequently altered in this tumor. 
9-11
 A recent study of the transcriptome of human LNCaP prostate 
cancer cells hypothesized that DHRS7, among several other genes, may play a role in sustaining de 
novo androgen synthesis and/or metabolism in CRPC, eventually leading to the reactivation of 
androgen receptor (AR), thus promoting cancer progression even upon ablation of testicular androgen 
production. 
12
  
DHRS7 was initially cloned from retinal pigment epithelium cells; 
13
 however, it is expressed in various 
tissues including the prostate. 
14, 15
 Little is known on the catalytic activity and physiological role of 
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DHRS7 and this enzyme has therefore to be considered as an “orphan” SDR. A recent study by 
Stambergova et al. suggested that DHRS7 possesses NADP(H) cofactor preference and enzymatic 
reducing activity towards endogenous substrates with a steroid structure (estrone, cortisone, 4-
androstene-3,17-dione) and exogenous substances bearing a carbonyl group (1,2-naphtoquinone, 
9,10-phenantrenequinone, benzoquinone,  nitrosamine 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-
butanone). 
16
 However, the evidence for a role of DHRS7 in the metabolism of these compounds was 
based on indirect measurements of NADPH consumption. Other investigators did not observe any 
activity towards steroids and retinoids.
13
 Nevertheless, some of the closest relatives of DHRS7, i.e. 
11β-HSD and 17β-HSD enzymes, have been associated with cancer. Especially, the fact that 17β-
HSDs are involved in the control of sex steroid metabolism and that their expression levels are altered 
in tumors, emphasized the importance of these SDRs in breast and prostate cancer. 
17-19
  
Based on the preliminary observations from microarray studies and the relation of DHRS7 to SDRs 
involved in PCa, we investigated the role of DHRS7 in PCa, taking advantage of a combination of 
human data obtained on a large cohort (n=348) of samples and in vitro experiments comprising 
modulation of DHRS7 expression by knockdown. To determine the effects of DHRS7 on the 
aggressiveness of prostate cells in vitro we evaluated cell proliferation, migration and adhesion after 
siRNA-mediated knockdown in three prostate cell lines, namely LNCaP, BPH1 and PC3. Furthermore, 
we performed a microarray experiment using LNCaP cells treated with siRNA against DHRS7 in order 
to obtain initial insights into pathways involved in its action. 
 
 
MATERIAL AND METHODS 
 
Tissue-microarray (TMA) construction and clinical pathology data 
The use of clinical specimens for the construction of tissue-microarrays (TMAs) was approved by the 
ethical committee of the University Hospital of Basel, Switzerland. The TMAs were manufactured as 
previously described. 
20, 21
 Briefly, the PCa progression TMAs consist of formalin-fixed and paraffin-
embedded (FFPE) specimens obtained from 551 prostate cancer patients plus 68 normal prostate 
tissues. To evaluate DHRS7 protein expression the TMAs were stained with an anti-DHRS7 antibody 
(rabbit anti-human DHRS7 polyclonal antibody, HPA031121, Sigma, St. Louis, USA, 1:200 dilution) 
and analyzed by an experienced pathologist (L.T.). Immunoreactivity was scored semi-quantitatively 
(0=negative and 3=highest intensity) by evaluating the staining intensity as described by Allred et al. 
22
  
 
Cell lines and cell culture 
The human prostate carcinoma cell line LNCaP was newly purchased from ATCC (LGC Standards 
GmbH, Wesel, Germany). PC3 cells and the benign prostate hyperplastic cell line BPH1 were 
available in-house and originally purchased from ATCC. The identity of the cell lines was verified by 
the multiplex human cell line authentication test (Multiplexion, Immenstaad, Germany). All cell lines 
were maintained in RPMI 1640 (R8758, Sigma) supplemented with 10% fetal calf serum (FCS) and 
penicillin (100 U/mL)/streptomycin (100 µg/mL). Cells were cultured at 37°C in a 5% CO2 atmosphere.  
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Immunohistochemical staining 
LNCaP, PC3 and BPH1 cells were seeded in 6-well plates containing a 18 mm round glass slide 
(Menzal-Glaser, Braunschweig, Germany) at 3 x 10
5
 cells per well. For indirect immunofluorescence 
experiments, culture medium was removed and cells were washed twice with PBS, fixed with 4% 
paraformaldehyde for 15 min and washed three times with PBS. Cells were permeabilized with 0.1% 
Triton X-100 for 10 min and blocked with 1% BSA for 20 min at room temperature. Blocking was 
followed by incubation with a primary antibody against DHRS7 (rabbit anti-human DHRS7 polyclonal 
antibody; 1:500 dilution in 1% BSA, HPA031121, Sigma) for 1 h at room temperature. After three 
washes with PBS, Hoechst-33342 (5 µg/ml, H3570, Invitrogen Life Technologies, Zug, Switzerland) 
and goat anti-rabbit HiLyte™ Fluor 488-labeled (1:2000, AS-61056-1-H488, Anaspec, Fremont, 
USA) secondary antibody was applied for 30 min at room temperature. Cells were washed three times 
with PBS, mounted in Mowiol 4-88 and slides were analyzed under a laser scanning confocal 
microscope (Fluoview 1000, Olympus, Shinjuku, Japan).  
 
Transfection with siRNA 
LNCaP, PC3 and BPH1 cells (3 x 10
5
) were reverse transfected on a 6-well plate using Lipofectamine 
RNAiMax reagent with 10 nM of siRNA targeting DHRS7 (D-009573-02, Thermo Scientific, Waltham, 
USA) or a non-targeting siRNA negative control (D-001810-03-20, Thermo Scientific). Effective 
knockdown was verified by qPCR as well as western blot and immunodetection. To choose the siRNA 
for the main experiments, we performed preliminary knockdown experiments with four different 
siRNAs and a pool of all of them (MQ-009573-00, Thermo Scientific), and determined the most 
effective knockdown by qPCR after 24 h, 48 h and 72 h (Supplementary Figure 1).  
 
 
Supplementary Figure 1: Comparison of the 
knockdown efficiency of four different siRNAs 
against DHRS7 mRNA levels. Four siRNAs against 
DHRS7 were assessed by single application and 
as pooled siRNA mixture at a concentration of 15 
nM for gene silencing in LNCaP cells after 24 h, 48 
h and 72 h. As a control, non-targeted siRNA was 
used. DHRS7 mRNA expression was normalized to 
the housekeeping gene for cyclophillin A (PPIA). 
 
To ensure that the siRNA effects observed for 
the specific siRNA (D-009573-02) were due to 
DHRS7 knockdown and not off-target effects, we 
additionally performed the proliferation assay in LNCaP with another DHRS7-specific siRNA (D-
009573-04) (Supplementary Figure 2). The results obtained were similar for both tested siRNAs. For 
the functional assays cells were used at 24 h post-transfection. 
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Supplementary Figure 2: Comparison of cell proliferation in LNCaP cells after knockdown of DHRS7 with 
two different siRNAs. The xCELLigence system was used to monitor dynamic cell proliferation in real-
time. Following 24 h of transfection with siRNA No.2 or No.4 against DHRS7 or non-targeted control 
siRNA, respectively, LNCaP cells were seeded in E-plates of the xCELLigene RTCA instrument and 
monitored for a further 48 h. 
 
Real-time qPCR 
Total RNA was isolated from cultured cells using TRI-reagent (T9424, Sigma) according to the 
manufacturer`s instructions. RNA quality and quantity was measured using a ND-1000 spectrometer 
(Nano-drop, Wilmington, USA). Reverse transcription was performed using the M-MLV Reverse 
Transcriptase Kit (M368B, Promega, Wallisellen, Switzerland) according to the manufacturer`s 
instructions. Relative quantification of mRNA expression levels was performed by real-time qPCR. 
Briefly, cDNA (10 ng), gene-specific oligonucleotide primers (Supplementary Table 1) (200 nM) and 
KAPA SYBR FAST qPCR reagent (KK4600, Kapa systems, Wilmington, USA) (5 μL), in a final volume 
of 10 μL, were analyzed by qPCR in a rotor-gene 3000A (Corbett Research, Sydney, Australia).  
 
Gene 
Primer 
forward (5'-3') reverse (5'-3') 
BRCA1 GAAACCGTGCCAAAAGACTTC CCAAGGTTAGAGAGTTGGACAC 
BRCA2 CACCCACCCTTAGTTCTACTGT CCAATGTGGTCTTTGCAGCTAT 
CDH1 CGAGAGACTACACGTTCACGG GGGTGTCGAGGGGAAAAATAGG 
CHEK1 ATATGAAGCGTGCCGTAGACT TGCCTATGTCTGGCTCTATTCTG 
CHEK2 TCTCGGGACTCGGATGTTGAG CCTGAGTGGACACTGTCTCTAA 
DHRS7 GAGTTTGGTAGAATCGACTTTCTG GAAAGAGGTACAGATATGATACCC 
FANCD2 AAAACGGGAGAGAGTCAGAATCA ACGCTCACAAGACAAAAGGCA 
PPIA CATCTGCACTGCCAAGACTGA TGCAATCCAGCTAGGCATG 
RAD51 CAACCCATTTCACGGTTAGAGC TTCTTTGGCGCATAGGCAACA 
 
Supplementary Table 1: Human oligonucleotide primers used for qPCR 
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Thermal cycler parameters were as follows: denaturation for 15 min at 95°C, followed by amplification 
of cDNA for 40 cycles with melting for 15 s at 94°C, annealing for 30 s at 56°C and extension for 30 s 
at 72°C. Relative gene expression normalized to the internal control gene coding for cyclophillin A 
(PPIA) was obtained by the 2
−ΔΔCt
 method 
23
.  
 
Western Blot  
Cells were lysed using RIPA buffer (R0278, Sigma) and centrifuged at 12,000 x g for 10 min at 4°C. 
The supernatant was collected and protein concentration quantified using the Pierce® biocinchonic 
acid protein assay kit (23225, Thermo Scientific). Samples were heated at 95°C for 5 min in Laemmli 
buffer (5 mM Tris HCl, pH 6.8, 10% glycerol (v/v), 0.2% sodium dodecyl sulfate (SDS) (w/v), 1% 
bromophenol blue (w/v)) and stored at -20°C until used. Lysates were separated by a 12.5% Tris-
glycine SDS-polyacrylamide gel, and transferred to Immun-Blot® polyvinylidene difluoride (PVDF) 
membranes (162-0177, Bio-Rad Laboratories, Hercules, USA) at constant 230 mA for 1 h. For 
detection of DHRS7 the membrane was blocked using 2% milk (v/v) for 1 h at room temperature, 
followed by incubation with the mouse anti-human DHRS7 polyclonal antibody (ab69348, abcam, 
Cambridge, UK) at a dilution of 1:500 (v/v) in 2% milk (v/v), overnight at 4°C. After washing with Tris-
buffered saline (20 mM Tris-base, 140 mM NaCl) containing 0.1% Tween-20 (v/v) (TBS-T), the 
membrane was subsequently incubated with horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (Jackson Immuno Research, Suffolk, UK) for 1 h at room temperature.  For 
cyclophilin-A detection, the membrane was blocked using 10% milk (v/v) overnight at 4°C, followed by 
incubation with the rabbit anti-human cyclophilin A polyclonal antibody (ab41684, abcam) at a dilution 
of 1:2,000 (v/v) in 2% milk for 1 h at room temperature.  After washing with TBS-T, the membrane was 
subsequently incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, USA) at a dilution of 1:1,000 (v/v) in 2% milk (v/v).  After 
washing the membranes in TBS-T, images were visualized using the Immobilon Western 
Chemiluminescent HRP substrate kit (Millipore, Schaffhausen, Switzerland), and a FujiFilm 
ImageQuant
TM
 LAS-4000 detector (GE Healthcare, Glattbrugg, Switzerland) using the 
chemiluminescence detection setting.  
 
xCELLigence cell proliferation assay 
The xCELLigence DP device (ACEA Biosciences, San Diego, USA) was used to monitor cell 
proliferation in real-time. LNCaP, PC3 and BPH1 cells were seeded in E-plates (E-Plate View™; 
ACEA) at 1 × 10
4
, 5 × 10
3
 and 5 x 10
3
 cells per well, respectively. Proliferation was determined 
kinetically over 48 h using the xCELLigence system according to the manufacturer’s protocol. Cell 
proliferation measurements were performed in triplicates with programmed signal detection every 15 
min. Data acquisition and analyses were performed using the RTCA software (version 1.2, ACEA).  
 
Ki-67 cell proliferation assay 
Following 24 h after DHRS7 siRNA transfection, cells were detached, diluted to 10,000 cells in 100 µL 
and placed onto a Superfrost
TM
 microscope slide using a Cytospin
TM
 centrifuge (Thermo Scientific). 
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The slides were fixed in delaune for 2 min and then left to dry at room temperature for 5 min. Ki-67 
staining was performed with a BenchMark Ultra platform automated IHC/ISH staining system (Roche, 
Rotkreuz, Switzerland). Ki-67 index was determined by ascertaining the percentage of Ki-67 positively 
stained cells in 5 fields scanned at 20x magnifications using ImageJ software (http://imagej.nih.gov/ij/).  
 
Transwell migration assay 
LNCaP, PC3 and BPH1 cells were re-seeded 24 h post-transfection into the top chamber of a 24-well 
non-coated insert (pore size 8 μm, Corning Inc., Lowell, MA, USA) at 1 x 10
5
, 0.5 x 10
5
 and 1 x 10
5
 
cells per well respectively. The upper chamber contained RPMI media supplemented with 1% FBS, 
whereas the bottom chamber contained 10% FBS as a chemoattractant. Following 24 h of incubation, 
cells were stained with 0.1% crystal violet (w/v) (C3886, Sigma) in 25% methanol (v/v). Non-migrated 
cells in the upper chamber were removed using a cotton swab. Images of migrated cells which 
adhered to the bottom of the filter were captured at 10x magnification using a light microscope (Zeiss 
Axiovert 100; Carl Zeiss Microscopy GmbH, Feldbach, Switzerland) and relative areas of staining were 
assessed using the threshold setting on Image J.  
 
Cell adhesion 
96-well plates were coated with 50 µg/mL fibronectin and blocked with 0.5% BSA in RPMI medium for 
45 min at room temperature. LNCaP, PC3 and BPH1 cells were seeded at 1 × 10
5
 cells per well and 
allowed to adhere for 60 min. Wells were then washed twice with PBS. The number of adherent cells 
in each well was quantified through staining with 0.1% crystal violet (w/v) in 25% methanol (v/v), 
followed by OD measurement.  
 
cRNA target synthesis and gene chip hybridization 
Total RNA for the microarray was isolated with Direct-Zol RNA MiniPrep Kit (Zymo Research, Irvine, 
USA) including on-column DNAse treatment. RNA concentration was assessed using a NanoDrop ND 
1000 (Nanodrop) and RNA integrity was monitored on a Bioanalyzer RNA 6000 Chip (Agilent, Basel, 
Switzerland). 270 ng of DNAse-treated total RNA was subjected to target synthesis using the WT 
Expression kit (Life Technologies), following the manufacturer`s recommendations. Fragmentation and 
labeling of amplified cDNA was performed using the WT Terminal Labeling Kit (Affymetrix, Santa 
Clara, USA). Synthesis reactions were carried out using a PCR machine (TProfessionnalTrio, 
Biometra, Goettingen, Germany) in 0.2 mL tubes. 85 µL of cocktail containing 23.4 ng/µL labeled DNA 
was loaded on a Affimetrix GeneChip Human Gene 2.0 ST Array (Cat# 902499) and hybridized for 17 
h (45°C, 60 rpm) in a hybridization oven 645 (Affymetrix). These gene chips have the particularity of 
interrogating all well-established annotation RefSeq coding transcripts (26,191) and in addition many 
well-established annotation RefSeq non-coding transcripts (3,391). The arrays were washed and 
stained on a Fluidics Stations 450 (Affymetrix), using the Hybridization Wash and Stain Kit according 
to the FS450_0002 protocol (Affymetrix). The gene chips were scanned with an Affymetrix GeneChip 
Scanner 3000 7G. DAT images and CEL files of the microarrays were generated using Affymetrix 
GeneChip Command Control software (version 4.0). Afterwards, CEL files were imported into Qlucore 
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software and Robust Multichip Average (RMA) normalized. Subsequently, principal component 
analysis to discriminate between engineered and control cells was performed. Quantile normalization 
and data processing were performed using the GeneSpringGXv11.5.1 software package (Agilent). The 
gene signature value was assessed using the BRB-ArrayTool (v4.3.2, NIH). Ingenuity software 
(Qiagen, Venlo, Netherlands) was use to perform pathways analysis.  
 
Statistics 
For the statistical analysis, the Chi-square test and the Fisher’s exact test for non-parametric variables 
and ANOVA or Student’s t-test for parametric variables were used, with all probabilities reported as 
two-tailed. Differences in patient survival were assessed using the Kaplan-Meier method and analyzed 
using the log-rank test in univariate analysis. All tests were two sided and p values < 0.05 considered 
being statistically significant. Cut-off scores were selected by evaluating the receiver- operating 
characteristic (ROC) curves. The point on the curve with the shortest distance to the coordinate (0, 1) 
was selected as the threshold value to classify cases as ‘positive/overexpressing’ or ‘negative/down 
regulated’. Analyses were performed using the SPSS software (IBM, Armonk, USA). 
 
 
RESULTS 
 
DHRS7 expression is down regulated in human prostate cancer with increasing tumor grade  To 
evaluate a potential role of DHRS7 in PCa, DHRS7 protein levels were analyzed by 
immunohistochemistry with a rabbit polyclonal anti-human DHRS7 antibody in a large collection of 
human prostate specimens using a set of TMAs. Representative pictures of DHRS7 staining are 
shown in Figure 1A and Supplementary Figure 3. Of the 491 stained tissue punches of PCa, 326 were 
suitable for analysis and 31 out of the 68 tissue punches from normal prostate could be used for this 
study. Tissues were excluded either as a consequence of poor staining quality or loss of the section 
from the slide. These analyses revealed DHRS7 to be highly expressed in normal prostate, with the 
vast majority of analyzed samples (80.6%) classified as benign with intensity 3 (scoring system: 
0=negative for DHRS7 and 3=highest intensity of DHRS7, as described under Materials and 
Methods). Conversely, most of the PCa specimens were scored having either score 2 or 1, 39% and 
34.4%, respectively (Figure 1B).  
10 
 
 
 
Figure 1: DHRS7 expression in human prostate samples. (A) Representative pictures of DHRS7 staining 
intensity in normal prostate versus PCa with different Gleason levels (GL). Formalin-fixed and paraffin-
embedded prostate specimens were analyzed using a rabbit polyclonal anti-human DHRS7 antibody. (B) 
DHRS7 staining intensity distribution plots highlight that DHRS7 expression is reduced in PCa compared 
with normal prostate. (C) Kaplan-Meier curves based on DHRS7 expression levels suggest no major 
impact on the survival of PCa patients. 
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Supplementary Figure 3: DHRS7 representative staining in human normal prostate and PCa samples. The 
spectrum of DHRS7 staining intensity ranges from absent/low (0) to very high/strong (3), from left to right 
side respectively, in tested samples. Normal prostate to PCa GL5 specimens are reported, going from up 
to down side respectively. 
 
Complete loss of DHRS7 was never observed in normal prostate tissue samples, while this was the 
case in 6.1% of PCa samples. Further stratification of PCa samples, based on their Gleason level 
(GL), outlined that the group of patients with the highest GL, namely GL5, presented with the lowest 
percentage of score 3 DHRS7 specimens (22.2%) (Table 1). These results suggest that the loss of 
DHRS7 is associated with PCa and tumor grade. Nevertheless, Kaplan-Meier plots did not reveal a 
significant association between DHRS7 expression and the survival of PCa patients (Figure 1C). 
 
Impact of DHRS7 knockdown on the proliferation of PCa cells  
Since DHRS7 expression decreases significantly as the tumor grade increases, we investigated the 
functional effects of silencing DHRS7 expression in prostate cell lines endogenously expressing 
DHRS7 at different amounts, as determined by real-time PCR, Western blotting and 
immunovisualisation, namely LNCaP (high), PC3 (moderate) and BPH1 (low) (Figure 2). 
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 Tissue type DHRS7 intensity n χ2 P 
  0 1 2 3     
Normal 
Prostate 
0 4 2 25     
PCa - GL2 3 5 2 6 11.10 0.01 
PCa - GL3 9 70 80 40 49.90 < 0.0001 
PCa - GL4 3 32 36 22 32.52 < 0.0001 
PCa - GL5 4 4 8 2 25.54 < 0.0001 
 
Table 1: Summary of observed DHRS7 protein levels in normal prostate and PCa samples. Stratification of 
PCa samples based on their Gleason level (GL) was performed by semi-quantitatively evaluating the 
immunostaining intensity as described by Allred et al. 22 Normal prostate (n=31), PCa - GL2 (n=16), PCa - 
GL3 (n=199), PCa - GL4 (n=93), PCa - GL5 (n=18). Results were analyzed using Chi-square test (χ2 test). 
 
SiRNA-mediated targeting efficiently depleted DHRS7 mRNA expression by more than 90% at all 
investigated time points (Figure 3A). The impact of siRNA-mediated knockdown of DHRS7 gene 
expression on protein levels was assessed by western blotting (Figure 3B). Although the mouse anti-
human DHRS7 polyclonal antibody used showed limited sensitivity in western blots, it was preferable 
over the rabbit anti-human DHRS7 polyclonal antibody and allowed qualitative assessment of protein 
expression. Protein levels were reduced to approximately 30-50% after 24 h and to below 10-20% 
after 48 h and 72 h in siRNA treated LNCaP cells. Knockdown of DHRS7 protein expression was also 
demonstrated in PC3 and BHP1 cells, whereby a very faint band was still detectable after 24 h but no 
longer after 48 h and 72 h. No morphological changes were observed following depletion of DHRS7 in 
these prostate cell lines (data not shown) 
 
 
Figure 2: Endogenous expression of DHRS7 in LNCaP, BPH1 and PC3 cells as assessed by qPCR, 
Western blot and immunovisualisation. (A) For qPCR 10 ng cDNA was used and data was normalized to 
cyclophilin A (PPIA) control. For western blotting an amount of 40 µg of total protein was separated by 
SDS-PAGE, proteins were transferred onto PVDF membranes, followed by detection using a mouse 
polyclonal anti-human DHRS7 antibody. (B) Immunofluorescence staining was performed using a rabbit 
polyclonal anti-human DHRS7 antibody. Nuclei were stained with Hoechst-33342.   
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Figure 3: Knockdown of DHRS7 in prostate cell lines. Real-time qPCR (A) and western blot (B) showed the 
efficacy of siRNA against DHRS7 compared with that of control siRNA after 24 h, 48 h and 72 h in LNCaP, 
BPH1 and PC3 cells. (A) For real-time PCR 10 ng cDNA was used. Cyclophilin A (PPIA) served as a house-
keeping control. Results are expressed as fold change of control and represent mean ± SD from three 
independent experiments conducted in triplicates. Statistical analysis was determined using the 
Student’s t-test. *p ≤ 0.0001. (B) For western blot 10 µg of total protein for LNCaP and 30 µg for BPH1 and 
37 µg for PC3 were subjected to SDS-PAGE and western blotting using a mouse polyclonal anti-human 
DHRS7 antibody. Representative experiments are shown.  
 
The impact of DHRS7 knockdown on cell proliferation was assessed using the xCELLigence system. 
Depletion of DHRS7 resulted in a 3-fold increase in LNCaP cell proliferation, which was supported by 
an enhanced Ki-67 staining (Figure 4A-C). The effect on cell proliferation upon knockdown of DHRS7 
was verified by using an independent siRNA molecule (Supplementary Figure 2).  
In contrast to LNCaP, no significant changes in cell proliferation following DHRS7 depletion could be 
observed for PC3 and BPH1 cells, and also Ki-67 staining was not different between control and 
knockdown. Interestingly, depletion of DHRS7 had no effect on the cell cycle as detected by flow 
cytometric analysis (Supplementary Figure 4). These results suggest that knockdown of DHRS7 
impairs cell proliferation, dependent on their basal proliferation rate and/or DHRS7 expression levels. 
 
Depletion of DHRS7 promotes cell migration and adhesion in PCa cells 
To study the effects of DHRS7 down regulation on the migratory and adhesive capabilities of LNCaP, 
PC3 and BPH1 cells transwell cell migration and fibronectin adhesion assays were performed. Cell 
migration was significantly enhanced in cells treated with siRNA against DHRS7 compared with cells 
treated with non-targeted control siRNA (p<0.05, Figures 4D and 4E). The effect was most 
pronounced in LNCaP cells where migration was increased 3-fold upon DHRS7 knockdown. The 
number of adherent cells following DHRS7 depletion was significantly reduced compared with controls 
(p<0.05, Figure 4F). These results suggest that loss of DHRS7 promotes cell migration and decreases 
adhesion in all three cell lines tested. 
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Figure 4: Influence of DHRS7 knockdown on proliferation, migration and adhesion in LNCaP, BPH1 and 
PC3 cells. (A) The xCELLigence system was used to monitor dynamic cell proliferation in real-time. 24 h 
after transfection with siRNA against DHRS7 or non-targeted control siRNA, LNCaP, BPH1 and PC3 cells 
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were seeded in E-plates of the xCELLigene RTCA instrument and monitored for a further 48 h. Cell index 
refers to a relative change in electrical impedance representing the number of cells detected on the 
microelectrodes on the bottom of the plate. (B,C) Immunohistochemical staining of Ki-67 expression in 
LNCaP, BPH and PC3 cells 48 h after knockdown of DHRS7, normalized to cells treated with control 
siRNA. Ki-67 index was determined by detecting the fraction of Ki-67 positively stained cells in 5 fields, 
scanned at 20x magnification using ImageJ.  Representative images are shown. (D, E) Migration of 
LNCaP, BPH1 and PC3 cells after knockdown of DHRS7 assessed by the transwell migration assay. Cells 
transfected with siRNA against DHRS7 or scrambled non-targeted control siRNA were seeded on Boyden 
chamber transwell inserts at 24 h post-transfection, followed by crystal violet staining after another 24 h. 
Stained cells in 5 fields scanned at 10x magnification setting were analysed using ImageJ. Representative 
pictures of Boyden chamber assays are shown. (F) Cell adhesion assay using fibronectin as an 
extracellular matrix (ECM) in LNCaP, BPH1 and PC3 cells. At 24 h post-transfection with siRNA against 
DHRS7 or scrambled non-targeted control siRNA cells were seeded in fibronectin coated plates. Adherent 
cells were quantified after 60 min by crystal violet staining. All data represent mean ± SD from at least 
three independent experiments conducted in triplicate. Statistical analysis was performed using the 
Student’s t-test; *p ≤ 0.0001 compared to the non-targeted control. 
The impact of DHRS7 knockdown on the gene expression profile of LNCaP cells 
Based on these in vitro findings, we investigated whether ablation of DHRS7 expression may impair 
the expression of genes involved in proliferation, migration and adhesion. For this purpose we used 
LNCaP cells, due to their high endogenous expression level and the pronounced effects of siRNA-
mediated knockdown, and conducted a microarray study using the Affymetrix GeneChip Human Gene 
2.0 ST Array. RNA was prepared at 24 h, 48 h and 72 h post-transfection with siRNA against DHRS7. 
Non-targeting siRNA was used as control. First, we assured that DHRS7 expression was efficiently 
decreased (Figure 5A). Following this, the transcriptome data was examined, revealing that DHRS7 
knockdown altered the global gene expression profile of LNCaP cells as early as 24 h after siRNA 
treatment, as shown by PCA analysis (Figure 5B) and hierarchical clustering (Figure 5C). The 
differences were more pronounced at 48 h and 72 h (Figure 5B). To validate our microarray data, we 
performed qPCR to confirm some of the expression changes observed in the microarray following 
DHRS7 knockdown. The target genes were selected based on the fold change between control and 
DHRS7 knockdown treatment and due to their potential role in cell proliferation or metastasis, namely: 
CLSPN, EIF3I, H2AFV and CDH1 (Figure 5D). In order to determine whether the differentially 
expressed genes had functional relationships in similar signaling pathways, we employed the 
interactive pathway analysis (IPA) tool with Ingenuity software. IPA revealed enrichment of pathways 
involved in DNA replication, cellular growth and proliferation, cellular assembly and organization, 
migration and adhesion as well as cancer (Supplementary Figure 5).  
 
 
 
Supplementary Figure 4: Histogram showing the percentages of 
cells in each phase of the cell cycle after DHRS7 knockdown. 
LNCaP cells were treated with siRNA against DHRS7 and 
collected after 24 h or 48 h. Subsequently, cells were subjected 
to propidium iodide staining and analyzed for DNA content by 
flow cytometry. 
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Figure 5: The impact of DHRS7 knockdown on the gene expression profile in LNCaP cells. (A) DHRS7 
expression was efficiently decreased as early as 24 h after siRNA treatment. Color scheme representing 
normalized (-2 to 2) gene expression fold-change. (B) PCA analysis showing profound alterations in the 
global gene expression profile of LNCaP cells upon DHRS7 knockdown. Each sphere represents one of 
the three replicates used for the microarray. Replicates samples obtained from DHRS7 knockdown cells 
cluster to each other but far away from the CTRL cells. Most profound gene expression profile differences 
in DHRS7 knockdown cells compared to CTRL are observed at 72 h after siRNA treatment. (C) 
Hierarchical clustering of samples based on significant differentially expressed genes (normalized fold-
change −2.0 to 2.0) with FDR (False discovery rate at p<0.05) highlights major differences in gene 
expression among analysed groups. (D) Validation of microarray data by qPCR on a selected pool of 
genes. (E) Genes involved in the BRCA1 pathway whose expression was altered in LNCaP cells upon 
DHRS7 knockdown. 
Among the different pathways influenced by DHRS7 depletion, the BRCA1 pathway was one of the 
most affected. We also validated the expression of genes related to this pathway following DHRS7 
knockdown by assessing the mRNA expression of BRCA1, BRCA2, FANCD2, FANCE, CHEK1, 
CHEK2 and RAD51 by qPCR (Figure 5E). Together, these results suggest that DHRS7 knockdown 
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alters the gene expression profile of LNCaP cells and supports our results described above 
concerning the effects on cell proliferation and migration. 
 
 
Supplementary Figure 5: Interactive pathway analysis (IPA)-based gene enrichment analysis. Graphical 
representation of most alerted diseases and cell functions (A), toxicity function related pathways (B) and 
cell cycle associated genes (C) in DHRS7 knockdown cells. 
 
DISCUSSION 
 
Uncharacterized SDRs may play important physiological and pathological roles in multiple diseases, 
including cancer. Elucidation of their function is likely to provide an improved understanding of disease 
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mechanisms, which is essential for the development of novel diagnostic and therapeutic applications. 
24
 The “orphan” enzyme DHRS7 belongs to this enzyme family. Microarray-based gene expression 
profiling studies suggested that DHRS7 expression is often decreased or even lost in PCa, 
9-11
 raising 
the question about its potential role in tumor progression, however its role in cancer has not been 
elucidated. Therefore, we decided to study the expression of DHRS7 in normal human prostate and in 
PCa tissue samples at different tumor stages. Furthermore, we assessed the effects of DHRS7 
knockdown in vitro using different human prostate cell lines.  
Through the analysis of hundreds of specimens from patients at different stages of disease, TMA 
technology has proven to serve as a powerful tool to promptly analyze clinical significance of new 
molecular markers in human tumors. Here, we took advantage of a prostate-specific TMA generated 
at our institution to asses DHRS7 expression in a large cohort of specimens (n=348). In line, with 
previously reported RNA-based microarray data, 
9-11
 we verified that DHRS7 expression is diminished 
in PCa compared with normal prostate tissue samples on the protein level using TMA. Importantly, we 
report for the first time that DHRS7 protein levels are decreased in PCa tissues and negatively 
correlate with the Gleason level. It remains to be established whether low DHRS7 expression levels in 
primary PCa tissue may predict a high subsequent risk of distant metastases, as such finding would 
have significant potential for diagnostic and therapeutic implications. To date, we have not observed a 
clear correlation between DHRS7 expression levels and the survival of patients. However, this is not 
surprising in the context of PCa since it is in line with the lack of predictive value of important tumor 
suppressor genes. For example, although frequently mutated in 5-20% of PCa, the p53 status also 
failed to serve as a prognostic marker for survival in localized prostate adenocarcinoma while it serves 
as a useful marker in locally advanced prostate cancer treated by androgen deprivation. 
25-27
  
We then sought to support the protein expression-based findings from analysis of human tissues with 
a set of in vitro experiments using different prostate-derived cell lines. First, DHRS7 expression levels 
in LNCaP, PC3 and BPH1 cells were evaluated and then the effect of DHRS7 knockdown on key 
characteristics of aggressive cancer phenotypes like cell proliferation, migration and adhesion was 
investigated. DHRS7 knockdown led to a dramatically increased proliferation rate of LNCaP cells; 
however, no significant increase in cell proliferation was observed for PC3 and BPH1 cells. This may 
be explained by the fact that the basal proliferation rate of LNCaP cells is much lower (approximately 
60 h doubling time) compared with that of PC3 and BPH1 cells (approximately 30-45 h doubling 
time).
28
 Furthermore, LNCaP show very high DHRS7 expression, whereas PC3 and BPH1 express 
only moderate to low levels. It should be noted that the proliferation of LNCaP cells is androgen-
dependent, whereas that of PC3 and BPH1 cells has been shown to be androgen-independent. 
29-31
 
Although the underlying mechanism remains unknown, it has been recently suggested that DHRS7 
may promote de novo androgen synthesis, thus directly influencing the activation of the androgen 
receptor (AR), thereby stimulating cancer progression. 
12
  
Currently, the substrate(s) of DHRS7 remains unknown. Although a recent study suggested that 
DHRS7 might catalyze the reduction of several steroids, including 4-androstene-3, 17-dione, as well 
as quinone containing xenobiotics, this evidence stems from indirect activity measurements and need 
to be confirmed. Using recombinant human DHRS7 expressed in HEK-293 cells, we were unable to 
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detect any activity on estrone/estradiol, cortisone/cortisol and 4-androstene-3, 17-dione /testosterone, 
in contrast to the potent activities that we observed for 17β-HSD1, 11β-HSD1 and 17β-HSD3, 
respectively (data not shown). It remains to be investigated whether DHRS7 might play a role in the 
production of androgens via the backdoor pathway 
32
 or whether it indirectly stimulates androgen-
dependent cancer cell proliferation.  
To evaluate a possible influence of DHRS7 on cell cycle, LNCaP cells were analyzed by flow 
cytometry. Nevertheless, no significant changes could be detected, (Supplementary Figure 4), 
indicating that DHRS7 knockdown is increasing proliferation of LNCaP cells without affecting the cell 
cycle. In addition to the changes in LNCaP cell proliferation, increased cell migration as well as 
decreased cell adhesion was observed for all three cell lines tested. These results are further 
supported by our microarray data analysis that underlines the effect of DHRS7 depletion on the 
expression of genes involved in cell proliferation and cell adhesion pathways in LNCaP cells. 
Moreover, the transcriptome profiling of DHRS7 knockdown versus control LNCaP cells revealed a 
decreased expression of CDH1 (also known as E-cadherin). Loss of E-cadherin promotes the 
transition of epithelial cells to the mesenchymal state (EMT), which is observed in metastasis. 
33
 E-
cadherin is an important switch in EMT, which could explain the increased migration and adhesion 
observed in the prostate cell lines. Another possible mechanism for the DHRS7-mediated regulation of 
prostate cancer progression could involve the BRCA1/2 pathway that was also affected based on the 
data from our microarray analysis. BRCA1 and BRCA2 both are prostate tumor suppressors and their 
loss is associated with enhanced cell proliferation and overall cancer progression. 
34, 35
 Nevertheless, 
further research is needed to investigate the impact of DHRS7 function on these pathways. 
In conclusion, our in vitro experiments provide compelling evidence for DHRS7 as a key regulator of 
PCa cancer cell properties. According to our results and those of others, DHRS7 possesses tumor 
suppressor functions in prostate cancer. Nevertheless, the mechanism underlying the effects of 
DHRS7 on cancer cell (and normal cell) behavior remains unknown and warrants further research. 
Future studies are required to identify the substrate(s) and product(s) of DHRS7 and to elucidate its 
regulation of expression. A better understanding of the tumor-suppressive role of DHRS7 may lead to 
the identification of a novel therapeutic prostate cancer target and/or the potential development of a 
diagnostic application.  
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